Boron heterocycle containing compounds as ENPP inhibitors, and uses thereof

Boron heterocycle containing benzoxazaborininols are developed to inhibit ENPP, particularly ENPPl, addressing the need for therapeutic agents in diseases such as cancer by effectively targeting ENPP activity.

WO2026236678A1PCT designated stage Publication Date: 2026-11-12AN2 THERAPEUTICS INC +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027393
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-02
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for effective ENPP inhibitors, particularly ENPPl inhibitors, to address various disease states including cancer, as ENPPl has been identified as a critical phosphodiesterase that degrades the stimulator of interferon genes (STING) ligand, cyclic GMP-AMP (cGAMP), which has potential applications in immunotherapy.

Method used

Development of boron heterocycle containing compounds, specifically benzoxazaborininols, that inhibit ENPP activity, including ENPPl, through covalent and non-covalent interactions, offering potential therapeutic applications.

Benefits of technology

The benzoxazaborininols effectively inhibit ENPP, providing a basis for treating diseases and disorders mediated by ENPP inhibition, including cancer, by interacting with biological targets like ENPPl.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000002_0002
    Figure IMGF000002_0002
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
Patent Text Reader

Abstract

Provided are compounds, compositions and methods that are ENPP inhibitors, including for example ENPP1 inhibitors, and have potential applications in treating various diseases, disorders and conditions mediated by ENPP, including for example ENPP1.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 314352001641BORON HETEROCYCLE CONTAINING COMPOUNDS AS ENPP INHIBITORS,AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U. S. Provisional Patent Application No.63 / 803,388, filed May 9, 2025, and International Patent Application No.PCT / CN2026 / 080795, filed March 2, 2026, each of which is incorporated herein by reference in its entirety.FIELD

[0002] The present disclosure relates generally to boron heterocycle containing compounds, and more specifically to benzoxazaborininols that inhibit ectonucleotide pyrophosphatase / phosphodiesterase (ENPP) activity, including for example ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPPl), and are useful for treatment of di seases, disorders and conditions treatable by such inhibition.BACKGROUND

[0003] Ecto-nucleotide pyrophosphatase / phosphodiesterase (ENPP) family members (ENPP 1-7) have been implicated in key biological and pathophysiological processes, including nucleotide and phospholipid signaling, bone mineralization, fibrotic diseases, and tumor-associated immune cell infiltration. See Borza et al., J. Biol. Chem. (2022) 298(2) 101526.

[0004] In particular, ENPPl has been identified as a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities, critical for purinergic signaling. Recently, ENPPl has emerged as a critical phosphodiesterase that degrades the stimulator of interferon genes (STING) ligand, cyclic GMP-AMP (cGAMP). cGAMP or analogs thereof have emerged as potent immunostimulatory agents, which have potential applications in immunotherapy. This emerging role of ENPPl has placed ENPPl at the frontier of immunotherapy. See Onyedibe et al., Molecules 2019, 24, 4192; see also Ruiz-Fernandez de Cordoba, et al., Clin Cancer Res; 29(12) June 15, 2023, 2184-2193.

[0005] Thus, what is desired in the art are ENPP inhibitors, including for example ENPPl inhibitors, that have potential applications in various disease states, including cancer.1MF-369911600Attorney Docket No.: 314352001641BRIEF SUMMARY

[0006] Provided herein are compounds that inhibit ENPP, including for example ENPP1, and are suitable for use in treating diseases, disorders and conditions that are treatable by such inhibition.

[0007] In some aspects, provided is a compound of Formula (A):or a pharmaceutically acceptable salt thereof, wherein:R1is H or alkyl;R2and R3are each independently H or alkyl;R4is H or alkyl;R5is an optionally substituted cyclic ring system that is fused or unfused, comprising at least one aromatic ring;each R⁶ is independently alkyl, haloalkyl, haloalkoxy, halo, cyano, or alkoxy;R' is H, alkyl, or haloalkyl;Y is a bond, alkyl, -alkyl-NRy-alkyl- or -O-alkyl, whereinRyis H or alkyl;ring F is 5-membered heteroaryl optionally substituted with one or more Rf, wherein each Rfis independently alkyl;ring G is optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, whereinring G is optionally substituted with one or more Rg;each Rgis independently alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, or oxo;m is 0-3; andn is 1-3.2MF-369911600Attorney Docket No.: 314352001641

[0008] In some aspects, provided is a compound of Formula (I):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are as defined for a compound of Formula (A).

[0009] In some aspects, provided is a compound of Formula (II):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R6, R7, ring F, ring G, Y, m, and n are as defined for a compound of Formula (A).

[0010] In some aspects, provided is a compound of Formula (III):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R6, R7, R3, n, and m are as defined for a compound of Formula (A).

[0011] In one aspect, provided is a compound of Table 1, or a pharmaceutically acceptable salt thereof.

[0012] In another aspect, provided are pharmaceutical compositions, comprising any one of the compounds disclosed herein; and at least one pharmaceutically acceptable excipient.

[0013] In other aspects, provided is a method of inhibiting ENPP (including, e.g., inhibiting ENPP1, or inhibiting both ENPP1 and ENPP3) in a subject in need thereof, comprising administering any one of the compounds or pharmaceutical compositions disclosed herein. In yet other aspects, provided is a method of treating a disease, disorder or3MF-369911600Attorney Docket No.: 314352001641condition mediated by inhibition of ENPP (including inhibition of ENPP1 or inhibition of both ENPP1 and ENPP3), comprising administering any one of the compounds or pharmaceutical compositions disclosed herein.DETAILED DESCRIPTION

[0014] The following description sets forth exemplary compounds, compositions, methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.

[0015] In some aspects, provided is a compound of Formula (A):or a pharmaceutically acceptable salt thereof, wherein:R1is H or alkyl;R2and R3are each independently H or alkyl;R4is H or alkyl;R5is an optionally substituted cyclic ring system that is fused or unfused, comprising at least one aromatic ring;each R6is independently alkyl, haloalkyl, haloalkoxy, halo, cyano, or alkoxy;R' is H, alkyl, or haloalkyl;Y is a bond, alkyl, -alkyl -NRy-alkyl- or -O-alkyl-, whereinRyis H or alkyl;ring F is 5-membered heteroaryl optionally substituted with one or more Rf, wherein each Rfis independently alkyl;ring G is optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, whereinring G is optionally substituted with one or more Rg;each Rgis independently alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, or oxo;4MF-369911600Attorney Docket No.: 314352001641m is 0-3; andn is 1-3.

[0016] In some embodiments:R1is H or Ci-ealkyl;R2and R3are each independently H or Ci- ealkyl;R4is H or Ci-ealkyl;R5is an optionally substituted 5-20 membered cyclic ring system that is fused or unfused, comprising at least one 5-6 membered aromatic ring;each R6is independently Ci-ealkyl, C i -ehaloalky 1, Ci-ehaloalkoxy, halo, cyano, or Ci- ealkoxy;R7is H, Ci-ealkyl, or Ci-ehaloalkyl;Y is a bond, Ci-ealkyl, -Ci-ealkyl-NIV'-Ci-ealkyl- or -O-Cj -ealkyl-, wherein Ryis H or Ci-ealkyl;ring F is 5-membered heteroaryl optionally substituted with one or more Rf, wherein each Rfis independently Ci-ealkyl;ring G is optionally substituted phenyl, optionally substituted 5-6 membered heterocyclyl, or optionally substituted 5-6 membered heteroaryl, wherein ring G is optionally substituted with one or more R8;each Rgis independently Ci-ealkoxy, Ci-ehaloalkoxy, cyano, Ci- ealkyl, Ci-ehaloalkyl, halo, hydroxyl, or oxo;m is 0-3; andn is 1-3.

[0017] In some embodiments:R1is H or alkyl;R2and R3are each independently H or alkyl;R4is H or alkyl;5MF-369911600Attorney Docket No.: 314352001641R5is an optionally substituted cyclic ring system that is fused or unfused, comprising at least one aromatic ring;each R6is independently alkyl, haloalkyl, haloalkoxy, halo, cyano, or alkoxy;R' is H, alkyl, or haloalkyl;Y is a bond, alkyl, -alkyl-NRy-alkyl- or -O-alkyl-, whereinRyis H or alkyl;ring F is 5-membered heteroaryl optionally substituted with one or more Rf, wherein each Rfis independently alkyl;ring G is optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, whereinring G is optionally substituted with one or more R8;each Rgis independently alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, or oxo;m is 0-3; andn is 1-3.

[0018] In some embodiments:R1is H or Ci-ealkyl;R2and R3are each independently H or Ci-6alkyl;R4is H or Ci-ealkyl;R5is an optionally substituted 5-20 membered cyclic ring system that is fused or unfused, comprising at least one 5-6 membered aromatic ring;each R6is independently Ci-6alkyl, Ci-ohaloalkyl, Ci-ehaloalkoxy, halo, cyano, or Ci- 6alkoxy;R7is H, Ci-ealkyl, or Ci-ohaloalkyl;Y is a bond, Ci-ealkyl, -Ci-6alkyl-NRy-Ci-6alkyl- or -O-Cj-salkyl-, wherein Ryis H or Ci-ealkyl;ring F is 5-membered heteroaryl optionally substituted with one or more Rf, wherein each Rfis independently Ci-ealkyl;ring G is optionally substituted phenyl, optionally substituted 5-6 membered heterocyclyl, or optionally substituted 5-6 membered heteroaryl, wherein6MF-369911600Attorney Docket No.: 314352001641ring G is optionally substituted with one or more Rg;each Rgis independently Cj-salkoxy, Ci -ehaloalkoxy, cyano, Ci- ealkyl, Ci-ehaloalkyl, halo, hydroxyl, or oxo;m is 0-3; andn is 1-3.

[0019] As used herein, “alky 1” refers to a monoradical unbranched or branched saturated hydrocarbon chain. In some embodiments, alkyl has 1 to 20 carbon atoms (z.e., C1-20 alkyl), 1 to 8 carbon atoms (i.e., Ci-s alkyl), 1 to 6 carbon atoms (z.e., Cj-6 alkyl), or 1 to 4 carbon atoms (z.e., C1-4 alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2 -hexyl, 3-hexyl, and 3 -m ethylpentyl. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons may be encompassed; thus, for example, “butyl” can include n-butyl, sec-butyl, isobutyl and t-butyl; “propyl” can include n-propyl and isopropyl. In some embodiments, “Ci+alkyl” refers to alkyl having at least 1 carbon atom, and includes, for example, methyl, ethyl, propyl, etc. Similarly, “Cj+alkyl” refers to alkyl having at least 2 carbon atoms, and includes, for example, ethyl, propyl, butyl, etc. In one variation, the alkyl is a C1-4 alkyl.

[0020] As used herein, “cycloalkyl” refers to a carbocyclic, non-aromatic group that is connected via a ring carbon atom, which contains only C and H when unsubstituted. The cycloalkyl may have one ring or multiple rings. In some variations, a cycloalkyl with more than one ring may be linked together by a C-C bond, fused, spiro or bridged, or combinations thereof. In some embodiments, cycloalkyl is a C3-10 cycloalkyl. In certain variations, the cycloalkyl is a C3-6 cycloalkyl. In one variation, cycloalkyl is cyclopropyl (C3) or cyclobutyl (C4).

[0021] “Haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moi eties attached. Examples of a haloalkyl group include di fluoromethyl (-CHF?) and trifluoromethyl (-CF3). It should be understood that trifluoromethyl (-CF3) may also be referred to as perfluoromethyl.

[0022] As used herein, “cyclic ring system” refers to any cyclic group. Unless otherwise stated, the cyclic ring system may have one ring or multiple rings. In some variations, a7MF-369911600Attorney Docket No.: 314352001641cyclic ring system with more than one ring may be fused, spiro or bridged, or combinations thereof. Each ring of the cyclic ring system may independently be saturated or unsaturated. Each ring of the cyclic ring system may independently comprise no heteroatoms, or may comprise one or more heteroatoms. In some embodiments, the cyclic ring system may have one or more aromatic rings. In some embodiments, the aromatic ring is heteroaromatic.

[0023] In some variations, the cyclic ring system is a heteroaromatic ring system.“Heteroaromatic ring system” refers to (i) one heteroaromatic ring, or (ii) two or more rings forming a fused ring system, in which at least one of the rings has one or more ring heteroatoms and is aromatic. In some variations, the heteroaromatic ring system is a fused ring system with two or more rings, in which at least one of the rings is heteroaromatic. In some embodiments, the heteroatoms are selected from nitrogen, oxygen and sulfur. In certain embodiments, at least one heteroatom is nitrogen, and one or more of the remaining heteroatoms is selected from oxygen and sulfur. In some variations, the heteroaromatic ring system contains at least one nitrogen atom, or contains 1-4 nitrogen atoms.

[0024] It should be understood that a heteroaromatic ring system also includes a ring or a fused ring system that is not aromatic provided that its corresponding tautomeric form is aromatic. For example, exemplary moiety (A) below, having tautomeric form (B), is considered a heteroaromatic ring system. Examples of heteroaromatic rings systems having an aromatic tautomeric form include but are not limited to pyridin-2(lH)-one, pyrido[2,3-d]pyrimidin-7(8H)-one, 2,7-naphthyridin-l(2H)-one, l,6-naphthyridin-2(lH)-one, 1,8-naphthyridin-2(lH)-one, pyrido[3,4-b]pyrazin-5(6H)-one.

[0025] Benzoxazaborininols in the presence of water may be present as a neutral form or as an anionic form (generic, exemplary structures shown as A-l and B-l and C-l below; see also Kazmi, M. Z. H. et al J. Med. Chem, 2023, 66, 13768-13787 and Kazmi, M. Z. H. et al J. Am, Chem, Soc. 2021, 143, 27, 10143-10156). This disclosure is intended to capture different forms and covalent variants thereof that result from the different potential equilibriums of the A-l form. Both C-l and B-l forms are predicted in literature, more recent literature indicated above suggests that form B-l is the preferred conjugate base.8MF-369911600Attorney Docket No.: 314352001641(C-1) (A-1) (B-1)

[0026] Benzoxazaborininols inhibitors may interact with a biological target, such as ENPP1, by forming a covalent bond via the boron atom. These boron heterocycles may also inhibit the biological target by non-covalent interactions, non-exclusive examples include electrostatic, Van der Waals, or hydrogen bonding interactions. In some embodiments, benzoxazaborininols inhibitors may interact with the biological target resulting in inhibition by combinations of some or all of the different possible interactions.

[0027] The term “substituted”, in some variations, means that any one or more hydrogen atoms on the designated atom or group is replaced with a moiety other than hydrogen, provided that the designated atom’s normal valence is not exceeded.

[0028] The symbol whether as a bond or displayed perpendicular to a bond indicates the point at which the displayed moiety is attached to the remainder of the molecule. The symbol ------ indicates a single or double bond.R2R3R3

[0029] In some embodiments, the moiety represented byor R3R2R3. In some embodiments, the moiety represented byisR2 R3. In some embodiments, the moiety represented byisR2R3. In some embodiments, the moiety represented byisR2R3. In some embodiments, the moiety represented byis9MF-369911600Attorney Docket No.: 314352001641

[0030] In some embodiments,embodiments, RxIn some embodiments,Rxis R5-O-. In some embodiments, RxisIn some embodiments, Rxis

[0031] In some embodiments, provided is a compound of Formula (I):or a pharmaceutically acceptable salt thereof, whereinR1is H or alkyl;R2and R3are each independently H or alkyl;R4is H or alkyl;R5is an optionally substituted cyclic ring system that is fused or unfused, comprising at least one aromatic ring;each R6is independently alkyl, haloalkyl, halo, cyano, or alkoxy;R7is H, alkyl, or haloalkyl;m is 0-3; andn is 1-3,

[0032] In some embodiments, provided is a compound of Formula (I-A):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R3, R6, R', m, and n are as defined for a compound of Formula (A).10MF-369911600Attorney Docket No.: 314352001641

[0033] In some embodiments, provided is a compound of Formula (I-B):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are as defined for a compound of Formula (A).

[0034] In some embodiments, R4is H or alkyl. In some embodiments, R4is H. In some embodiments, R4is alkyl.

[0035] In some embodiments, provided is a compound of Formula (III):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6, R', m, and n are as defined for a compound of Formula (A).

[0036] In some embodiments, provided is a compound of Formula (III- A):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6, R7, m, and n are as defined for a compound of Formula (A).

[0037] In some embodiments, provided is a compound of Formula (III-B):11MF-369911600Attorney Docket No.: 314352001641or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6, R7, m, and n are as defined for a compound of Formula (A).

[0038] In some embodiments, R5is an optionally substituted cyclic ring system that is fused or unfused, comprising at least one aromatic ring. In some embodiments, the cyclic ring system is fused. In other embodiments, the cyclic ring system is unfused. In some embodiments, the at least one aromatic ring is aryl. In some embodiments, the at least one aromatic ring is phenyl. In some embodiments, the at least one aromatic ring is heteroaromatic. In some embodiments, the at least one aromatic ring is pyridyl or pyrimidinyl.

[0039] In some embodiments, R5is optionally substituted heteroaromatic ring system that is fused or unfused. In some embodiments, R3is optionally substituted heteroaromatic ring system that is fused. In some embodiments, R5is optionally substituted heteroaromatic ring system that is unfused. In some variations of the foregoing, R5is optionally substituted heteroaromatic ring system comprising 1-4 nitrogen atoms. In some embodiments, R5is un substituted. In other embodiments, R5is substituted with one or more groups independently selected from the group consisting of alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, oxo, O-phenyl, alkyl-O-alkyl, and -NRaRb, wherein each Raand Rbis independently H or alkyl. In some embodiments, R5is substituted with one or more groups independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo. In some embodiments, R3is substituted with one or more groups independently selected from the group consisting of methoxy, cyano, methyl, F, hydroxyl, and oxo. In some embodiments, R5is substituted with 1, 2, or 3 groups. In some embodiments, R5is substituted with 1 or 2 groups.

[0040] In other variations, R5is a fused heteroaromatic ring system represented by the formula:wherein:X1a, X2a, and X3aare each independently -CH- or -N-, wherein at least one of Xla, X2a, and X3ais -N-; and12MF-369911600Attorney Docket No.: 314352001641ring A is phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclyl,wherein the fused heteroaromatic ring system is optionally substituted with one or more substituents selected from the group consisting of alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, oxo, O-phenyl, alkyl-O-alkyl, and -NRaRb, wherein each Raand Rbis independently H or alkyl.13MF-369911600Attorney Docket No.: 314352001641some embodiments, each R? is optionally substituted with one or more groups independently selected from the group consisting of alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, oxo, O-phenyl, alkyl-O-alkyl, and -NRaRb, wherein each Raand Rbis independently H or alkyl.14MF-369911600Attorney Docket No.: 31435200164115MF-369911600Attorney Docket No.: 314352001641

[0043] In some embodiments, provided is a compound of Formula (I-C 1 ):or a pharmaceutically acceptable salt thereof, whereinYeais H, alkoxy, or halo;each Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano;Rlcand R2care each independently selected from the group consisting of O-phenyl, -alkyl- O-alkyl, and H, orRlcand R2care taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo; andR3, R6, R ', and m are as defined for a compound of Formula (A).16MF-369911600Attorney Docket No.: 314352001641

[0044] In some embodiments, provided is a compound of Formula (I-C):or a pharmaceutically acceptable salt thereof, whereineach Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano;Rlcand R2care each independently selected from the group consisting of -OPh, -alkyl-O- alkyl, and H, orRlcand R2Care taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo; andR3, R6, R7, and m are as defined for a compound of Formula (A).

[0045] In some embodiments, provided is a compound of Formula (III-C1):(in-ci) or a pharmaceutically acceptable salt thereof, whereinYcais H, alkoxy, or halo;each Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, alkyl- O-alkyl, and H, orRlcand R2eare taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo; andR3, R6, R7, and m are as defined for a compound of Formula (A).17MF-369911600Attorney Docket No.: 314352001641

[0046] In some embodiments, provided is a compound of Formula (III-C):or a pharmaceutically acceptable salt thereof, whereineach Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, alkyl- O-alkyl, and H, orR,cand R2eare taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo; andR3, R6, R7, and m are as defined for a compound of Formula (A).

[0047] In some embodiments, Ycais alkoxy. In some embodiments, Ycais methoxy. In some embodiments, Ycais hydrogen. In some embodiments, Ycais halo. In one variation, Ycais Cl.

[0048] In some embodiments, each Ycis -N-. In some embodiments, one Ycis -N- and the other is CH. In some embodiments, one Ycis -N- and the other is -C-CN.

[0049] In some embodiments, R2cis O-Ph (or O-phenyl) and Rlcis H.

[0050] In some embodiments, R,cand R2eare taken together to form a phenyl, 5 -or 6-membered heteroaryl, or 5- or 6-membered heterocyclyl optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo. In some embodiments, Rlcand R2care taken together to form a phenyl optionally substituted with alkoxy. In some embodiments, Rlcand R2care taken together to form a phenyl optionally substituted with methoxy. In some embodiments, Rlcand R2Care taken together to form a phenyl substituted once with methoxy and once with halo. In some embodiments, Rleand R2care taken together to form a phenyl substituted twice with methoxy. In some embodiments, Rlcand R2care taken together to form a pyrrolyl optionally substituted with alkyl. In some embodiments, Rlcand R2care taken together to form a pyrrolyl optionally substituted with methyl. In some embodiments, Ricand R2care18MF-369911600Attorney Docket No.: 314352001641taken together to form a ring having the structure,wherein each§indicates a point of attachment to the ring bearing the Ycgroups. In some embodiments, Rleand R2caretaken together to form a ring having the structure,wherein each5indicates a point of attachment to the ring bearing the Ycgroups. In some embodiments, Ricand R2care taken together to form a pyridinyl optionally substituted with hydroxyl or alkoxy. In some embodiments, Rlcand R2care taken together to form a pyridinyl substituted with methoxy. In some embodiments, Rlcand R2care taken together to form a pyrrolidinyl optionally substituted with oxo. In some embodiments, Rlcand R2eare taken together to form a tetrahydrofuranyl optionally substituted with oxo. In some embodiments, Rlcand R2care taken together to form a fused ring. In some embodiments, Ricand R2care taken together toform a fused ring, having a structure selected from the group consisting ofeach of which is optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein eachindicates a point of attachment to the ring bearing the Ycgroups.

[0051] In some embodiments, the moiety represented,19MF-369911600Attorney Docket No.: 314352001641

[0052] In some embodiments, provided is a compound of Formula (I-D):or a pharmaceutically acceptable salt thereof, wherein R3, R5, R6, R7, and m are as defined for a compound of Formula (A).R2R3R3

[0053] In some embodiments, the moiety represented by

[0054] In some embodiments, provided is a compound of Formula (II):or a pharmaceutically acceptable salt thereof, whereinR1is H or alkyl;R2and R3are each independently H or alkyl;each R6is independently alkyl, haloalkyl, haloalkoxy, halo, cyano, or alkoxy;R' is H, alkyl, or haloalkyl;Y is a bond, alkyl, -alkyl -NRy-alkyl- or -O-alkyl, whereinRyis H or alkyl;ring F is 5-membered heteroaryl optionally substituted with one or more Rf, wherein 20MF-369911600Attorney Docket No.: 314352001641each Rfis independently alkyl;ring G is optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, whereinring G is optionally substituted with one or more Rg,each Rgis independently alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, or oxo;m is 0-3; andn is 1-3.

[0055] In some embodiments, provided is a compound of Formula (II- A):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R6, R7, Y, ring F, ring G, m, and n are as defined for a compound of Formula (A).

[0056] In some embodiments, provided is a compound of Formula (II-B):or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R6, R7, Y, ring F, ring G, m, and n are as defined for a compound of Formula (A).

[0057] In some embodiments, Y is a bond, alkyl, -alkyl-NRy-alkyl- or -O-alkyl, wherein Ryis H or alkyl. In some embodiments, Y is a bond,

[0058] In some embodiments, ring F is 5-membered heteroaryl optionally substituted with one or more Rf, wherein each Rfis independently alkyl. In some embodiments, ring F is 5-membered heteroaryl comprising one or more N atoms, optionally substituted with one or more Rf. In some embodiments, ring F is pyrazolyl or triazolyl optionally substituted with one or more Rf. In some embodiments, ring F is triazolyl optionally substituted with one or more Rf. In some embodiments, ring G is optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl wherein ring G is optionally substituted with 21MF-369911600Attorney Docket No.: 314352001641one or more Rg; each Rgis independently alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, or oxo. In some embodiments. In some embodiments, ring G is phenyl or pyridyl, each optionally substituted with one or more RgIn some embodiments, ring G is substituted with 1, 2, or 3 Rggroups. In some embodiments, ring G is substituted with 1 or 2 Rggroups. In some variations, ring G is unsubstituted phenyl, unsubstituted heterocyclyl, or unsubstituted heteroaryl. In some embodiments, ring G is unsubstituted phenyl or unsubstituted pyridyl. In some embodiments, ring G is optionally substituted with 1 Rggroup, wherein Rgis alkoxy. In some embodiments, Rgis methoxy.R2R3

[0059] In some embodiments, the moiety represented byIn some embodiments, the moietyother embodiments, the moiety represented

[0060] In some embodiments, R1is H or alkyl. In some embodiments, R1is H. In some embodiments, R1is alkyl.

[0061] In some embodiments, R2and R3are each independently H or alkyl. In some embodiments, R2is H, and R3is H or alkyl. In some embodiments, R2is H, and R3is alkyl. In some embodiments, R2is H and R3is Ci-4 alkyl. In some embodiments, R2is H and R3is methyl. In some embodiments, each of R2and R3is H. In other embodiments, each of R2and R3is alkyl. In some embodiments, each of R2and R3is methyl.

[0062] In some embodiments, each R6is independently alkyl, haloalkyl, haloalkoxy, halo, cyano, or alkoxy. In some embodiments, each R6is independently Ci-ealkyl, cyano, Cj- 22MF-369911600Attorney Docket No.: 314352001641ehaloalkyl, Ci-ohaloalkoxy, halo, or Ci-ealkoxy. In some embodiments, R6is Ci-ealkyl. In some embodiments, R6is halo. In some embodiments, R6is Ci-ealkoxy, In some embodiments, R6is Ci-ehaloalkoxy. In some embodiments, R6is F, methyl, -OCH3, or - OCF2H.

[0063] In some embodiments, m is 0-3. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 1 and R6is methyl, methoxy, or F.

[0064] In some embodiments, R7is H, alkyl, or haloalkyl. In some embodiments, R7is H or C1- alkyl. In some embodiments, R7is H. In some embodiments, R7is alkyl. In some embodiments, R7is methyl. In some embodiments, R7is haloalkyl. In some embodiments, R7is CF3or CF2H.

[0065] In some embodiments, n is 1-3. In some embodiments, n is 1.

[0066] In some embodiments, the compound of formula (A) is a compound of formula (I), (I- A), (I-B), (I-C), (I-Cl), (I-D), (II), (II- A), (II-B), (III), (III- A), (III-B), (III-C), or (III-Cl), or a pharmaceutically acceptable salt thereof.

[0067] In some aspects, provided is a compound selected from a compound of Table 1 below, or a pharmaceutically acceptable salt thereof, including any isomers and tautomers thereof. In some variations of the foregoing compounds (e.g, in Table 1), the compounds are in salt form, such as hydrochloride (HQ) or trifluoroacetate salt.MF-369911600Attorney Docket No.: 314352001641Table 1. Exemplary CompoundsMF-369911600Attorney Docket No.: 31435200164125MF-369911600Attorney Docket No.: 31435200164126MF-369911600Attorney Docket No.: 314352001641MF-369911600Attorney Docket No.: 314352001641MF-369911600Attorney Docket No.: 314352001641MF-369911600Attorney Docket No.: 31435200164130MF-369911600Attorney Docket No.: 31435200164131MF-369911600Attorney Docket No.: 31435200164132MF-369911600Attorney Docket No.: 31435200164133MF-369911600Attorney Docket No.: 31435200164134MF-369911600Attorney Docket No.: 31435200164135MF-369911600Attorney Docket No.: 31435200164136MF-369911600Attorney Docket No.: 31435200164137MF-369911600Attorney Docket No.: 314352001641

[0068] The term “pharmaceutically acceptable salts” includes salts of the active compounds prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. In some embodiments, the salt is a hydrochloride (HC1) or trifluoroacetate salt.Preparation of Compounds

[0069] The compounds described herein may be prepared in accordance with the general synthetic schemes set forth below.

[0070] Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, e.g., Smith and March, March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001; or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).

[0071] Compounds as described herein can be purified by any purification protocol known in the art, including chromatography, such as HPLC, preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. In certain embodiments, the disclosed compounds are purified via silica gel and / or alumina chromatography. See, e.g., Introduction to Modem Liquid Chromatography, 2nd Edition, ed. L. R. Snyder and J. J. Kirkland, John Wiley and Sons, 1979; and Thin Layer Chromatography, ed E. Stahl, Springer- Verlag, New York, 1969.

[0072] During any of the processes for preparation of the subject compounds, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as J. F. W. McOmie, “Protective Groups in Organic Chemistry”, Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, in “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in “Methoden der organischen Chemie”, Houben-Weyl, 4th edition, Vol. 15 / 1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, “Aminosauren, Peptide, Proteine”, Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and / or in Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide and Derivate”, Georg Thieme 38MF-369911600Attorney Docket No.: 314352001641Verlag, Stuttgart 1974. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

[0073] The subject compounds, including compounds that are not commercially available, can be synthesized via a variety of different synthetic routes using commercially available starting materials and / or starting materials prepared by conventional synthetic methods. A variety of examples of synthetic routes that can be used to synthesize the compounds disclosed herein are described in the schemes below.

[0074] The starting materials and reagents employed in the schemes below may be obtained commercially or through conventional techniques. Some intermediates in one or more of the schemes below can be purchased or alternatively generated utilizing known literature procedures. The synthesis of the benzoxazaborininol core has been previously described by Kazmi, M. Z. H. et al J, Med. Chem, 2023, 66, 13768-13787 and Kazmi, M. Z. H. et al J. Am. Chem. Soc. 2021, 143, 27, 10143-10156. The schemes below provide examples of methods to generate the compounds of the present disclosure where the exact steps and materials will depend on the functional groups present. The selection of the starting materials, reagent, substrates, base, protecting group, solvent and leaving group are known to one of ordinary skilled in the art.39MF-369911600Attorney Docket No.: 314352001641Scheme ASynthesis of compounds of Formula (I)Key AmineIntermediateX. Rs-L.substitution or ''-^palladium coupling

[0075] It should be understood that for the formulae described in Scheme A above, X is O ff, Br or I; L is a suitable leaving group, such as X; and additional depicted variables are as defined herein.

[0076] One skilled in the art will understand that selection of n and the substituents R2and R3can allow for incorporation of the desired Boc-protected amine via a palladium catalyzed cross coupling. The depicted OH can then be converted to a tritiate, a non-limiting example is by use of PhNTfj and a base. One can incorporate the boronic acid, or an alternative suitable boronic ester, by using palladium coupling, with a non-limiting example using bis(pinacolato)diboron. The boron heterocycle can be formed by reaction with hydroxylamine. Removal of the Boc group will generate the Key Amine Intermediate.Conversion of the Key Amine Intermediate to a compound of Formula (I) can be achieved with many different approaches that can be envisioned by one skilled in the art. For example, a compound of Formula (I) may be prepared by reaction of the amine of the Key Amine Intermediate with R5bound to a leaving group (L) in the presence of a base, a non-limiting example of which is triethylamine. Alternatively, the compound of Formula (I) may be prepared by a palladium catalyzed cross coupling. When R4is alkyl, introduction of the R440MF-369911600Attorney Docket No.: 314352001641group may be accomplished by alkylation using base, some non-limiting examples are sodium hydride or potassium tert-butoxide, followed by treatment with R4-L.Scheme BSynthesis of Compound of Formula (I)

[0077] It should be understood that for the formulae described in Scheme B above, X is OTf, Br or I; L is a suitable leaving group, such as X; additional depicted variables are as defined herein.

[0078] Incorporation the boronic acid, or an alternative suitable boronic ester, may be accomplished by use of a palladium coupling reaction, utilizing, for example, bis(pinacolato)diboron. The depicted OH can then be converted to a triflate, a non-limiting example is by use of PhNTfz and a base. The boron heterocycle can then be formed by reaction with hydroxylamine. A Stille reaction can then be used to convert the triflate to the ethoxyvinyl substituent, which upon treatment with acid forms the corresponding ketone. A subsequent three step sequence comprising: (1) reactions of the (R)- or (S)-2-methylpropane-2-sulfinamide with Ti(OEtX (2) reduction with L-selectride, and (3) treatment with acid allows for production of the enantioenriched Key Amine Intermediate. Conversion of the enantioenriched Key Amine Intermediate to a compound of Formula (I) can be achieved with many different approaches that can be envisioned by one skilled in the art. For example, a compound of Formula I may be prepared by reaction of the amine of the Key Amine41MF-369911600Attorney Docket No.: 314352001641Intermediate with R5bound to a leaving group (L) in the presence of a base, a non-limiting example of which is tri ethyl amine. Alternatively, the compound of Formula (I) may be prepared by a palladium catalyzed cross coupling. When R4is alkyl, introduction of the R4group may be accomplished by alkylation using base, some non-limiting examples are sodium hydride or potassium tert-butoxide, followed by treatment with R4-L.Scheme CSynthesis of Compounds of Formula (II)

[0079] It should be understood that for the formulae described in Scheme C above, Ac is an acetyl group; L is a suitable leaving group, such as MsO, Cl, Br, and I; additional depicted variables are as defined herein.42MF-369911600Attorney Docket No.: 314352001641

[0080] Scheme C provides a method to generate compounds of Formula (II). One skilled in the art can envision alternate sequences, reagent and chemistries depending on the precise compound being synthesized. A bromo intermediate, can be converted to an acetate ester, such as by displacement with acetate, for example with potassium acetate. Palladium coupling will introduce the boronic acid, which alternatively may be present as a pinacol ester or similar variation. Contact of this intermediate with hydroxylamine will generate the desired 6-membered boron heterocycle in addition to converting the acetate ester to the corresponding alcohol. The corresponding alcohol can be converted to a leaving group, one non-limiting example is a methanesulfonate ester using methansulfonyl chloride. The leaving group can then be displaced with an azide source, such as sodium azide. There are multiple other possible reagents and methods to convert an alcohol to an azide and another direct, nonlimiting example is using diphenylphosphoryl azide with Mitsunobu conditions or with base depending on the alcohol reactivity. Formation of the heteroaromatic group proceeds with 'Click Chemistry' that is known to one skilled in the art. This chemistry uses metal catalysis, some non-limiting examples are copper or ruthenium (e.g. Cp*Ru(COD)Cl), which couples the azide to an alkyne to generate a triazole product.Scheme DSynthesis of Compounds of Formula (II)Formula (II)43MF-369911600Attorney Docket No.: 314352001641

[0081] It should be understood that for the formulae described in Scheme D above, L is a suitable leaving group, such as MsO, Cl, Br, and I; Xis Br, I, or OTf; additional depicted variables are as defined herein.

[0082] Scheme D provides an alternative method to generate compounds of Formula (II). One skilled in the art can envision alternate sequences, reagent and chemistries depending on the precise compound being synthesized. An alcohol starting material can be converted to a leaving group, such as a methanesulfonate ester using methansulfonyl chloride. The leaving group can then be displaced with an azide source, such as sodium azide. There are multiple other possible reagents and methods to convert an alcohol to an azide and another direct, non¬ limiting example is using diphenylphosphoryl azide with Mitsunobu conditions or with base depending on the alcohol reactivity. Formation of the heteroaromatic group with or without substitution proceeds with 'Click Chemistry' that is known to one skilled in the art. This chemistry uses copper or ruthenium catalysis (e.g. Cp*Ru(COD)Cl), which couples the azide to an alkyne to generate a triazole product. Palladium coupling can then introduce the boronic acid, which alternatively may be present as a pinacol ester or similar variation. Boron heterocycle formation by reaction with hydroxylamine will generate the compounds of Formula (II).Scheme ESynthesis of Compounds of Formula (III)

[0083] It should be understood that for the formulae described in Scheme E above, L is OTf, OMs, F, Cl, Br or I; and additional depicted variables are as defined herein.44MF-369911600Attorney Docket No.: 314352001641

[0084] Scheme E provides a method to generate compounds of Formula (III). One skilled in the art can envision alternate sequences, reagent and chemistries depending on the precise compound being synthesized. For example, forming the R5to O ether bond before installing the boron and forming the benzoxazaborininol ring system would be one non-limiting example of an alternate sequence. In Scheme E, the alcohol, as a non-limiting example as was generated in Scheme C, can be contacted with base, one non-limiting example is with potassium tert-butoxide, in a suitable solvent, a non-limiting example is THF, and then the resulting species is contacted with R5with a leaving group (L) resulting in SxAr displacement of the L group to generate compounds of Formula (III). Alternatively, as in Scheme C, the alcohol can be converted to a leaving group (L), one non-limiting example is a methanesulfonate ester using methansulfonyl chloride. Treatment of R’-OII, or a tautomer thereof, with a suitable base, a non-limiting example is sodium hydride, in a suitable solvent, a non-limiting example is DMF, followed by contact with the leaving group activated alcohol, or a halide version thereof, results in displacement by the oxygen of R’-OH and the formation of compounds of Formula (III).

[0085] Schemes A, B, C, D, and E are meant to be non-limiting examples only, and one of ordinary skill in the art will understand that alternate reagents, solvents, order of reactions or starting materials can be used to make compounds of the present disclosure and / or other intermediates or compounds contained herein. The Examples and Schemes described herein may be utilized together to inform additional and alternative synthetic schemes.

[0086] Compounds of the invention can exist in particular geometric or stereoisomeric forms. The invention contemplates all such compounds, including cis - and trans -isomers, (-)- and (+)-enantiomers, (R)~ and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, as falling within the scope of the invention. In some variations, the compound of Formula (I), (I-A), (I-B), (I-C), (I-CI), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-C 1), or a compound in Table 1, is an (R)-enantiomer. In some variations, the compound of Formula (I), (I-A), (I-B), (I-C), (I-Cl), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-C 1), or a compound in Table 1, is an (S)-enantiomer. In some embodiments, the subject matter described herein is directed to a composition comprising a compound of formula (I), (I-A), (I-B), (I-C), (I-Cl), (I-D), (II), (II-A), (II-B), (III), (III-A), (III-B), (III-C), or (III-C 1 ), or a compound in Table 1, wherein the compound is present as a mixture of (R) and (S) enantiomers. In some variations, the mixture45MF-369911600Attorney Docket No.: 314352001641is a racemic mixture. Additional asymmetric carbon atoms can be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.Pharmaceutical Compositions

[0087] In certain aspects, provided is a pharmaceutical composition comprising any of the compounds disclosed herein, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient. Such compounds include the compounds of Formula (A), as well as the compounds of Table 1, or pharmaceutically acceptable salts thereof. Such compounds include the compounds of Formula (I), (I-A), (I-B), (I-C), (I-CI), (I-D), (II), (II-A), (II-B), (III), (III- A), (III-B), (III-C), or (III-C 1), and any variations thereof, as well as the compounds of Table 1, or pharmaceutically acceptable salts thereof.

[0088] The term “pharmaceutically acceptable excipient” refers to an excipient that is not biologically or otherwise undesirable; for example, the material may be added to a pharmaceutical composition and administered to a subject without causing significant undesirable effects.

[0089] The compounds or phar aceutical compositions of the present disclosure may be administered by various methods including, for example, oral, rectal, buccal, intranasal, and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

[0090] Compounds and phar aceutical compositions of the present disclosure may be administered to individuals in any form of generally accepted oral compositions (for example, tablets, coated tablets, gel capsules in a hard or in soft shell, emulsions or suspensions).Methods of Treatment

[0091] In certain aspects, provided is a method of treating a disease, disorder or condition in a subject in need thereof, comprising administering a therapeutically effective amount of any of the compounds, or pharmaceutically acceptable salts thereof, or compositions, including pharmaceutical compositions, described herein. In some variations, the method46MF-369911600Attorney Docket No.: 314352001641treats a disease, disorder or condition mediated by inhibition of ENPP1. In some variations, the method treats a disease, disorder or condition mediated by inhibition of ENPP1 and / or ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3). In one variation, the method treats a disease, disorder or condition mediated by inhibition of both ENPP1 and ENPP3 In some embodiments, the subject is a human. Such compounds include the compounds of Formula (I), (I- A), (I-B), (I-C), (I-C 1), (I-D), (II), (II- A), (II-B), (III), (III- A), (III-B), (III-C), or (I I I-C I ), and any variations thereof, as well as the compounds of Table 1 and in the Examples, or pharmaceutically acceptable salts thereof. In some variations, the compound, or a pharmaceutically acceptable salt thereof, is a dual ENPP1 / ENPP3 inhibitor.

[0092] In some variations of the foregoing, the disease, disorder or condition is cancer. In a certain variation, the cancer is a solid tumor. In other variations, the cancer is cervical cancer, colorectal cancer, lung cancer, prostate cancer, esophageal cancer, liver cancer, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, or breast cancer. In other vari ations of the foregoing, the disease, disorder or condition is an inflammatory disease, a metabolic disease, or a microbial infection, e.g., mediated by ENPP1. In other variations of the foregoing, the disease, disorder, or condition is an inflammatory disease, a metabolic disease, or a microbial infection, e.g., mediated by ENPP1 and / or ENPP3 In one variation of the foregoing, the disease, disorder, or condition is an inflammatory disease, a metabolic disease, or a microbial infection, e.g., mediated by both ENPP1 and ENPP3. In other variations, the disease, disorder or condition is an autoimmune disease or an autoinflammatory disease. In certain embodiments, the autoimmune disease is systemic lupus erythematosus (SLE). In other variations of the foregoing, the disease, disorder or condition is hypophosphatasia (IFPP). HPP is a rare inherited metabolic disorder that causes weak, soft bones and teeth due to a lack of the enzyme alkaline phosphatase (ALP). In certain variations, the disease, disorder or condition is a cardiovascular disease. In certain variations, the cardiovascular disease is myocardial infarction. In certain variations, the compound, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition as described herein augments cardiac repair and postinfarct heart function. In one variation, the methods provided herein may treat any combinations of the diseases, disorders and conditions described.

[0093] In some variations, the term “therapeutically effective” applied to dose or amount refers to that quantity of a compound or pharmaceutical formul tion, such as those described elsewhere herein, that is sufficient to result in a desired clinical benefit after administration to47MF-369911600Attorney Docket No.: 314352001641a patient in need thereof. It is to be understood that an effective amount may be in one or more doses, e.g., a single dose or multiple doses may be needed to achieve the desired treatment endpoint.

[0094] The specific safe and effective amount or therapeutically effective amount will vary' with such factors as the particular condition being treated, the physical condition of the subject, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.

[0095] The terms “treating” or “treatment”, as used herein, refer to a method or procedure for obtaining beneficial or desired results — for example, clinical results. Beneficial or desired results may include: (1) alleviating one or more symptoms caused by or associated with a disease, disorder, or condition; (2) reducing the extent of the disease, disorder, or condition; (3) slowing or stopping the development or progression of one or more symptoms caused by or associated with the disease, disorder, or condition (for example, stabilizing the disease, disorder, or condition); and (4) relieving the disease, for example, by causing the regression of one or more clinical symptoms (e.g., ameliorating the disease state, enhancing the effect of another medication, delaying or stopping the progression of the disease, increasing the quality of life, and / or prolonging survival rates).

[0096] In some embodiments, provided herein is the use of a compound or a pharmaceutical composition, as described elsewhere herein, in any of the methods described elsewhere herein. In other embodiments, provided herein is a compound or a pharmaceutical composition, as described elsewhere herein, for use in the manufacture of a medicament for use in any of the methods described elsewhere herein. In other embodiments, provided herein is a compound or a pharmaceutical composition, as described elsewhere herein, for use in any of the methods described herein.

[0097] In certain aspects, articles of manufacture are also provided herein, wherein the article of manufacture comprises any of the compounds, or pharmaceutically acceptable salts thereof, or compositions, including pharm ceutical compositions, described herein, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, or intravenous bag.

[0098] The present disclosure further provides kits for carrying out the methods of the invention. The kits may comprise any of the compounds, or pharmaceutically acceptable salts thereof, or compositions, including pharmaceutical compositions, described herein, and48MF-369911600Attorney Docket No.: 314352001641suitable packaging. The kits may comprise one or more containers comprising any compound described herein. In one aspect, a kit includes a compound of the disclosure or a pharmaceutically acceptable salt thereof, and a label and / or instructions for use of the compound in the treatment of a disease or condition described herein. The kits may comprise a unit dosage form of the compound.

[0099] In certain aspects, provided herein are articles of manufacturing (such as kits), comprising: (i) an effective amount of any of the compounds, or pharmaceutically acceptable salts thereof, or compositions, including pharmaceutical compositions, described herein; and (ii) instructions for use in treating a disease or condition described herein.ENUMERATED EMBODIMENTS

[0100] The following Enumerated Embodiments are representative of some aspects of the invention.

[0101] Embodiment 1. A compound of Formula (A):or a pharmaceutically acceptable salt thereof, wherein:R1is H or alkyl;R2and R3are each independently H or alkyl;R4is H or alkyl;R5is an optionally substituted cyclic ring system that is fused or unfused, comprising at least one aromatic ring;each R6is independently alkyl, haloalkyl, haloalkoxy, halo, cyano, or alkoxy;R' is H, alkyl, or haloalkyl;Y is a bond, alkyl, -alkyl-NRy-alkyl- or -O-alkyl-, whereinRyis H or alkyl;49MF-369911600Attorney Docket No.: 314352001641ring F is 5-membered heteroaryl optionally substituted with one or more R\ wherein each R1is independently alkyl;ring G is optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, whereinring G is optionally substituted with one or more Rg;each Rgis independently alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, or oxo;m is 0-3; andn is 1-3.

[0102] Embodiment 2, The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein the at least one aromatic ring of R5is heteroaromatic.

[0103] Embodiment 3. The compound of Embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I):or a pharmaceutically acceptable salt thereof.

[0104] Embodiment 4. The compound of any one of Embodiments 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-A):or a pharmaceutically acceptable salt thereof.

[0105] Embodiment 5. The compound of any one of Embodiments 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-B):50MF-369911600Attorney Docket No.: 314352001641or a pharmaceutically acceptable salt thereof.

[0106] Embodiment 6. The compound of any one of Embodiments 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroarom tic ring system that is unfused.

[0107] Embodiment 7. The compound of any one of Embodiments 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R3is optionally substituted heteroaromatic ring system that is fused.

[0108] Embodiment 8. The compound of any one of Embodiments 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system comprising 1-4 nitrogen atoms.

[0109] Embodiment 9. The compound of any one of Embodiments 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R3is substituted with one or more groups independently selected from the group consisting of alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, oxo, O-phenyl, alky 1-0 -alkyl, and -NRaRb, wherein each Raand Rbis independently H or alkyl.

[0110] Embodiment 10. The compound of any one of Embodiments 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R3is substituted with one or more groups independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

[0111] Embodiment 11. The compound of any one of Embodiments 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with 1, 2, or 3 groups.

[0112] Embodiment 12. The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt thereof wherein R3is51MF-369911600Attorney Docket No.: 314352001641each optionally substituted; or wherein R? is52MF-369911600Attorney Docket No.: 314352001641

[0113] Embodiment 13. The compound of any one of Embodiments 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R4is H.

[0114] Embodiment 14. The compound of any one of Embodiments 1 to 13, or aR2R3pharmaceutically acceptable salt thereof, wherein the moiety represented by, is(wherein n:::l).

[0115] Embodiment 15. The compound of any one of Embodiments 1, and 3 to 14, or a pharmaceutically acceptable salt thereof wherein the compound is a compound of:(i) Formula (I-Cl):or a pharmaceutically acceptable salt thereof, whereinYcais H, alkoxy, or halo;53MF-369911600Attorney Docket No.: 314352001641each Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, alkyl- O-alkyl, and H, orRlcand R2Care taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo; or(ii) Formula (I-C):or a pharmaceutically acceptable salt thereof, whereineach Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, alkyl- O-alkyl, and H, orR,cand R2eare taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

[0116] Embodiment 16. The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formul a (II):or a pharmaceutically acceptable salt thereof.

[0117] Embodiment 17. The compound of Embodiment 1 or 16, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (II-A):54MF-369911600Attorney Docket No.: 314352001641or a pharmaceutically acceptable salt thereof.

[0118] Embodiment 18. The compound of Embodiment 1 or 16, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (II-B):or a pharmaceutically acceptable salt thereof.

[0119] Embodiment 19. The compound of any one of Embodiments 1, and 16 to 18, or a pharmaceutically acceptable salt thereof, wherein ring F is triazolyl optionally substituted with one or more Rf.

[0120] Embodiment 20. The compound of any one of Embodiments 1, and 16 to 19, or a pharmaceutically acceptable salt thereof, wherein Y is a bond.

[0121] Embodiment 21. The compound of any one of Embodiments 1, and 16 to 20, or a pharmaceutically acceptable salt thereof, wherein ring G is phenyl or pyridyl, each optionally substituted with one or more R8

[0122] Embodiment 22. The compound of any one of Embodiments 1, and 16 to 21, or a pharmaceutically acceptable salt thereof, wherein ring G is optionally substituted with 1 or 2 Rsgroups.

[0123] Embodiment 23. The compound of any one of Embodiments 1, and 16 to 22, or a R2R3pharmaceutically acceptable salt thereof, wherein the moiety represented by(wherein n=l).55MF-369911600Attorney Docket No.: 314352001641

[0124] Embodiment 24. The compound of Embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (III):or a pharmaceutically acceptable salt thereof.

[0125] Embodiment 25. The compound of any one of Embodiments 1, 2, and 24, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (III-A):or a pharmaceutically acceptable salt thereof.

[0126] Embodiment 26. The compound of any one of Embodiments 1, 2, and 24, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (III-B):or a pharmaceutically acceptable salt thereof.

[0127] Embodiment 27. The compound of any one of Embodiments 1, 2, and 24 to 26, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system that is unfused.

[0128] Embodiment 28. The compound of any one of Embodiments 1, 2, and 24 to 26, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system that is fused.56MF-369911600Attorney Docket No.: 314352001641

[0129] Embodiment 29. The compound of any one of Embodiments 1, 2, and 24 to 28, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system comprising 1-4 nitrogen atoms.

[0130] Embodiment 30. The compound of any one of Embodiments 1, 2, and 24 to 29, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with one or more groups independently selected from the group consisting of alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, oxo, O-phenyl, alkyl-O-alkyl, and -NRaRb, wherein each Raand Rbis independently H or alkyl.

[0131] Embodiment 31. The compound of any one of Embodiments 1, 2, and 24 to 30, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with one or more groups independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

[0132] Embodiment 32. The compound of any one of Embodiments 1, 2, and 24 to 31, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with 1, 2, or 3 groups.

[0133] Embodiment 33. The compound of any one of Embodiments 1, 2, and 24 to 32, or a pharmaceutically acceptable salt thereof, wherein R5is:57MF-369911600Attorney Docket No.: 314352001641

[0134] Embodiment 34. The compound of any one of Embodiments 1, 2, and 24 to 33, or R2R3a pharmaceutically acceptable salt thereof, wherein the moiety represented by,(wherein n=l).

[0135] Embodiment 35. The compound of any one of Embodiments 1, and 24 to 34, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of:(i) Formula (III-C1):or a pharmaceutically acceptable salt thereof, whereinYcais H, alkoxy, or halo;each Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, alkyl- O-alkyl, and H, orR,cand R2eare taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo; or58MF-369911600Attorney Docket No.: 314352001641(ii) Formula (III-C):or a pharmaceutically acceptable salt thereof, whereineach Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, al ky 1 - O-alkyl, and H, orRlcand R2care taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

[0136] Embodiment 36. The compound of any one of Embodiments 1 to 14, and 16 to 34, or a pharmaceutically acceptable salt thereof, wherein Rlis H.

[0137] Embodiment 37. The compound of any one of Embodiments 1 to 36, or a pharmaceutically acceptable salt thereof, wherein m is 0.

[0138] Embodiment 38. The compound of any one of Embodiments 1 to 37, or a pharmaceutically acceptable salt thereof, wherein m is 1 and R6is methyl, methoxy, or F.

[0139] Embodiment 39. The compound of any one of Embodiments 1 to 38, or a pharmaceutically acceptable salt thereof, wherein R7is H.

[0140] Embodiment 40. The compound of any one of Embodiments 1 to 38, or a pharmaceutically acceptable salt thereof, wherein R' is methyl.

[0141] Embodiment 41. The compound of any one of Embodiments 1 to 38, or a pharmaceutically acceptable salt thereof, wherein R' is CF3 or CF2H.

[0142] Embodiment 42. The compound of any one of Embodiments 1 to 41, or a pharmaceutically acceptable salt thereof, wherein each R2is H, and each RJis independently H or alkyl.

[0143] Embodiment 43. The compound of any one of Embodiments 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R2is H, and each R3is methyl.59MF-369911600Attorney Docket No.: 314352001641

[0144] Embodiment 44. The compound of any one of Embodiments 1 to 42, or a pharmaceutically acceptable salt thereof, wherein R2and R3are each H.

[0145] Embodiment 45. The compound of any one of Embodiments 1 to 13, 16 to 22, 24 to 33, and 36 to 44, or a pharmaceutically acceptable salt thereof, wherein n is 1.

[0146] Embodiment 46. A compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0147] Embodiment 47. A pharmaceutical composition, comprising:a compound of any one of Embodiments 1 to 46, or a pharmaceutically acceptable salt thereof; andat least one pharmaceutically acceptable excipient.

[0148] Embodiment 48. A method of inhibiting ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) in a subject in need thereof, comprising: administering to the subject a compound of any one of Embodiments 1 to 46, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition of Embodiment 47; or,a method of inhibiting ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) and / or ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3) in a subject in need thereof, comprising:administering to the subject a compound of any one of Embodiments 1 to 46, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition of Embodiment 47;

[0149] Embodiment 49. A method of treating a disorder, disease, or condition mediated by ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) in a subject in need thereof, comprising:administering to the subject a compound of any one of Embodiments 1 to 46, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition of Embodiment 47; or,60MF-369911600Attorney Docket No.: 314352001641a method of treating a disorder, disease, or condition mediated by ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) and / or ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP3) in a subject in need thereof, comprising:administering to the subject a compound of any one of Embodiments 1 to 46, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition of Embodiment 47.

[0150] Embodiment 50. The method of Embodiment 49, wherein the disorder, disease, or condition is cancer.

[0151] Embodiment 51. The method of Embodiment 50, wherein the cancer is a solid tumor.

[0152] Embodiment 52. The method of Embodiment 50, wherein the cancer is cervical cancer, colorectal cancer, lung cancer, prostate cancer, esophageal cancer, liver cancer, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, or breast cancer, or any combination thereof.

[0153] Embodiment 53. The method of Embodiment 49, wherein the disorder, disease, or condition is an inflammatory disease, a metabolic disease, or a microbial infection, or any combination thereof,

[0154] Embodiment 54. The method of Embodiment 49, the disease, disorder or condition is an autoimmune disease or an autoinflammatory disease.

[0155] Embodiment 55. The method of Embodiment 49, wherein the disorder, disease or condition is hypophosphatasia (HPP)

[0156] Embodiment 56. The method of Embodiment 49, wherein the disorder, disease, or condition is a cardiovascular disease.

[0157] Embodiment 57. The method of any one of Embodiments 48 to 56, wherein the subject is a human.

[0158] Embodiment 58. The method of Embodiment 48 or 49, wherein the compound, or a pharmaceutically acceptable salt thereof, is a dual ENPP1 / ENPP3 inhibitor.61MF-369911600Attorney Docket No.: 314352001641EXAMPLES

[0159] The presently disclosed subject matter will be better understood by reference to the following Examples, which are provided as exemplary of the invention, and not by way of limitation.Synthesis and Characterization of Exemplary Compounds

[0160] All solvents used were commercially available and were used without further purification. Starting materials used were either available from commercial sources or prepared according to literature procedures. Reactions were typically run using anhydrous solvents under an inert atmosphere such as N2. Reactions commonly used oven-dried glassware, and were stirred at ambient temperatures unless otherwise indicated.

[0161] Nuclear Magnetic Resonance (NMR) spectroscopy was commonly performed at 400 MHz using a commercially available spectrometer,13C and19F NMR were typically recorded at 400 MHz for proton, 100 MHz for carbon-13, and 376 MHz for fluorine-19. Deuterated solvents that contained 0.03% to 0.05% v / v tetramethylsilane set that reference signal to 0.00 ppm for both1H and13C or alternatively for1HNMR the residual H signal for the solvent was used as a secondary reference (for example, DMSO-ds signal in DMSO-de was set to 2.50 ppm or CHCI3 in CDCI3 set to 7.26 ppm for the1HNMR). The19FNMR chemical shifts are in relation to CFCI3 (0 ppm). In certain instances, automated NMR processing tools were used to extract spectral parameters including chemical shifts, coupling constants, and proton numbers from NMR spectra.

[0162] Combined liquid chromatography - mass spectra (LC / MS) analyses were commonly performed on commercially available equipment under acidic or basic conditions, or using any other suitable methods and techniques known in the art.

[0163] Typical high-performance liquid chromatography (HPLC) analyses were performed on commercially available equipment under acidic or basic conditions, or using any other suitable methods and techniques known in the art.

[0164] Preparative chromatography was usually performed using commercially available purification system using acidic or basic conditions, or using any other suitable methods and techniques known in the art.

[0165] Compounds are named using ChemDraw 23.0 or 23.1, or 1UPAC nomenclature or if commercially available their catalogue or common name. Abbreviations consistent with 62MF-369911600Attorney Docket No.: 314352001641that found in the organic chemistry literature were used. Some non-exclusive examples are the following: Ac (acetyl), AcOH (acetic acid), ACN or MeCN (acetonitrile), ADMP (2-azido-l,3-dimethylimidazolinium hexafluorophosphate), AIBN (azobi si sobutyronitrile), Boc (tert-butyloxy carbonyl), BOC2O (di -tert-butyl di carbonate), B(Oi Pr)s, BOP (benzotri azol- 1-yloxytris(dimethylamino)phosphonium hexafluorophosphate), B2(Pin)2 (bis(pinacolato)diboron or 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane)), BPO (benzoyl peroxide), tBuOH (tert-butanol), nBuLi (n-butyl lithium), Cp*Ru(COD)Cl (chloro(pentamethylcyclopentadienyl)(cyclooctadiene) ruthenium(II)), DCE (1,2-di chloroethane), DCM (dichloromethane), DIAD (diisopropyl azodicarboxylate), DIEA (N, N-diisopropylethylamine), dioxane (1,4-dioxane), DMF (N, N-dimethylformamide), DMP (l,l-bis(acetyloxy)-3-oxo-3H-lk5,2-benziodaoxol-l-yl acetate or Dess-Martin periodinane), DMSO (dimethylsulfoxide), EA or EtOAc (ethyl acetate), Et (ethyl), EtOH (ethanol), Et2O (diethyl ether), FA (formic acid), HCCP (hexachlorocyclotriphosphazene), HPLC (high- performance liquid chromatography), [lr(dtbbpy)(ppy)2]PF6 ([4,4'-bis(l,l-dimethylethyl)-2,2'-bipyridine-N 1, N1 ']bis[2-(2-pyridinyl-N)phenyl-C]iridium(III) hexafluorophosphate), KOAc or AcOK (potassium acetate), L-selectride (lithium tri-sec-butylhydroborate), Me (methyl), MeOH (methanol), MOMBr (bromo(methoxy)methane or bromomethyl methyl ether), MOM (methoxymethyl), Ms (methanesulfonyl), MsCl (methansulfonyl chloride), NBS (N-bromosuccinimide), NIS (N-iodosuccinimide), Pd / C (palladium on carbon), Pd(dppf)C12 ([l,r-bis(diphenylphosphino)ferrocene] dichloropalladium(II)), PE (petroleum ether), Ph (phenyl), Pd(OH)2 / C (palladium(II)hydroxide on carbon), prep-HPLC (preparative high-performance liquid chromatography), iPr (isopropyl), PPI13 (triphenyl phosphine), PyBOP (benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate), TBAF (tetra-n-butylammonium fluoride), TBDMSC1 or TBSC1 (tert-butyldimethylsilyl chloride), TMSCN (trimethyl silyl cyanide), TEA (tri ethyl amine), TFA (trifluoroacetic acid), Tf (trifluoromethylsulfonyl), TfjO (trifluoromethanesulfonic anhydride), THF (tetrahydrofuran), and THP (tetrahydropyranyl ).Example 1Synthesis of 4-(((1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)methyl)amino)-8-methoxyquinoline-3-carbonitrile63MF-369911600Attorney Docket No.: 314352001641

[0166] The compound above was synthesized using Scheme I.Scheme 1tert-Butyl (3-formyl-4-hydroxybenzyl)carbamate ( 1-3)

[0167] To a stirred solution of 5-bromo-2-hydroxybenzaldehyde (1-1) (1.0 g, 5.0 mmol, 1.0 equiv.) and potassium (((tert-butoxycarbonyl)amino)methyl)trifluoroborate (1-2) (1.3 g, 5.5 mmol, 1.1 equiv.) in 1,4-dioxane (10 mL) and H2O (1 mL) were added XPhos (474 mg, 1.0 mmol, 0.2 equiv.) and Pd(OAc)2 (112 mg, 0.5 mmol, 0.1 equiv.) in portions at room temperature. To the above mixture was added CS2CO3 (3.2 g, 9.9 mmol, 2.0 equiv.) in portions at room temperature. The resulting mixture was stirred at 80 °C overnight. The reaction mixture was concentrated under reduced pressure and the product was purified by silica gel column chromatography, by elution with PE / EA ( 1 / 1 ) to afford tert-butyl rV-[(3-formyl-4-hydroxyphenyl)methyl]carbamate (1-3) (700 mg, 58.4% yield) as a yellow solid.

[0168] LCMS (ESI): [M-H]': 2504-( ((tert-Biitoxycarbonyl)amino)methyl)-2-formylphenyl trifluoromethanesulfonate (1-4)

[0169] To a stirred solution of tert-butyl (3-formyl-4-hydroxybenzyl)carbamate (1-3) (3.0 g, 11.9 mmol, 1.0 equiv.) and 1,1,1-trifluoro-N-phenyl-N-(trifluoromethane)sulfonylmethanesulfonamide (12.8 g, 35.8 mmol, 3.0 equiv.) in DMF (30 mL) was added NaH (1.43 g, 35.8 mmol, 3.0 equiv., 60% purity) in portions at room temperature. The resulting mixture was stirred at room temperature for 6 hours. The reaction64MF-369911600Attorney Docket No.: 314352001641was quenched with ice water (80 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 50 mL), The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, by elution with PE / EA (1 / 1) to afford 4-(((tert-butoxycarbonyl)amino)methyl)-2-formylphenyl trifluoromethanesulfonate (1-4) (3.0 g, 65.5% yield ) as a yellow oil.

[0170] LCMS (ESI): [M+H]+: 328(4-(((tert-Butoxycarbonyl)amino)methyl)-2-formylphenyl)boronic acid (1-5)

[0171] To a stirred solution of 4-(((tert-butoxycarbonyl)amino)methyl)-2-formylphenyl trifluoromethanesulfonate (1-4) (3.0 g, 7.8 mmol, 1,0 equiv.) and Pin2B2 (4.9 g, 19.6 mmol, 2.5 equiv.) in 1,4-dioxane (50 mL) were added Pd(PPh3)2Cl2 (549 mg, 0.8 mmol, 0.1 equiv.) and AcOK (2.3 g, 23.5 mmol, 3.0 equiv.) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 80 °C overnight under nitrogen atmosphere. The product was purified by reversed -phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 0% to 100% gradient in 35 min; detector, UV 254 nm. This resulted in (4-(((tert-butoxycarbonyl)amino)methyl)-2-formylphenyl)boronic acid (1-5) (1.9 g, 87.0% yield) as a yellow oil.

[0172] LCMS (ESI): [M+H]+: 280tert-Butyl ((1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)methyl)carbamate (1-6)

[0173] To a stirred solution of (4-(((tert-butoxycarbonyl)amino)methyl)-2- formylphenyl)boronic acid (1-5) (1,3 g, 4.6 mmol, 1.0 equiv.) and H2O (6 mL) in THF (6 mL) was added hydroxylamine hydrochloride (971 mg, 13.9 mmol, 3.0 equiv.) in portions at room temperature. The resulting mixture was stirred at 30 °C for 1 hour. The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in tert-butyl ((l-hydroxy-l / 7-benzo[<7][l,2,6]oxazaborinin-6-yl)methyl)carbamate (1-6) (1.1 g, 85.5% yield) as a yellow oil. This material was used in the next step without further purification.

[0174] LCMS (ESI): [M+H]+: 2776-(Aminomethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol, hydrochloride salt (1-7)65MF-369911600Attorney Docket No.: 314352001641

[0175] A solution of fert-butyl ((l-hydroxy-l / 7-benzo[< ][l,2,6]oxazaborinin-6-yl)methyl)carbamate (1-6) (1,7 g, 6.2 mmol, 1,0 equiv.) in HC1 in 1,4-dioxane (4.0 M, 20 mL) was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. This resulted in 6-(aminomethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol, hydrochloride (1-7) (1.7 g, crude) as a yellow solid, which was used directly in the next step without further purification.

[0176] LCMS (ESI): [M+H]+: 1774-{[(1-Hydroxy-2,3,1-benzoxazaborinin-6-yl)methyl]amino}-8-methoxyquinoline-3-carbonitrile hydrochloride (1)

[0177] A mixture of 6-(aminomethyl)-2,3, 1 -benzoxazaborinin-l-ol, hydrochloride (1-7) (350 mg, 1.9 mmol, 1.0 equiv.), K2CO3 (825 mg, 5.9 mmol, 3.0 equiv.), KF (347 mg, 5.9 mmol, 3,0 equiv.) and 4-chloro-8-methoxyquinoline-3-carbonitrile (1-8) (522 mg, 2.4 mmol, 1.2 equiv.) in DMSO (5 mL) was stirred at room temperature for 4 hours. The product was purified by reversed-phase flash chromatography with the following conditions: Column: XSelect CSH Phenyl-Hexyl OBD Prep Column, 5 pm, 30 mm X 150 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 17%B in 8 min; Wave Length: 254 nm / 220 nm; RT1 (min): 6.42. This resulted in 4-{[(1-hydroxy-2,3,1-benzoxazaborinin-6-yl)methyl]amino}-8-methoxyquinoline-3-carbonitrile hydrochloride (1) (46.3 mg, 5.8% yield) as a white solid.

[0178] LCMS (ESI): [M-H]‘: 359

[0179] ’HNMR (400 MHz, DMSCWe) 6 10.79 (s, 1H) 8.86 (s, 1H), 8.49 (d, J= 8.6 Hz, 1H), 7.83 (t, J= 8.3 Hz, 1H), 7.76 (dd, J = 7.8, 1.7 Hz, 1H), 7.73 - 7.65 (m, 2H), 5.41 (d, J= 6.5 Hz, 2H), 4.10 (s, 5H).Example 2Synthesis of 4-((1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)amino)-8-methoxyquinoline-3-carbonitrile2

[0180] The compound above was synthesized using Scheme 2.66MF-369911600Attorney Docket No.: 314352001641Scheme 2tert-Butyl N'-[(4-formyl-3-hydroxyphenyl)methyl]carbamate (2-3)

[0181] To a stirred solution of 4-bromo-2-hydroxybenzaldehyde (2-1 ) (5.0 g, 24.8 mmol, 1.0 equiv.) and potassium (((tert-butoxycarbonyl)amino)methyl)trifluoroborate (2-2, 1-2 in Scheme 1) (8.8 g, 37.3 mmol, 1.5 equiv.) in dioxane / H2O (200 mL / 20 mL) were added Pd(PPh3)2C12 (1.7 g, 2.4 mmol, 0.1 equiv.) and CS2CO3 (24.3 g, 74.6 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was heated to 80 °C overnight under nitrogen atmosphere. The resulting mixture was diluted with water (100 mL) and then extracted with EtOAc (3 x lOOmL). The combined organic layers were washed with brine (2 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, by elution with PE / EA (1 / 1) to afford te / 7-butyl A-[(4-formyl-3-hydroxyphenyl)methyl]carbamate (2-3) (5.6 g, 89.6% yield) as a yellow solid.

[0182] LCMS (ESI): [M-H]’: 250tert-Butyl N-{[4-forinyl-3-(trifluoromethanesulfonyloxy)phenyl]methyl}carbamate (2-4)

[0183] To a stirred solution of tert-butyl A-[(4-formyl-3-hydroxyphenyl)methyl]carbamate (2-3) (5.6 g, 22.2 mmol, 1.0 equiv.) and l,l,l-trifluoro- / V-phenyl-Ar-(trifluoromethane)sulfonylmethanesulfonamide (19.9 g, 55.7 mmol, 2.5 equiv.) in THF (200 mL) was added CS2CO3 (21.8 g, 66.8 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature overnight under nitrogen atmosphere. The resulting mixture was diluted with water (100 mL) and then extracted with EtOAc (3 x 100mL). The combined organic layers were washed with brine (2 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, by elution with PE / EA (1 / 1) to afford tert-butyl ’-{[4-fomiyl-3-67MF-369911600Attorney Docket No.: 314352001641(trifluoromethanesulfonyloxy)phenyl]methyl}carbamate (2-4) (9.0 g crude) as a yellow oil, which was used directly in the next step without further purification.5-{[(tert-Butoxycarbonyl)amino]methyl}-2-formylphenylboronic acid (2-5)

[0184] To a stirred solution of / er / -butyl N-{ [4-formyl-3-(trifluoromethanesulfonyloxy)phenyl]methyl} carbamate (2-4) (9.0 g, 23.4 mmol, 1.0 equiv.) and B2Pin2 (8.9 g, 35.2 mmol, 1.5 equiv.) in 1,4-dioxane (200 mL) were added KOAc (5.8 g, 58.6 mmol, 2.5 equiv.) and Pd(PPh3)2Cl2 (1.6 g, 2.3 mmol, 0.1 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was heated to 80 °C overnight under nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with EtOAc (2 x 10 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase combi-flash chromatography with the following conditions: column, C18; mobile phase, MeCN in Water, 50% to 100% gradient in 10 min; detector, UV 254 nm to afford 5-{[(tert-butoxycarbonyl)amino]methyl}-2-formylphenylboronic acid (2-5) (7.3 g, crude) as a brown oil, which was used directly in the next step without further purification.

[0185] LCMS (ESI): [M-H]": 278tert-Butyl N-[(1-hydroxy-2,3,1-benzoxazaborinin-7-yl)methyl]carbamate (2-6)

[0186] To a stirred solution of 5-{[(tert-butoxycarbonyl)amino]methyl}-2-formylphenylboronic acid (2-5) (7.3 g, 26.1 mmol, 1.0 equiv.) in THF / H2O (50 mL / 50 mL) was added hydroxylamine hydrochloride (5.5 g, 78.4 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere The resulting mixture was stirred at room temperature for 2 hours under nitrogen atmosphere. The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford tert-butyl N-[(1-hydroxy-2,3,1-benzoxazaborinin-7-yl)methyl]carbamate (2-6) (7.0 g, 96.9% yield) as a yellow solid.

[0187] LCMS (ESI): [M+H]+: 2777 -(Aminomethyl) -2, 3, 1-benzoxazaborinin-l-ol (2-7)

[0188] A solution of / er / -butyl A-[(l-hydroxy-2,3, l-benzoxazaborinin-7-yl)methyl]carbamate (2-6) (1.2 g, 4.3 mmol, 1.0 equiv.) in HC1 (4 M in 1,4-dioxane, 10 mL) was stirred at room temperature for 2 hours under nitrogen atmosphere. The resulting mixture was concentrated under vacuum to afford 7-(aminomethyl)-2, 3, 1-benzoxazaborinin-l-ol,68MF-369911600Attorney Docket No.: 314352001641hydrochloride salt (2-7) (1.0 g crude) as a light brown solid, which was used directly in the next step without further purification.

[0189] LCMS (ESI): [M+H]+: 1774-{[( 1 -Hydroxy-2, 3, 1-benzoxazaborinin- 7-yl)methyl ]amino}-8-methoxyquinoline-3-carbonitrile (2)

[0190] To a stirred solution of 4-chloro-8-methoxyquinoline-3 -carbonitrile (2-8) (200 mg, 0.9 mmol, 1.0 equiv.) and 7-(aminomethyl)-2,3,l-benzoxazaborinin-l-ol, hydrochloride salt (2-7) (322 mg, 1.8 mmol, 2.0 equiv.) in DMSO (6 mL) were added TEA (462 mg, 4.5 mmol, 5.0 equiv.) and KF (160 nig, 2.7 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature overnight under nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The product was purified by Prep-HPLC with the following conditions: Column: YMC Triart Cl 8 ExRs 5 pm, 30 mm * 150 mm; Mobile PhaseWater (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 niL / min; Gradient (B%): 8% B to 20% B in 8min; Wave Length:254 / 220 nm; RT1 (min): 6.83. This resulted in 4-{[(l -hydroxy-2, 3, l-benzoxazaborinin-7-yl)methyl]amino}-8-methoxyquinoline-3-carbonitrile (2) (117.1 mg, 35.7% yield) as a white solid.

[0191] LCMS (ESI): [M+H]+: 359

[0192] 'HNMR (400 MHz, DMSO-r / 6) 69.34 (s, 1H), 8.69 (t, J= 6.6 Hz, 1H), 8.62 (s, 1H), 8.39 (s, 1H), 8.00 (t, J= 4.4 Hz, 2H), 7.75 (d, J= 2.2 Hz, 2H), 7.56 (t, J = 8.2 Hz, 1H), 7.31 (d, J = 7.8 Hz, IH), 5.18 (d, J= 6.1 Hz, 2H), 3.93 (s, 3H).Example 3Synthesis of 4-(((1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one

[0193] The compound was synthesized using Scheme 3.69MF-369911600Attorney Docket No.: 314352001641Scheme 3.Methyl (E)-3-(4, 6-dichloropyrimidm-5-yl)acrylate (3-2B)

[0194] A solution of 4,6-dichloropyrimidine-5-carbaldehyde (3-2A) (2.0 g, 11.3 mmol, 1.0 equiv.) and methyl 2-(triphenyl-15-phosphaneylidene)acetate (4.5 g, 13.6 mmol, 1.2 equiv.) in tetrahydrofuran (50 mL) was stirred at room temperature for 24hours under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by silica gel column chromatography, by elution with PE / EA (5 / 1) to afford methyl (E)-3-(4,6-dichloropyrimidin-5-yl)acrylate (3-2B) (1.5 g, 57.0% yield) as a white solid.Methyl (E)-3-(4-amino-6-chloropyrimidin-5-yl)acrylate (3-2)

[0195] A solution of methyl (E)-3-(4,6-dichloropyrimidin-5-yl)acrylate (3-2B) (1.1 g, 4.7 mmol, 1,0 equiv.) in ammonia solution (0.4 M in THF, 100 mL) was stirred at60 °C overnight under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. This resulted in methyl (£)-3-(4-amino-6-chloropyrimidin-5-yl)acrylate (3- 2) (1.1 g) as a yellow solid, which was used directly in the next step without further purification.Methyl (2E)-3-(4-amino-6-{[(1-hydroxy-2,3,1-benzoxazaborinin-7-yl)methyl]amino}pyrimidin-5-yl)prop-2-enoate (3-3)

[0196] To a stirred solution of methyl (2E)-3-(4-amino-6-chloropyrimidin-5-yl)prop-2- enoate (3-2) (250 nig, 1.1 mmol, 1.0 equiv.) and 7-(aminomethyl)-2,3,l-benzoxazaborinin-l- ol (3-1, 2-7 in Scheme 2) (309 mg, 1.7 mmol, 1.5 equiv.) in DMSO (10 mL) were added TEA (592 mg, 5.8 mmol, 5.0 equiv.) and KF (204 mg, 3.5 mmol, 3.0 equiv.) at room temperature70MF-369911600Attorney Docket No.: 314352001641under nitrogen atmosphere. The resulting mixture was heated to 100 °C overnight under nitrogen atmosphere. The reaction residue was directly purified by reversed-phase combi-flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 20% to 40% gradient in 10 min; detector, UV 254 nm to afford (2£')-3-(4-amino-6-{[(1 -hydroxy-2, 3, l-benzoxazaborinin-7-yl)methyl]amino}pyrimidin-5-yl)prop-2-enoate (3-3 ) (300 mg, 72.6% yield) as a yellow solid.

[0197] LCMS (ESI): [M+H]+: 3544-{[(l -Hydroxy-2, 3,l-benzoxazaborinm-7-yl)methyl]amino}-8H-pyrido[2,3-d]pyrimidm-7- one (3)

[0198] To a stirred solution of methyl (2E)-3-(4-amino-6-{[(l-hydroxy-2,3,l -benzoxazaborinin-7-yl)niethyl]amino}pyrimidin-5-yl)prop-2-enoate (3-3) (600 mg, 1.7 mmol, 1,0 equiv.) in methanol (30 mL) was added sodium thiomethoxide (476 mg, 6.8 mmol, 4.0 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was heated to 80 °C for 2 hours. The resulting mixture was concentrated under reduced pressure. The product was separated by CHIRAL-SFC with the following conditions: Column:CHIRALPAK IH, 3.0 * 50 mm, 3 pm; Mobile Phase A: CO2, Mobile Phase B: MeOH: DCM = 1:1 (1% 2 M NHs-MeOH); Flow rate: 90 mL / min; Gradient (B%): isocratic 45% B;Column Temperature (°C): 35; Back Pressure (bar): 100; Wave Length: 25411m; RT2 (min): 3,47; Sample Solvent: MeOH; Injection Volume: 0.3 mL to afford a partially purified product. The product was further purified by Prep-HPLC with the following conditions: Column: YMC Triart CI8 ExRs 5 pm, 30 mm * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 3% B to 13% B in 8min; Wave Length: 254 / 220 nm; RT1 (min): 5.92, after which the solid was triturated with DMSO / H2O (0.2 / 3 mL). This resulted in the 4-{ [(1 -hydroxy-2, 3,1-benzoxazaborinin-7-yl)methyl]amino}-8 / 7-pyrido[2,3-d]pyrimidin-7-one (3) (59.4 mg, 10.9% yield,) as a white solid.

[0199] LCMS (ESI): [M+H]+: 322

[0200] ‘HNMR (400 MHz, DMSCW6) 8 12.00 (s, IH), 9.37 (s, IH), 8.70 (t, J= 5.9 Hz, IH), 8.61 (s, IH), 8.27 (s, IH), 8.20 (d, J = 9.7 Hz, IH), 8.00 (d, J -- 1.7 Hz, 11!) 7.78 (dd, J = 8.0, 1.8 Hz, IH), 7.71 (d, J= 8.0 Hz, IH), 6.45 (d, J= 9.6 Hz, IH), 4.85 (d, J= 5.8 Hz, 2H).71MF-369911600Attorney Docket No.: 314352001641Example 4Synthesis of 4-( fl -hydroxy-lH-benzo [d] [ 1, 2, 6 ]oxazaborinin-6-yl)methyl)amino)pyrido[2, 3- djpyrimidin- 7(8H)-one

[0201] The compound was synthesized using Scheme 4.Scheme 4Methyl (E)-3-(4-amino-6-( fl -hydroxy-lH-benzo[d][l, 2, 6 ]oxazaborinin-6- yl)methyl)ammo)pyrimidin-5-yl)acrylate ( 4-3 )

[0202] To a stirred solution of 6-(aminomethyl)-l / 7-benzo[<7][l,2,6]oxazaborinin-l-ol, hydrochloride salt (4-1, 1-7 in Scheme 1) (450 mg, 2.6 mmol, 1,0 equiv.) and methyl (£)-3- (4-amino-6-chloropyrimidin-5-yl)acrylate (4-2, 3-2 from Example 3) (450 mg, 2.1 mmol, 1.2 eq.) in DMSO (45 mL) was added KF (2.3 g, 38.3 mmol, 15.0 equiv.) in portions at room temperature. The resulting mixture was stirred at 100 °C overnight. The reaction residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 0% to 90% gradient in 30 min; detector, UV 254 nm. This resulted in methyl (E)-3-(4-amino-6-(((l-hydroxy-lH-benzo[d][l,2,6]oxazaborinin-6-yl)methyl)amino)pyrimidin-5-yl)acrylate (4-3) (400 mg, crude) as a yellow solid, which was used in the next step directly without further purification.

[0203] LCMS (ESI): [M+H]+: 3544-( ( ( 1 -Hydroxy- 1H -benzo [d] [L 2, 6 ]oxazabormin-6-yl)melhyl)ammo)pyrido[2, 3-d]pyrimidin- 7(8H)-one (4)72MF-369911600Attorney Docket No.: 314352001641

[0204] To a stirred solution of intermediate methyl (2E)-3 -(4-amino-6-{[(l -hydroxy -2,3,l-benzoxazaborinin-6-yl)methyl]amino}pyrimidin-5-yl)prop-2-enoate (4-3) (480 mg, 1.4 mmol, 1.0 equiv.) in methanol (25 niL) was added sodium thiomethoxide (400 mg, 5.7 mmol, 4,2 equiv.) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 80 °C for 4 hours. The product was purified by Prep-HPLC with the following conditions (Column: XBridge BEH C18 OBD Prep Column, 5 pm, 30 mm * 150 mm;Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 3% B to 15% B in lOmin; Wave Length: 254 / 220 nm; RT1 (min): 7.2) to afford 100 mg of a white solid. The product was further purified by trituration with water (2 mL) and DMSO (0.1 mL). This resulted in 4-{[(l-hydroxy-2,3,l-benzoxazaborinin-6-yl)methyl]amino}-8 / / -pyrido[2,3- ]pyrimidin-7-one (4) (70.3 mg, 19.3% yield,) as a white solid.

[0205] LCMS (ESI): [M+H]L 322

[0206] 'HNMR (400 MHz, DMSCW6) 0 12.03 (s, 1H), 9.33 (s, 1H), 8.69 (t, J= 5.9 Hz, IH), 8.64 (s, IH), 8.26 (s, 1H), 8.20 (d,. / = 9.8 Hz, IH), 8.037.8 Hz, IH), 7.71 (dd, J = 7.8, 1.6 Hz, IH), 7.67 (s, IH), 6.45 (d, J = 9.7 Hz, IH), 4.85 (d, J = 5.8 Hz, 2H).Example 5Synthesis of 7-{[(8-Methoxyquinazolin-4-yl)ammo ]methyl}-2, 3, 1-benzoxazaborinm-l-ol

[0207] The compound was synthesized using Scheme 5.Scheme 57-{[ (8-Methoxyqianazolin-4-yl)amino]methyl}-2, 3, l-benzoxazaborinin-l-ol (5)73MF-369911600Attorney Docket No.: 314352001641

[0208] To a stirred mixture of 7-(aminomethyl)-2,3, 1-benzoxazaborinin-l-ol, hydrochloride (5-1, 2-7 from Scheme 2) (70 mg, 0,4 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (5-2) (91 mg, 0.5 mmol, 1.2 equiv.) in DMSO (2 mL) was added CsF (151 mg, 1.0 mmol, 2.5 equiv.) at room temperature. The reaction was stirred for2 hours. The resulting mixture was concentrated under reduced pressure. The product was purified by reverse phase flash with the following conditions (Column: YMC Triart C18 ExRs 5 pm, 30 mm * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / niin; Gradient (B%): 3% B to 20% B in 8 min; Wave Length: 254 / 220 nm; RT1 (min): 6.78), which generated 7-{ [(8-m ethoxy quinazolin-4-yl)amino]methyl} -2, 3, 1-benzoxazaborinin-l-ol (5) (29.3 nig, 22.0% yield) as a white solid.

[0209] LCMS (ESI): [M+H]+: 335

[0210] 3 9.34 (s, 1H), 8.84 (s, 1H), 8.60 (s, 1H), 8.40 (s, 1H), 8.02 (s, 1H), 7.84 - 7.80 (m, 2H), 7.70 (d, 7.9 Hz, 1H), 7.47 (t, J= 8.2 Hz, 1H), 7.28 (d, J= 7.9 Hz, 1H), 4.91 (d, J= 5.9 Hz, 2H), 3.91 (s, 3H).Example 6Synthesis of 6-{[(8-methoxyquinazolin-4-yl)amino]methyl}-2, 3, 1-benzoxazaborinin-l-ol hydrochloride

[0211] The compound was synthesized using Scheme 6.Scheme 674MF-369911600Attorney Docket No.: 3143520016416-{ [(8-Methoxyquinazolin-4-yl)amino]methyl } -2,3,1 -benzoxazaborinin- 1 -ol hydrochloride (6)

[0212] To a stirred solution of 6-(aminomethyl)-2,3,l-benzoxazaborinin-l -ol, hydrochloride (6-1, 1-7 in Scheme 1) (400 mg, 2.2 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (6-2) (530 mg, 2.7 mmol, 1.2 equiv.) in DMSO (5 mb) was added CsF (1.7 g, 11.3 mmol, 5.0 equiv.) in one portion at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The product was purified by reversed-phase flash chromatography with the following conditions: column, YMC Triart Cl 8 ExRs 5 pm, 30 mm * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 3% B to 17% B in 8min; Wave Length:254 / 220 nm. The product was further purified by reversed-phase flash chromatography with the following conditions: column, Xselect CSH Cl 85 pm, 30 mm X 150 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 4% B to 17%B in 8 min; Wave Length: 254 nm / 220 nm. This generated 6-{[(8-methoxyquinazolin-4-yl)amino]methyl}-2,3,l-benzoxazaborinin-l-ol hydrochloride (6) (32.8 mg, 3.9% yield) as a light-yellow solid.

[0213] LCMS (ESI): [M+H]+: 335

[0214] 11.39 (s, 1H), 8.73 (s, 1H), 8.60 (s, 1H), 8.35 (d, J= 8.3 Hz, 1H), 8.06 (d, J= 7.7 Hz, 1H), 7.79 (d, J= 7.8 Hz, 1H), 7.74 (s, 1H), 7.65 (d, J -- 8.1 Hz, 1H), 5,06 (d, J 5.8 Hz, 1H), 4.55 (br, 3H), 4.05 (s, 2H).Example 7Synthesis of 7-( ( (7-methoxyquinazolin-4-yl)amino)methyl)- lH-benzo[d] [ 1, 2, 6 ]oxazaborinin-l-ol

[0215] The compound above was synthesized using Scheme 7.75MF-369911600Attorney Docket No.: 314352001641Scheme 77-(((7-Methoxyquinazolin-4-yl)ammo)methyl)-lH-benzo[d][l,2,6]oxazabormin-l-ol (7)

[0216] To a stirred solution of 4-chloro-7-methoxyquinazoline (7-1) (219.6 mg, 1.13 mmol, 1.2 equiv.) in DMSO (3 mL) was added 7-(ami nomethyl)- 1 / 7-benzo[< / ][l,2,6]oxazaborinin-l-ol hydrochloride (2-7 in Scheme 2) (200 mg, 0.94 mmol, 1.0 equiv.) followed by CsF (429.9 mg, 2.83 mmol, 3.0 equiv.) at room temperature and stirred for 1 hour. After consumption of the starting material, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The aqueous layer was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 0.1% TF buffer, 0% to 98% gradient in 32 min [Time / % ACN: 0.01 / 10, 2 / 10, 8 / 25, 18 / 25, 20 / 95, 27 / 10, 32 / 10]; PDA detector, UV 220 and 254 nm; which generated 7-(((7-m ethoxy quinazolin-4-yl)amino)methyl)- 1 / / -benzo[<7][l,2,6]oxazaborinin-l-ol (7) (35 mg, 11.1% yield) as an off-white solid.

[0217] LCMS: [M+H]+: 335

[0218] 'H-NMR (400 MHz, DMSO- e) 69.34 (s, 1H), 8.83 (t, J= 5.6 Hz, 1H), 8.60 (s, 1H), 8.38 (s, 1H), 8.23 (d, J 9.2 Hz, 1H), 8.02 (s, 1H), 7.79 (dd, J 2.0, 8.0 Hz, 1H), 7.70 (d, J= 8.0 Hz, 1H), 7.17 (dd,.7= 2.4, 9.0 Hz, 1H), 7.11 (d,.7= 2.4 Hz, 1H), 4.90 (d,.7= 6,0 Hz, 2H), 3.90 (s, 3H).Example 8Synthesis of 6-( ( (7-methoxyquinazolin-4-yl)ammo)methyl)-l H-benzo [d] [ 1, 2, 6 ]oxazaborinin-l-ol76MF-369911600Attorney Docket No.: 314352001641

[0219] The compound above was synthesized using Scheme 8.Scheme 86-(((7-Methoxyqujnazolin-4-yl)amino)methyl)-lH-benzo[d][l,2,6]oxazabormin-l-ol (8)

[0220] To a stirred solution of 4-chloro-7-methoxyquinazoline (7-1 in scheme 7) (150 mg, 0.77 mmol, 1.0 equiv.) in IPA (3 mL) was added 6-(aminomethyl)-l / 7-benzo[ ][l,2,6]oxazaborinin-l-ol hydrochloride (1-7 in Scheme 1) (196.4 mg, 0.92 mmol, 1.2 equiv.) followed by / VpV-diisopropyl ethylamine (0.67 mL, 3.85 mmol, 5.0 equiv.) at room temperature. The reaction mixture was heated at 90 °C for 16 hours. After consumption of the starting materials, the reaction mixture was concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna C 18 (250X30 mm, 5 gm); mobile phase, ACN in 0.1% formic acid buffer, 0% to 98% gradient in 32 min [Time / % ACN: 0.01 / 5, 2 / 5, 10 / 20, 18 / 20, 25 / 95]; PDA detector, UV 220 and 254 nm followed by chiral-HPLC purification with the following conditions: column, CELLULOSE 5 (250x30 mm, 5pm); mobile phase, (Isocratic), Hexane: EtOH (70:30) gradient in 32 min [Time / % EtOH: 0.01 / 100, 5 / 100, 10 / 100, 15 / 100, 25 / 100]; which generated 6-(((7-methoxyquinazolin-4-yl)amino)methyl)-l / 7-benzo[<7][l,2,6]oxazaborinin-l -ol (8) (14 mg, 5.4% yield) as an off-white solid.

[0221] LCMS: [M+H]4: 335

[0222] JH-NMR (400 MHz, DMSO-6) 69.32 (s, 1 H), 8.78 (t,. / 6.0 Hz, 1H), 8.63 (s, 1H), 8.37 (s, 1H), 8.23 (d, J= 9.2 Hz, 1H), 8.02 (d, J= 8.0 Hz, 1H), 7.73 (dd, J= 1.6, 7.8 Hz,77MF-369911600Attomey Docket No.: 3143520016411H), 7.68 (s, 1H), 7.16 (dd, J= 2.8, 9.0 Hz, 1H), 7.11 (d, J= 2.4 Hz, 1H), 4.90 (d, J= 6.0 Hz, 21:1), 3.90 (s, 3H)Examples 9 and 10 (Omitted)Example 11Synthesis of l-[( I -hydroxy-2, 3, 1 -benzoxazabor inin-7 -yl)methylamino ]isoquinoline-4-carbonitrile

[0223] The compound above was synthesized using Scheme 9.l-[ ( 1 -Hydroxy-2, 3, 1-benzoxazaborinin- 7-yl)methylamino ]isoquinoline-4-carbonitrile l 1 )

[0224] A microwave reaction vessel was charged with 1 -chloroisoquin oline-4-carbonitrile (9-1) (150 mg, 0.79 mmol, 1.0 equiv.), 7-( minomethyl )-lH-benzo[d][l,2,6]oxaz.aborinin-l-ol hydrochloride (2-7 in Scheme 2) (169 mg, 0.79 mmol, 1.0 equiv.) and fvV-diisopropylethylamine (0.69 mL, 3.97 mmol, 5.0 equiv.) in IPA (3 mL). The reaction mixture was subjected to microwave irradiation at 90 °C for 2 hours. After consumption of the starting materials, the reaction mixture was concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 0.1% formic acid buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 25, 2 / 25, 8 / 55, 15 / 55, 30 / 70, 31 / 98]; PDA detector, UV 220 and 254 nm; which generated 1-[(1 -hydroxy-2, 3,1-78MF-369911600Attorney Docket No.: 314352001641benzoxazaborinin-7-yl)methylamino]isoquinoline-4-carbonitrile (11) (32 mg, 12.3% yield) as an off-white solid.

[0225] LCMS: [M+H]+: 329

[0226] 'H-NMR (400 MHz, DMSO-rfc) 59.35 (s, 1H), 9.14 (t, J= 5.6 Hz, 1H), 8.61 (s, 1H), 8.49 (d, J= 8.4 Hz, 1H), 8.42 (s, 1H), 8.03 (s, 1H), 7.93-7.85 (m, 2H), 7.80 (dd, J= 1.6, 8.0 Hz, 1H), 7.75-7.69 (m, 2H), 4.97 (d,.7= 5.6 Hz, 2H).Example 12Synthesis of 1 -(((1 -hydroxy- lH-benzo[d] [1,2, 6]oxazabormin-6-yl)methyl)amino)isoqumoUne-4-carbonitrile

[0227] The compound above was synthesized using Scheme 10.Scheme 10l-(((l-Hydroxy-lH-benzo[d] [ 1,2,6] oxazabormm-6-yl)methyl)ammo)isoquinoline-4-carbonitrile (12)

[0228] To a stirred solution of 1 -chloroisoquinoline-4-carbonitrile (9-1 in Scheme 9) (150 mg, 0.79 mmol, 1.0 equiv.) in DMSO (5 mL) was added 6-(aminom ethyl)- 1 / 7-benzo[<7][I,2,6]oxazaborinin-l -ol hydrochloride (1-7 in Scheme 1) (202 mg, 0.95 mmol, 1,0 equiv.) followed by KF (18.5 mg, 3.19 mmol, 4.0 equiv.) and TEA (0.54 mL, 3.98 mmol, 5.079MF-369911600Attorney Docket No.: 314352001641equiv) at room temperature and stirred for 4 hours. After consumption of the starting material, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC (conditions: column, Luna Cl 8 (250x30 mm, 5 pm); mobile phase, ACN in 10 MM ammonium acetate buffer, 0% to 98% gradient in 40 min [Time / % ACN: 0.01 / 25, 2 / 10, 10 / 43, 18 / 43, 25 / 95, 28 / 98]; PDA detector, UV 220 and 254 nm; which generated 1 -(((1 -hydroxy- 1 / 7-benzo[<7][I,2,6]oxazaborinin-6-yl)methyl)amino)isoquinoiine-4-carbonitrile (12) (22 mg, 8.4% yield) as an off-white solid.

[0229] LCMS: [M+H]4: 329

[0230] ^I-NMR (400 MHz, DMSO-d6) 59.32 (s, 1H), 9.13 (t,. / 6.0 Hz, 1 H), 8.62 (s, 1H), 8.48 (d, J= 8.4 Hz, 1H), 8.41 (s, 1H), 8.02 (d, J= 7.60 Hz, 1H), 7.90-7.84 (m, 2H), 7.74-7.69 (m, 3H), 4.96 (d, J === 6.0 Hz, 2H).Example 13Synthesis of 7-( ( <5-methyl-5H-pyrrolo [ 3, 2-d]pyrimidin-4-yl)amino)methyl )-lH-benzo[d][ 1, 2, 6 oxazaborinin-l-ol

[0231] The compound above was synthesized using Scheme 11.Scheme 1180MF-369911600Attorney Docket No.: 3143520016417-(((5-Methyl-5H-pyrrolo[3,2-dpyrimidin-4-yl)amino)methyl)-lH-benzo d] [1, 2, 6 ]oxazabormin-l-ol fl 3)

[0232] To a stirred solution of 7-(aminomethyl)-l / 7-benzo[<7][l,2,6]oxazaborinin-l-ol hydrochloride (2-7 in Scheme 2) (100 mg, 0.47 mmol, 1.0 equiv.) in DMSO (1.5 mL) was added 4-chloro-5-methyl-5J7-pyrrolo[3,2-< / |pyrimidine (11-1) (94 mg, 0.56 mmol, 1.2 equiv.) followed by CsF (214 mg, 1.41 mmol, 3.0 equiv.) and DIPEA (0.81 mL, 4.7 mmol, 10.0 equiv.) at room temperature. The reaction mixture was heated to 70 °C for 2 hours. After consumption of the starting material, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, GEMINI C18 (250x30mm) 5pm; mobile phase, ACN in 10 MM ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 15, 2 / 15, 16 / 85, 20 / 85, 28 / 95, 30 / 98]; PDA detector, UV 220 and 254 nm; which generated 7-(((5-methyl-5 / / -pyrrolo[3,2-tZ]pyrimidin-4-yl)amino)methyl)-l / 7-benzo[t / ][l,2,6]oxazaborinin-l-ol (13) (17 mg, 10.4% yield) as an off-white solid.

[0233] LCMS: [M+H]+: 308

[0234] 'H-NMR (400 MHz, DMSO- s) 59.33 (s, 1H), 8.59 (s, 1H), 8.06 (d, 4.8 Hz, 2H), 7.82 (dd, J= 2.0, 7.8 Hz, 1H), 7.68 (d, J= 8.0 Hz, 1H), 7.42 (t, J= 6.0 Hz, 2H), 6.32 (d, J= 2.8 Hz, 1H), 4.85 (d, J= 8.0 Hz, 2H), 4.11 (s, 3H).Example 14Synthesis of 6-(((5-methyl-5H-pyrrolo[3, 2-d]pyrimidin-4-yl)amino)methyl)-lH-benzo[d][ 1,2,6 ]oxazaborinin-l-ol

[0235] The compound above was synthesized using Scheme 12.81MF-369911600Attorney Docket No.: 3143520016416-(((5-N4ethyl-5H-pyrrolo[3,2-dlpyrimidin-4-yl)amino)methyl)-lH-benzo[d][ l,2,6]oxazaborinin-l-ol (14)

[0236] To a stirred solution of 4-chloro-5-methyl-5#-pyrrolo[3,2-< ]pyrimidine (11-1 in Scheme 11) (235 mg, 1,4 mmol, 2.0 equiv.) in DMSO (2 mL) was added 6-(aminomethyl)-177-benzo[<7][l,2,6]oxazaborinin-l-ol hydrochloride (1-7 in Scheme 1) (150 mg, 0.70 mmol, 1.0 equiv.) followed by CsF (429 mg, 2,8 mmol, 4.0 equiv.) and DIPEA (0.36 mL, 2.1 mmol, 3.0 equiv) at room temperature and allowed to stir at 80 °C for 16 hours. After consumption of the starting material, the reaction mixture was diluted with water (8 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 10MM ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 3 / 10, 11 / 45, 25 / 95, 28 / 98]; PDA detector, UV 220 and 254 nm; which generated 6-(((5-methyl-57 / -pyrrolo[3,2- jpyrimidin-4-yl)amino)methyl)- 1 H-benzo[<7j[ 1,2,6]oxazaborinin-l -ol (14) (14 mg, 6.5% yield) as an off-white solid.

[0237] LCMS: [M+H]+: 308

[0238] JH-NMR (400 MHz, DMSO-6) 59.3 (s, 1H), 8.62 (s, 1H), 8.07 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.76 (dd, J= 1.6, 7.8 Hz, 1H), 7.72 (s, 1H), 7.43 (d, J= 3.2 Hz, 1H), 7.41 (s, 1H), 6.32 (d, J - 3.2 Hz, 1H), 4.86 (d, J 5.6 Hz, 2H), 4.12 (s, 3H).Example 15Synthesis of 7 -((( 7 -methyl- 7H-pyrrolo[ 2, 3-d]pyrimidin-4-yl )amino)methyl)-IH-benzo[d][ 1, 2, 6 oxazaborinm-l-ol82MF-369911600Attorney Docket No.: 31435200164115

[0239] The compound above was synthesized using Scheme 13.7-(((7-Methyl-7H-pyrrolo[2, 3-d]pyrimjdm-4-yl)ammo)methyl)-lH-benzo d] [1, 2, 6 ]oxazaborinin-l-ol (15)

[0240] To a stirred solution of 4-chloro-7-methyl-7H-pyrrolo[2,3- ]pyrimidine (13-1) (94 mg, 0.56 mmol, 1.2 equiv.) in DMSO (2 mL) was added 7-(aminom ethyl)- 1 / 7-benzo[<7][l,2,6]oxazaborinin-l -ol hydrochloride (2-7 in Scheme 2) (110 mg, 0.47 mmol, 1.0 equiv.) followed by CsF (214 mg, 1.41 mmol, 3.0 equiv.) and DIPEA (0.82 mL, 4.7 mmol, 5.0 equiv.) at room temperature. The reaction mixture was heated to 70 °C for 2 hours. After consumption of the starting material, the reaction mixture was diluted with water (8 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 10MM ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 2 / 10, 10 / 50, 20 / 70, 25 / 95, 28 / 98]; PDA detector, UV 220 and 254 nm; which generated 7-(((7-methyl-7 / / -pyrrolo[2,3-tZ]pyrimidin-4-yl)amino)methyl)-l / / -benzo[<7][l,2,6]oxazaborinin-l-ol (15) (20 mg, 13.9% yield) as an off-white solid.

[0241] LCMS: [M+H]+: 308

[0242] 'H-NMR (400 MHz, DMSO- e) 59.25 (s, 1H), 8.53 (s, 1H), 8.05 (t, J= 8.0 Hz, 2H), 7.93 (s, 1H), 7.70 (dd, J ------ 1.6, 8.0 Hz, 1H), 7.62 (d,. / 8.0 Hz, 1H), 7.08 (d,. / 3.2 Hz, 1H), 6.53 (d,. / = 3.2 Hz, 1H), 4.78 (d, J= 6.0 Hz, 2H), 3.63 (s, 3H).83MF-369911600Attomey Docket No.: 314352001641Example 16Synthesis of 6-(((7-methyl~7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)methyl)-lH- benz [d] [L 2,6]oxazaborinm-l-ol

[0243] The compound above was synthesized using Scheme 14.6-( ( 7 -Methyl- 7H -pyrrolof 2, 3-d ’]pyrimidin-4-yl)amino) methyl)- 1H -benzofdjf l,2,6]oxazaborinin-l-ol l6)

[0244] To a stirred solution of 4-chloro-7-methyl-77 / -pyrrolo[2,3-t / ]pyrimidine (13-1 in Scheme 13 ) (236 mg, l,4mmol, 2.0 equiv.) in DMSO (2 mL) was added 6-(aminomethyl)-17f-benzo[<7][l,2,6]oxazaborinin-l-ol hydrochloride (1-7 in Scheme 1) (150 mg, 0.70 mmol, 1.0 equiv.) followed by KF (102 mg, 1.75 mmol, 2.5 equiv.) and triethylamine (0,29 mL, 2.1 mmol, 3.0 equiv.) at room temperature and allowed to stir at 70 °C for 24 hours. After consumption of the starting material, the reaction mixture was diluted with water (8 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna Cl 8 (250x30 mm, 5pm); mobile phase, ACN in 10MM ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 3 / 10, 11 / 45, 20 / 45, 26 / 95, 28 / 98]; PDA detector, UV 220 and 254 nm; which generated 6- (((7-methyl-777-pyrrolo[2,3-t7]pyrimidin-4-yl)amino)methyl)-177-benzo[<7][l,2,6]oxazaborinin-l-ol (16) (25 nig, 11.57% yield) as an off-white solid.84MF-369911600Attorney Docket No.: 314352001641

[0245] LCMS: [M+H]+: 308

[0246] 'H-NMR (400 MHz, DMSO-6) 59.31 (s, 1H), 8.62 (s, 1H), 8.13 (s, 2H), 8.02 (d, J = 8.0 Hz, 1H), 7.71 (d,.7= 6.4 Hz, 1H), 7.66 (s, 1H), 7.16 (d, J= 3.2 Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 4.85 (d, J = 6.0 Hz, 2H), 3.70 (s, 3H).Example 17 (Omitted)Example 18Synthesis of 6-( ( f-methoxyquinolin-4-yl)aTnino)methyl)-lH-benzo[d][ 1, 2, 6 ]oxazaborinin-l-ol

[0247] The compound above was synthesized using Scheme 15.Scheme 15Methyl 2-bromo-5-(bromomethyl)benzoate (T5-2)

[0248] To a solution of methyl 2-bromo-5-methylbenzoate (15-1) (20.0 g, 87.3 mmol, 1.0 equiv.) in CCh (200 niL) was added NBS (17.09 g, 96.03 mmol, 1.1 equiv.) followed by85MF-369911600Attorney Docket No.: 314352001641BPO (2.11 g, 8.73 mmol, 0.1 equiv.) at room temperature and heated to 90 °C for 12 hours under nitrogen atmosphere. After consumption of the starting material, the reaction mixture was diluted with cold water (300 mL) and extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with water (2 x 200 mL), followed by a brine solution (100 mL), and dried over NazSCU. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography over silica gel using 0% to 10% EtOAc in hexane as eluent, which afforded methyl 2-bromo-5-(bromomethyl)benzoate (15-2) (19.0 g, 70.7% yield) as an off white gummy liquid.

[0249] 'H-NMR (400 MHz, DMSO- s) 67.82 (d, J = 2.4 Hz, 1H), 7.65-7.63 (m, 1H), 7.36 (dd, J= 2.4, 8.4 Hz, 1H), 4.44 (s, 2H), 3.94 (s, 3H).4-Amino-7 -methoxyquinoline fl 5-4)

[0250] An autoclave containing 4-chloro-7-methoxy quinoline (15-3) (20 g, 103.28 mmol, 1 equiv.) and IN ammonia in MeOH (44.26 mL, 0.309 mol, 3 equiv.) was heated to 150 °C for 24 hours. After consumption of the starting material, the reaction mixture was concentrated under reduced pressure. The resulting residue was triturated with DCM (3 x 200 mL) to separate the unreacted starting material and the obtained solids were dried under reduced pressure, which afforded 7-methoxyquinolin-4-amine (15-4) (8.2 g, 45.6% yield) as a yellow solid. This compound was used for the next step without any further purification.

[0251] LCMS: [M+H]+: 175Methyl 2-bromo-5-( ( (7-methoxyquinolin-4-yl)amino)methyl)benzoate fl 5-5)

[0252] To a 0 °C cooled solution of 7-methoxyquinolin-4-amine (1 -4) (3 x 1.4 g, 8.03 mmol, 1 equiv.) in anhydrous THF (30 mL) was added 1.0M lithium bis(trimethylsilyl)amide in THF (16.07 mL, 16.07 mmol, 2 equiv.) slowly over 15 minutes and the stirring was continued for an additional 30 minutes. Methyl 2-bromo-5-(bromomethyl) benzoate (15-2) (2.97 g, 9.63 mmol, 1.2 equiv.) was then added, and the reaction mixture was allowed to stir at room temperature for 12 hours. After consumption of the starting material, all 3 batches were quenched with a saturated H4CI solution (200 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layers were dried over Na2SO4. / Xfter filtration, the filtrate was concentrated under reduced pressure. The resulting residue was purified by flash chromatography over silica gel using 5-10% MeOH in DCM as eluent; which generated methyl 2-bromo-5-(((7-methoxyquinolin-4-yl)amino)methyl)benzoate (15-5) (4.5 g, 46.5% yield) as a yellow solid.86MF-369911600Attorney Docket No.: 314352001641

[0253] LCMS: [M+H]+: 401

[0254] 'H-NMR (400 MHz, DMSO- s) 59.01 (s, 1H), 8.62 (d, 7.6 Hz, 1H), 8.41 (d, J = 9.2 Hz, 1H), 7.80 (d, J= 2.4 Hz, 1H), 7.75 (d,. / = 8.4 Hz, 1H), 7.38-7.34 (m, 2H), 7.23 (d, J= 2.00 Hz, 1H), 6.77 (d, J= 7.20 Hz, 1H), 5.82 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H)(2-Bromo-5-(((7-methoxyquinolm-4-yl)amino)methyl)phenyl)methanol (15-6

[0255] To a 0 °C cooled solution of methyl 2-bromo-5-(((7-methoxyquinolin-4-yl)amino)methyl)benzoate (15-5) (2 x 600 mg, 1.49 mmol, 1.0 equiv.) in anhydrous THF (10 mL) was added 1.0 M DIBAL-Zfin THF (4.48 mL, 4.48 mmol, 3 equiv.) slowly dropwise at same temperature and allowed to stir at room temperature for 6 hours. After consumption of the starting material, both batches were quenched with a saturated NH4CI solution (100 L) and extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with water, followed by a brine solution (50 mL) and dried over a2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography over silica gel using 5-10% MeOH in DCM as eluent, which generated (2- bromo-5-(((7-methoxyquinolin-4-yl)amino)methyl)phenyl)methanol (15-6) (0.8 g, 72.1% yield) as an off-white solid.

[0256] LCMS: [M+H]+: 3732-Bromo-5-( ( (7-methoxyquinolin-4-yl)amino)inethyl)benzaldehyde fl 5-7 )

[0257] To a stirred solution of (2-bromo-5-(((7-methoxyquinolin-4-yl)amino)methyl)phenyl)methanol (15-6) (700 mg, 1,88 mmol, 1.0 equiv.) in DCM: DM SO (3:1, 20 mL) was added DMP (1.2 g, 2.81 mmol, 1.5 equiv.) at 0 °C under nitrogen atmosphere and allowed to stir at room temperature for 2 hours. After consumption of the starting material, the reaction mixture was diluted with EtOAc (200 mL), and 5% sodium thiosulfate solution (50 mL) under stirring. After 15 minutes, the organic layer was separated. The organic layer was washed with a saturated NaHCOs solution (2 x 30 mL), followed by a brine solution (30 mL) and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography over silica gel using 5-10% MeOH in DCM as eluent, which generated 2-bromo-5-(((7-methoxyquinolin-4-yl)amino)methyl)benzaldehyde (15-7) (320 mg, 46.0% yield) as a gummy liquid.

[0258] LCMS: [M+H]+: 373(2-Formyl-4-(( (7-methoxyqianolin-4-yl)ammo)methyl)phenyl)bororiic acid fl 5-8)87MF-369911600Attorney Docket No.: 314352001641

[0259] To a sealed tube containing 2-bromo-5-(((7-methoxyquinolin-4-yl)amino)methyl)benzaldehyde (15-7) (350 mg, 0.94 mmol, 1,0 equiv.) in 1,4-dioxane (10 mL) was added bis(pinacolato)diboron (358 mg, 1.41 mmol, 1.5 equiv.) followed by potassium acetate (278 mg, 2,83 mmol, 3.0 equiv.) at room temperature and degassed with argon for 10 minutes. bis(triphenylphosphine)palladium chloride (66 mg, 0.09 mmol, 0.1 equiv.) was then added under argon atmosphere and heated to 90 °C for 4 hours. After consumption of the starting material, the reaction mixture was filtered through a celite pad and washed with EtOAc (150 mL) and water (50 mL). The aqueous layer was separated and concentrated under reduced pressure, which afforded (2 -f ormyl-4-(((7-m ethoxy quinolin-4-yl)amino)methyl)phenyl)boronic acid (15-8) (300 mg) as a pale brown solid. This compound was used for the next step without any further purification.

[0260] LCMS: [M+H]+: 3376-(((7-Methoxyquinolin-4-yl)amino)methyl)-lH-benzo[d] [l,2,6]oxazaborinin-l-ol fl8)

[0261] To a stirred solution of (2-formyl-4-(((7-methoxyquinolin-4-yl)amino)methyl)phenyl)boronic acid (15-8) (300 mg, 0.89 mmol, 1.0 equiv.) in EtOH and water (3:1, 8 mL) was added hydroxylamine hydrochloride (94 mg, 1.33 mmol, 1.5 equiv.) at room temperature under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 5 hours. After consumption of the starting material, the reaction was concentrated under reduced pressure. The obtained residue was diluted with water (10 mL) and washed with EtOAc (2 x 10 mL). The aqueous layer was purified by reverse phase prep-HPLC with the following conditions: column: Luna C18 (250x30 mm, 5um); mobile phase, ACN in 0.1% formic acid buffer, 10% to 98% gradient in 35 min [Time / % ACN: 0.01 / 15, 2 / 15, 12 / 40, 16 / 40, 22 / 70, 28 / 95, 30 / 95, 35 / 15]; PDA detector, UV 220 and 254 nm; which afforded 6-(((7-methoxyquinolin-4-yl)amino)methyl)-17 / -benzo[<7][l,2,6]oxazaborinin-l-ol (18) (5 mg, 1.7% yield) as an off-white solid.

[0262] LCMS: [M+H]+: 334

[0263] 'H-NMR (400 MHz, DMSO- s) 59.28 (s, 1H), 8.61 (s, 1H), 8.22-8.20 (m, 2H), 8.03 (d, 7 = 7.6 Hz, IH), 7.94 (t,.7= 6.0 Hz, IH), 7.75 (dd,.7 = 1.6, 7.8 Hz, IH), 7.70 (s, IH), 7.18 (d, J = 2.4 Hz, IH), 7.11 (dd, J = 2.4, 9.2 Hz, IH), 6.19 (d, J = 5.2 Hz, IH), 4.68 (d, J = 5.6 Hz, 2H), 3.87 (s, 3H)88MF-369911600Attorney Docket No.: 314352001641Example 19Synthesis of 7-( • ( 6-phenoxypyrimidin-4-yl)amino)methyl)-lH-benzo[d] [ 1, 2, 6 ]oxazaborinin-l-ol

[0264] The compound above was synthesized using Scheme 16.Scheme 167-(((6-Phenoxypyrimidin-4-yl)amino)methyl)-lH-benzo[d] [1,2,6]oxazaborinin-l-ol (T9)

[0265] To a stirred solution of 4-chloro-6-phenoxy pyrimidine (16-1) (174 mg, 0.79 mmol, 1.2 equiv.) in DMSO (2 mL) was added 7-(aminom ethyl)- 1H-benzo[t / ][l,2,6]oxazaborinin-l-ol hydrochloride (2-7 in Scheme 2)) (150 mg, 0.706 mmol, 1.0 equiv.) followed by CsF (321 mg, 2.11 mmol, 3.0 equiv.) at room temperature and stirred for 24 hours. After consumption of the starting material, the reaction mixture was diluted with water (8 mL) and extracted with EtO / Xc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Gemini C18 (250x30 mm, 5pm); mobile phase, ACN in 10MM ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 2 / 10, 10 / 43, 18 / 43, 25 / 95, 30 / 98]; PDA detector, UV 220 and 254 nm; which afforded 7-(((6-phenoxypyrimidin-4-yl)amino)methyl)-l / / -benzo[ ][l,2,6]oxazaborinin-l-ol (19) (50 mg, 20.5% yield) as an off-white solid.

[0266] LCMS: [M+H]+: 34789MF-369911600Attorney Docket No.: 314352001641

[0267] ’H-NMR (400 MHz, DMSO- e) 69.35 (s, 1H), 8.61 (s, 1H), 8.14 (s, 1H), 8.02 (brs, 1H), 7.96 (s, 1H), 7.74-7.69 (m, 2H), 7.41 (d, J 7.2 Hz, 2H), 7.24 (t,. / 7.2 Hz, 1H), 7.19-7.08 (m, 2H), 5.86 (s, 1H), 4.65 (brs, 2H).Example 20Synthesis of 6-( ( ( 6-Phenoxypyrimidm-4-yl)amlno) methyl)-! H-benzo[d] [ 1, 2, 6 oxazaborinin- l-o I20

[0268] The compound above was synthesized using Scheme 17.Scheme 17CsF, DIPEA, DMSO, 70 °C, 4 h1-7 206-( ((6-Phenoxypyrimidm-4-yl)ammo)methyl)-lH-benzo[d] [1, 2, 6]oxazaborinin-l-ol (20)

[0269] To a stirred solution of 4-chloro-6-phenoxy pyrimidine (16-1 in Scheme 16) (233 mg, 1.13 mmol, 1.2 equiv.) in DMSO (3 mb) was added 6-(aminomethyl)-lH-benzo[t / ][l,2,6]oxazaborinin-l-ol hydrochloride (1-7 in Scheme 1) (200 mg, 0.94 mmol, 1.0 equiv.) followed by CsF (573 mg, 3.77 mmol, 4.0 equiv.) and DIPEA (0.82 L, 4.71 mmol, 5.0 equiv) at room temperature and heated to 70 °C for 4 hours. After consumption of the starting material, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The product was purified by reverse phase prep-HPLC with the following conditions', column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 10 MM ammonium acetate buffer, 0% to 95% gradient in 35 min [Time / % ACN: 0.01 / 20, 3 / 20, 14 / 80, 20 / 80, 26 / 95, 35 / 20]; PDA detector, UV 220 and 254 nm; which generated 6-(((6- 90MF-369911600Attorney Docket No.: 314352001641phenoxypyrimidin-4-yl)amino)metliyl)-17 / -benzo[t / ][l,2,6]oxazaborinin-l-ol (20) (25 mg, 7.7% yield) as an off-white solid.

[0270] LCMS: [M+H]+: 347

[0271] 'H-NMR (400 MHz, DMSO-tfc) 59.39 (s, 1H), 8.64 (s, 1H), 8.15 (s, 1H), 8.03 (d, J= 7.6 Hz, 2H), 7.68-7.63 (m, 2H), 7.42 (t, J = 7.2 Hz, 2H), 7.24 (t,7.2 Hz, 1H), 7.13 (d, J= 6.0 Hz, 2H), 5.87 (s, 1H), 4.65 (s, 2H).Example 21Synthesis of 7-( ((6-methoxyquinazolin-4-yl)amino)methyl)-lH-benzo[d [ 1, 2, 6 oxazaborinm- I-ol

[0272] The compound above was synthesized using Scheme 18.Scheme 187-(((6-Methoxyquinazolm-4-yl)amino)methyl)-lH-benzo[d [l,2,6]oxazabormm-l-ol (21)

[0273] To a stirred solution of 4-chloro-6-methoxyquinazoline (18-1) (164 mg, 0.84 mmol, 1.2 equiv.) in DMSO (2 mL) was added 7-(aminomethyl)-l / f-benzo[ ][l,2,6]oxazaborinin-l-ol hydrochloride (2-7 in Scheme 2) (150 mg, 0.70 mmol, 1.0 equiv.) followed by KF (123 mg, 2.11 mmol, 3.0 equiv.), TEA (0.6 L, 4.23 mmol, 6.0 equiv.) and Celite (84 mg, 1.41 mmol, 2.0 equiv.) at room temperature and stirred for 2 hours. After consumption of the starting material, the reaction mixture was diluted with water 91MF-369911600Attorney Docket No.: 314352001641(8 niL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Gemini (250x30 mm, 5pm); mobile phase, ACN in 10 MM ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 2 / 10, 8 / 55, 16 / 75, 28 / 98, 30 / 98]; PDA detector, UV 220 and 254 nm; which generated 7-(((6-methoxyquinazolin-4-yl)amino)methyl)- 1 / -benzo[ ] [ 1,2,6]oxazaborinin-l -ol (21) (50 mg, 21.3% yield) as an off-white solid.

[0274] LCMS: [M+H]+: 335

[0275] ^-NMR (400 MHz, DMSO- ) 59.37 (s, 1H), 8.79 (t, J= 5.6 Hz, 1H), 8.61 (s, 1H), 8.35 (s, 1H), 8.04 (s, 1H), 7.81 (dd, J= 1.6, 7.8 Hz, 1H), 7.75-7.71 (m, 2H), 7.66 (d, J = 8.8 Hz, 1H), 7.43 (dd, J --- 2.8, 9.0 Hz, 1 H), 4.93 (d, J 6.0 Hz, 2H), 3.90 (s, 3H).Example 22Synthesis of 6-( ( ( 6-methoxyquinazolin-4-yl)amino)methyl)-I H-benzo [d] [ 1, 2, 6 oxazaborinin-l-ol

[0276] The compound above was synthesized using Scheme 19.6-(((6-Methoxyquinazolin-4-yl)ammo)methyl)-l H-benzo [d][l, 2,6]oxazabormin-l-ol (22)

[0277] To a stirred solution of 4-chloro-6-methoxyquinazoline (18-1 in Scheme 18) (219 mg, 1.12 mmol, 1.2 equiv.) in DMSO (2 mL) was added 6-(aminom ethyl)- 1 / 7- benzo[<7][l,2,6]oxazaborinin-l-ol hydrochloride (1-7 in Scheme 1) (200 mg, 0.94 mmol, 1.092MF-369911600Attorney Docket No.: 314352001641equiv.) followed by KF (164 mg, 2.82 mmol, 3.0 equiv.) and TEA (0.78 niL, 3.97 mmol, 6.0 equiv.) and celite (114 mg, 1.88 mmol, 2.0 equiv.) at room temperature and stirred for 2 hours. After consumption of the starting material, the reaction mixture was diluted with water (8 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 0.1% formic acid buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 5, 2 / 5, 10 / 25, 14 / 25, 25 / 98, 30 / 98]; PDA detector, UV 220 and 254 nm, which afforded 6-(((6-methoxyquinazolin-4-yl)amino)methyl)-l / / -benzo[tZ][l,2,6]oxazaborinin-l-ol (22) (14 mg, 4.5% yield) as an off-white solid.

[0278] LCMS: [M+H]+: 335

[0279] 'H-NMR (400 MHz, DMSO-^) 69.34 (s, 1H), 8.79 (t, J= 6.0 Hz, 1H), 8.64 (s, 1H), 8.35 (s, 1H), 8.04 (d, J 8.0 Hz, 1H), 7.75-7.73 (m, 2H), 7.70 (s. 111) 7.66 (d, J 8.8 Hz, 1H), 7.44 (dd,. / = 2.8, 9.0 Hz, 1H), 4.93 (d, J= 6.0 Hz, 2H), 3.90 (s, 3H).Example 23Synthesis of 7-( ( 6-(methoxymethyl)pyrimidin-4-yl)amino)methyl)-lH-benzo[d][ 1,2,6 ]oxazahorinin-l-ol

[0280] The compound above was synthesized using Scheme 20.Scheme 2093MF-369911600Attorney Docket No.: 3143520016417-( ( 6-(S4ethoxymethyl)pyrimidin-4-yl)ammo)methyl)- IH-benzo [d] [ 1, 2, 6 oxazaborinin-l-ol

[0281] To a stirred solution of 4-chloro-6-(methoxymethyl)pyrimidine (20-1) (134 mg, 0.84 mmol, 1.2 equiv.) in DMSO (I mL) was added 7-(aminomethyl)-l / T- benzo[ ][l,2,6]oxazaborinin-l-ol hydrochloride (2-7 in Scheme 2) (150 mg, 0.70 mmol, 1.0 equiv.) followed by CsF (321 mg, 2.1 mmol, 3.0 equiv.) at room temperature and stirred for 24 hours. After consumption of the starting material, the reaction mixture was diluted with water (8 mL) and extracted with EtOAc (2 x 15 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna Cl 8 (250x30 mm, 5pm); mobile phase, ACN in 0.1% TFA buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 2 / 10, 12 / 22, 18 / 22, 28 / 45, 30 / 98]; PDA detector, UV 220 and 254 nm; which generated 7-(((6-(methoxymethyl)pyrimidin-4-yl)amino)methyl)-17f-benzo[ ][l,2,6]oxazaborinin-l-ol (23) (28 mg, 13.3% yield) as an off-white solid.

[0282] LCMS: [M+H]d: 299

[0283] ’H-NMR (400 MHz, DMSO-t / s) 69.38 (s, 1H), 9.06 (s, 1H), 8.62 (s, 1H), 8.57 (s, 1H), 7.97 (s, 1H), 7.72-7.77 (m, 2H), 6.72 (s, 1H), 4.78 (s, 2H), 4.38 (s, 2H), 3.38 (s, 3H).Example 24Synthesis of 6-(((6-(methoxymethyl)pyrimidin-4-yl)amino)methyl)-lH-benzo[d][ 1, 2, 6]oxazaborinin-l-ol

[0284] The compound above was synthesized using Scheme 21.94MF-369911600Attorney Docket No.: 314352001641Scheme 216-( ( 6-( 4ethoxymethyl)pyrimidin-4-yl)amino)methyl)- IH-benzo [d] [ 1, 2, 6 oxazaborinin-l-ol (24)

[0285] To a stirred solution of 4-chloro-6-(metlioxymethyl)pyrimidine (20-1 in Scheme 20) (134.6 mg, 0.84 mmol, 1.2 equiv.) in DMSO (3 mL) was added 6-(aminom ethyl)- 1H- benzo[ ][l,2,6]oxazaborinin-l-ol (1-7 in Scheme 1) (150 mg, 0.7 mmol, 1.0 equiv.) followed by CsF (429.9 mg, 2.83 mmol, 4.0 equiv.) and TEA (0.29 mL, 2.12 mmol, 3.0 equiv.) at room temperature and stirred for 24 hours. After consumption of the starting material, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 10 mL). The aqueous layer was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 0.1% TFA buffer, 0% to 98% gradient in 35 min [Time / % ACN: 0.01 / 10, 2 / 10, 10 / 27, 18 / 30, 22 / 85, 28 / 95, 30 / 10, 35 / 10]; PDA detector, UV 220 and 254 nm; which generated 6-(((6-(methoxymethyl)pyrimidin-4-yi)amino)methyl)-l / 7-benzo[r / j[l,2,6]oxazaborinin-l-ol (24) (25 mg, 11.9% yield) as an off- white solid.

[0286] LCMS: [M+H]+: 299

[0287] 'H-NMR (400 MHz, DMSO- e) 69.36 (brs, 2H), 8.59 (d, J= 14.8 Hz, 2H), 7.99 (d, J ------ 7.6 Hz, 1H), 7.64-7.60 (m, 2H), 6.71 (s, 1H), 4.76 (s, 2H), 4.37 (s, 2H), 3.33 (s, 3H).Example 25Synthesis of 7-( ( f-fluoro-6-methoxyquinazolin-4-yl)ainino)methyl)-lH-benzo[d][ 1, 2, 6 oxazaborinin-l-ol95MF-369911600Attorney Docket No.: 314352001641

[0288] The compound above was synthesized using Scheme 22.Scheme 22Methyl 4-fluoro-3-methoxybenzoate (22-2)

[0289] To a stirred solution of 4-fluoro-3-methoxybenzoic acid (22-1) (15.0 g, 88.16 mmol, 1.0 equiv.) in DMF (100 mL) was added K2CO3 (30.46 g, 220.4 mmol, 2.5 equiv.) at room temperature followed by CH3I (25.02 g, 176.32 mmol, 2,0 equiv.) and stirred for 2 hours. After consumption of the starting material, the reaction was diluted with cold water (300 mL) and extracted with diethyl ether (2 x 500 ml.,). The combined organic layers were washed with water (300 mL), followed by a brine solution (200 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by combiflash column chromatography, by elution with 0-30% EtOAc in hexane; which generated methyl 4-fluoro-3-m ethoxybenzoate (22-2) (12.2 g, 75.2% yield) as colorless liquid.

[0290] ’H-NMR (400 MHz, DMSO- e) 67.66-7.61 (m, 2H), 7.12 (dd,,7= 8.0, 10.8 Hz, 1H), 3.94 (s, 3H), 3.91 (s, 3H).Methyl 4-fhioro-5-methoxy-2-mtrobenzoate (22-3)

[0291] To a -10 °C cooled solution of H2SO4 (8.4 mL) and concentrated HNO3 (47.89 g, 760,16 mmol, 10.0 equiv.) was added methyl 4-fluoro-3 -methoxybenzoate (22-2) (14.0 g, 76.01 mmol, 1.0 equiv.) and stirred for 15 minutes at same temperature. After consumption of the starting material, the reaction mixture was added to cold water (100 mL) and extracted with EtOAc (2 x 250 mL). The combined organic layers were washed with water (300 mL), followed by a brine solution (200 mL), and dried over Na2SO4. After filtration, the filtrate was96MF-369911600Attorney Docket No.: 314352001641concentrated under reduced pressure. The product was purified by conibiflash column chromatography, by elution with 0-30% EtOAc in hexane; which generated methyl 4-fluoro-5-methoxy-2-nitrobenzoate (22-3) (7.0 g, 40.2% yield) as pale-yellow solid.

[0292] 'H-NMR (400 MHz, DMSO- s) 67.79 (d, J= 10.4 Hz, 1H), 7.17 (d, J= 7.6 Hz, 1H), 4.01 (s, 3H), 3.93 (s, 3H).Methyl 2-amino-4-fluoro-5-Tnethoxybenzoate (22-4)

[0293] To a stirred solution of methyl 4-fluoro-5-methoxy-2-nitrobenzoate (22-3) (7.0 g, 30.54 mmol, 1.0 equiv.) in EtOH: H2O (7:3, 70 mL) was added Zn dust (19.97 g, 305.46 mmol, 10.0 equiv.) followed by NH4CI (16.33 g, 305.46 mmol, 10.0 equiv.) at room temperature and heated to 90 °C for 3 hours. After consumption of the starting material, the reaction mixture was diluted with water (50 mL) and filtered through celite pad and washed with EtOAc (200 mL). The filtrate was washed with water (100 mL), followed by a brine solution (100 mL) and dried over NazSO-i. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0-70% EtOAc in hexane, which afforded methyl 2-amino-4-fluoro-5-methoxybenzoate (22-4) (3.5 g, 57.6% yield) as a pale brown solid.

[0294] ft-LNMR (400 MHz, DMSO-6) 67.34 (d, J 10.0 Hz, 1 H), 6.64 (d, J 13.6 Hz, 1H), 6.54 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H).7-Fhtoro-6-methoxyqttinazohn-4-ol ( 22-5)

[0295] To a stirred solution of methyl 2-amino-4-fluoro-5-methoxybenzoate (22-4) (1.0 g, 5.02 mmol, 1.0 equiv.) in 11-BuOH (10 mL) was added formamidine acetate (0.52 g, 5.02 mmol, 1.0 equiv.) at room temperature under nitrogen atmosphere and allowed to stir at 110 °C for 16 hours. After consumption of the starting material, the reaction mixture was cooled to 0 °C, the obtained solids were filtered and washed with pentane (20 mL), dried under reduced pressure; which generated 7-fluoro-6-methoxyquinazolin-4-ol (22-5) (900 mg, 92.4% yield) as an off-white solid.

[0296] 'H-NMR (400 MHz, DMSO-6) 5 12.29 (s, 1H), 8.04 (s, 1H), 7.67 (d, 9.6 Hz, 1H), 7.53 (d, J= 12.4 Hz, 1H), 3.96 (s, 3H).4-Chloro- 7-fluoro-6-methoxyquinazoline (22-6)

[0297] To a stirred solution of 7-fluoro-6-m ethoxy quinazolin-4-ol (22-5) (1.0 g, 5.15 mmol, 1.0 equiv.) in SOCh (15 mL) was added DMF (0.9 mL) at 0 °C. The reaction mixture was heated to 80 °C for 6 hours. After consumption of the starting material, the reaction 97MF-369911600Attorney Docket No.: 314352001641mixture was concentrated under reduced pressure. The residue was diluted with cold water (20 ml.), the obtained solids were filtered and washed with pentane (20 mL), which afforded 4-chloro-7-fluoro-6-methoxyquinazoline (22-6) (700 mg, 64.2% yield) as a pale-yellow solid. This compound was used for the next step without any further purification.

[0298] 58.95 (s, 1H), 7.72 (d, J === 11.2 Hz, 1H), 7.55 (d, J= 8.8 Hz, 1H), 4.10 (s, 3H).7-(((7-Fluoro~6-methoxy>quinazolin-4-yl)amino)methyl)-lH-benzo[d] [1,2,6]oxazaborinin-l- ol (25>

[0299] To a stirred solution of 4-chloro-7-fluoro-6-methoxyquinazoline (22-6) (160 mg, 0.75 mmol, 1.0 equiv.) in DMSO (3 mL) was added 7-(aminomethyl)-l / 7-benzo[ ][l,2,6]oxazaborinin-l-ol hydrochloride (2-7 in Scheme 2) (200 mg, 0.94 mmol, 1.0 equiv.) followed by CsF (357 mg, 2.35 mmol, 2.5 equiv.) at room temperature and stirred for 16 hours. After consumption of the starting material, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna Cl 8 (250x30 mm, 5pm); mobile phase, ACN in 0.1% formic acid buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 5, 3 / 5, 10 / 23, 18 / 23, 25 / 45, 28 / 98]; PDA detector, UV 220 and 254 nm; which generated 7-(((7-fluoro-6-methoxyquinazolin-4-yl)amino)methyl)-17f-benzo[d][l,2,6]oxazaborinin-l-ol (25) (45 mg, 13.6% yield) as an off-white solid.

[0300] LCMS: [M+H]+: 353

[0301] 'H-NMR (400 MHz, DMSO-6): 59.36 (s, 1H), 8.91 (t, J= 5.6 Hz, 1H), 8.61 (s, 1H), 8.40 (s, 1H), 8.04 (s, 1H), 7.96 (d,. / 8.8 Hz, 1H), 7.81 (d, J = 6.4 Hz, 1H), 7.72 (d, J ------8.0 Hz, 1H), 7.53 (d,. / = 12.0 Hz, 1H), 4.95 (d,. / = 5.6 Hz, 2H), 3.97 (s, 3H).Example 26Synthesis of 6-(((7-fluoro-6-methoxyquinazolin-4-yl)amino)methyl)-lH-henzo[d] [1, 2,6]oxazaborinin-l-ol98MF-369911600Attorney Docket No.: 314352001641

[0302] The compound above was synthesized using Scheme 23.Scheme 236-(((7~Fluoro-6-methoxyquinazolin~4-yl)amino)methyl)- lH-benzo[d] [ 1, 2, 6 ]oxazaborinin-l-ol (26)

[0303] To a stirred solution of 4-chloro-7-fluoro-6-methoxyquinazoline (22-6 in Scheme 22) (220 mg, 1.04 mmol, 1.1 equiv.) in DM SO (5 mL) was added 6-(aminomethyl)-lJ / -benzo[ ][l,2,6]oxazaborinin-l-ol hydrochloride (1-7 in scheme 1) (200 mg, 0.94 mmol, 1.0 equiv.) followed by KF (81.78 mg, 1.41 mmol, 1,5 equiv.) and TEA (0.66 mL, 4,71 mmol, 5.0 equiv.) at room temperature and stirred for 16 hours. After consumption of the starting material, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (2 x 20 mL). The aqueous layer was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 0.1% formic acid buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 25, 3 / 10, 6 / 30, 12 / 30, 25 / 95, 27 / 10]; PDA detector, UV 220 and 254 nm; which generated 6-(((7-fluoro-6-methoxyquinazolm-4-yl)amino)methyl)-lJ -benzo[ Z][l,2,6]oxazaborinin-l-ol (26) (32 mg, 9.7% yield) as an off-white solid.

[0304] LCMS: [M+H]4: 353

[0305] ^I-NMR (400 MHz, DMSO- e): 6 10.26 (d, J ------ 12.4 Hz, 1H), 9.40 (s, 1H), 8.81 (s, 1H), 8.64 (s, 1H), 8.16 (d, J= 8.4 Hz, 1H), 8.07 (d, J= 7.6 Hz, 1H), 7.79 (dd, J= 1.6, 7.6 Hz, 1H), 7.75 (s, 1H), 7.68 (d, J= 11.2 Hz, 1H), 5.10 (d, 6.0 Hz, 2H), 4.03 (s, 3H).99MF-369911600Attorney Docket No.: 314352001641Example 27Synthesis of 7-((quinazolin-4-ylammo)methyl)-lH-benzo[d] [ 1, 2, 6]oxazaborinin-l-ol

[0306] The compound above was synthesized using Scheme 24.Scheme 247-((Quinazolin-4-ylamino)methyl)-lH-benzo[d][ 1, 2, 6 ]oxazaborinin-l-ol (27 )

[0307] To a stirred solution of 4-chloroquinazoline (24-1 in Scheme 24) (139 mg, 0.84 mmol, 1.2 equiv.) in DMSO (2 mL) was added 7-(aminomethyl)-lFf-benzo[ ][l,2,6]oxazaborinin-l-ol hydrochloride (2-7 in Scheme 2) (150 mg, 0.706 mmol, 1.0 equiv.) followed by KF (123 mg, 2.11 mmol, 3.0 equiv.), TEA (0.59 mL, 4.23 mmol, 6.0 equiv.) and Celite (84 mg, 1.41 mmol, 2.0 equiv.) at room temperature and stirred for 2 hours. After consumption of the starting material, the reaction mixture was diluted with water (8 mL) and extracted with EtOAc (2 x 20 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 0.1% formic acid buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 2 / 10, 10 / 40, 17 / 45, 28 / 85, 30 / 98]; PDA detector, UV 220 and 254 nm; which generated 7-((quinazolin-4-ylamino)methyl)-l / 7-benzo[rZ][l,2,6]oxazaborinin-l-ol (27) (65 mg, 30.4% yield) as an off-white solid.

[0308] LCMS: [M+H]: 305

[0309] ^I-NMR (400 MHz, D3-MeOD) 58.52 (s, 1H), 8.33 (s, 1H), 8.24 (dd, J --- 0.8, 8.2 Hz, 1H), 7.86-7.90 (m, 2H), 7.75 (d, J= 8.0 Hz, 1H), 7.61-7.69 (m, 2H), 7.56 (d, J= 8.0 Hz, 1H), 5.02 (s, 2H),100MF-369911600Attorney Docket No.: 314352001641Example 28Synthesis of 6-((quinazolm-4-ylamino)methyl)-lH-benzo[d] [l,2,6]oxazaborinm-l-ol

[0310] The compound above was synthesized using Scheme 25.Scheme 254-Bromo-3 -( di bromomethyl) benzonitrile (25-2)

[0311] To a stirred solution of 4-bromo-3 -methylbenzonitrile (25-1) (50.0 g, 255.04 mmol, 1.0 equiv.) in CCU (500 niL) was added NBS (181.63 g, 1020.4 mmol, 4.0 equiv.) followed by AIBN (16.75 g, 102.02 mmol, 0.4 equiv.) at room temperature and heated to 80 °C for 6 hours under nitrogen atmosphere. After consumption of the starting material, the reaction mixture was diluted with water (1000 mL) and extracted with EtOAc (2 x 1000 mL).101MF-369911600Attorney Docket No.: 314352001641The combined organic layers were washed with water (2 x 500 mL), followed by a brine solution (200 mL) and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by column chromatography and eluted with 0% to 10% EtOAc in hexane; which afforded 4-bromo-3-(dibromomethyl)benzonitrile (25-2) (76 g, 84.2% yield) as a pale brown gummy liquid. This material was used in the next step without further purification.

[0312] ft-LNMR (400 MHz, DMSO- d6) 58.37 (s, 1H), 8.16 (d, J === 1.6 Hz, 1 H), 7.80 (dd, J = 1.6, 6.4 Hz, 1H), 7.35 (s, 1H).4-Bromo-3-formylbenzonitrile (25 -3)

[0313] To a stirred solution of 4-bromo-3-(dibromomethyl)benzonitrile (25-2) (75,0 g, 211.86 mmol, 1.0 equiv.) in EtOH (650 mL) was added silver nitrate (71.97 g, 423.72 mmol, 2.0 equiv.) in water (150 mL) at room temperature and stirred at 90 °C for 1 hour. After consumption of the starting material, the reaction mixture was diluted with water (1000 mL) and extracted with EtOAc (2 x 1000 mL). The combined organic layers were filtered through a celite pad and the filtrate was washed with a brine solution (500 mL), dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by column chromatography and eluted with 0% to 60% EtOAc in hexane, which generated 4-bromo-3 -formylbenzonitrile (25-3) (26.50 g, 59.5% yield) as an off-white solid.

[0314] 'H-NMR (400 MHz, DMSO- s) 6 10.18 (s, 1H), 8.09 (d, J= 2.0 Hz, 1H), 8.05 (d, J= 1.6 Hz, 1H), 7.86 (dd, J= 2.4, 8.2 Hz, 1H).tert-Butyl (4-bromo-3-(hydroxymethyl)benzyl)carbamate (25-4)

[0315] To a 0 °C cooled solution of 4-bromo-3-formylbenzonitrile (25-3) (53.0 g, 252.4 mmol, 1.0 equiv.) in MeOH (600 mL), were added N1CI2.6H2O (23.96 g, 100.8 mmol, 0.4 equiv.) and di-tert-butyl dicarbonate (165.1 g, 757.2 mmol, 3.0 equiv) and stirred at same temperature for 20 minutes. Then, NaBH₄ (38.18 g, 1009.6 mmol, 4.0 equiv.) was added portion wise at 0 °C and allowed to room temperature. The reaction was stirred at room temperature for 12 hours. After consumption of the starting material, the reaction mixture was concentrated under reduced pressure to remove MeOH and the residue was diluted with EtOAc (1000 mL). The mixture was filtered through a celite pad, washed with more EtOAc (1 L). The organic layer was separated and washed with water (2 x 500 mL) and a brine solution (300 ml.,). The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The product was purified by column chromatography using a102MF-369911600Attorney Docket No.: 314352001641gradient of 0-60% EtOAc in hexane, which generated tert-butyl (4-bromo-3-(hydroxymethyl)benzyl)carbamate (25-4) (32.02 g, 40, 1% yield) as a gummy liquid,

[0316] ^-NMR (400 MHz, DMSO- ) 57.49 (d,.7 = 8.0 Hz, 1H), 7.43 (s, 2H), 7.05 (dd, J= 2.0, 8.2 Hz, 1H), 5.43 (t, J= 5.6 Hz, 1H), 4.49 (d, 5.6 Hz, 2H), 4.10 (d, J= 6.0 Hz, 2H), 1.42 (s, 9H).tert-Butyl (4-bromo-3-forinylbenzyl)carbamate (25-5 )

[0317] To a stirred solution of tert-butyl (4-bromo-3-(hydroxymethyl)benzyl)carbamate (25-4) (32.0 g, 101.20 mmol, 1.0 equiv.) in DCM (500 mL) was added DMP (64.38 g, 151.8 mmol, 1.5 equiv.) portion-wise at 0 °C under nitrogen atmosphere and allowed to stir at room temperature for 2 hours. After consumption of the starting material, the reaction mixture was diluted with EtOAc (1000 mL), a 5% sodium thiosulfate solution (500 mL) was added and stirred for 15 minutes. The organic layer was separated. The organic layer was washed with saturated NaHCOs solution (2 x 500 mL), followed by a brine solution (300 L) and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by column chromatography using 0-30% EtOAc in hexane as eluent, which afforded tert-butyl (4-bromo-3-formylbenzyl)carbamate (25-5) (19.0 g, 59.8% yield) as a gummy liquid.

[0318] 'H-NMR (400 MHz, DMSO-rfc) 5 10.22 (s, 1H), 7.77-7.73 (m, 2H), 7.54-7.47 (m, 2H), 4.15 (d, J= 6.0 Hz, 2H), 1.40 (s, 9H).5-(Aminom.ethyl)-2-bromobenzaldehyde hydrochloride ( 25-6)

[0319] To a stirred solution of tert-butyl (4-bromo-3-formylbenzyl)carbamate (25-5) (2.0 g, 6.36 mmol, 1,0 equiv.) in DCM (20 mL) was added 4M hydrochloric acid in 1,4-dioxane (15.9 mL, 63.6 mmol, 10.0 equiv.) at 0 °C and reaction mixture was allowed to stir at room temperature for 2 hours. After consumption of the starting material, the reaction mixture was concentrated under reduced pressure. The obtained residue was co-di stilled with DCM (2 x 50 mL) and washed with n-pentane (2 x 50 mL), which afforded 5-(aminomethyl)-2-bromobenzaldehyde hydrochloride 25-6) (1.2 g, 75,4% yield) as a white solid. This compound was used for the next step without any further purification.

[0320] LCMS: [M+H] % 214(E)-N'-(2-Cyanophenyl)-N, N-dimethylformiinidamide (25-8)103MF-369911600Attorney Docket No.: 314352001641

[0321] To a stirred solution of 2-aminobenzonitrile (25-7) (1.0 g, 8.47 mmol, 1.0 equiv.) in DMF (10 mL) was added DMF-DMA (15.18 g, 127.05 mmol, 15.0 equiv.) at room temperature and stirred at 90 °C for 4 hours. After consumption of the starting material, the reaction mixture was diluted with cold water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with cold water (3x 50 mL), followed by a brine solution (50 mL) and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by column chromatography and eluted with 0% to 50% EtOAc in hexane, which afforded (£)-A'r'-(2-cyanophenyl)-A(A’-dimethylformimidamide (25-8) (950 mg, 65.1% yield) as a brown gummy liquid.

[0322] ’H-NMR (400 MHz, CDCh) 67.58 (s, 1H), 7.53 (dd, J= 1.2, 7.8 Hz, 1H), 7.43- 7.39 (m, 1H), 7.01- 6.97 (m, 1H), 6.94 (d, J= 8.0 Hz, 1H), 3.08 (d, J= 9.6 Hz, 6H).2-Bromo-5-((quinazolin-4-ylamino) methyl) benzaldehyde 625-91

[0323] To a stirred solution of (A)-A'-(2-cyanophenyl)-Ar, / V-dimethylformimidamide (25- 8) (750 mg, 4.43 mmol, 1.0 equiv.) in acetic acid (10 mL) was added 5-(aminomethyl)-2-bromobenzaldehyde hydrochloride (25-6) (1.11 g, 4.43 mmol, 1.0 equiv.) at room temperature and stirred at 110 °C for 4 hours. After consumption of the starting material, the reaction mixture was concentrated under reduced pressure to remove acetic acid. The crude reaction mixture was diluted with cold water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with a brine solution (50 mL) and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by column chromatography and eluted with 0% to 60% EtOAc in hexane, which generated 2-bromo-5-((quinazolin-4-ylamino)methyl)benzaldehyde (25-9) (605 mg, 40.8% yield) as a brown solid.

[0324] 10.31 (s. 111). 8.64 (s, 1H), 7.90 (d, J 2.4 Hz, 1H), 7.86-7.74 (m, 4H), 7.59 (d, J= 8.0 Hz, 1H), 7.56-7.45 (m, 1H), 6.51 (m, 1H), 4.88 (d, J - 5.6 Hz, 2H).5-((Quinazolm-4-ylamino)methyl)-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) benzaldehyde 25 - 10)

[0325] To a sealed tube containing 2-bromo-5-((quinazolin-4-ylamino)methyl)benzaldehyde (25-9) (600 mg, 1.76 mmol, 1.0 equiv.) in 1,4-dioxane (15 mL) was added bis(pinacolato)diboron (665.2 mg, 2.64 mmol, 1.5 equiv.) followed by potassium acetate (518 mg, 5.28 mmol, 3.0 equiv.) at room temperature and degassed with104MF-369911600Attorney Docket No.: 314352001641argon for 10 minutes. bis(Triphenylphosphine)palladium chloride (119 mg, 0.17 mmol, 0.1 equiv.) was then added under argon atmosphere and heated to 95 °C for 4 hours. After consumption of the starting material, the reaction mixture was filtered through a celite pad and washed with EtOAc (150 mL). The filtrate was washed with water (50 mL), followed by a brine solution (30 mL) and dried over Na₂SO₄. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0-70% EtOAc in hexane, which generated a mixture of 5-((quinazolin-4-ylamino)methyl)-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzaldehyde (25-10) and (2-formyl-4-((quinazolin-4-ylamino)methyl)phenyl)boronic acid (25-10A) (505 mg) as a pale brown solid. This compound was used for the next step without further purification.

[0326] LCMS: [M+H]+: 3086-((Quinazoliri-4-ylamino)methyl)-lH-benzo[d] [ 1, 2, 6 ]oxazaborinin-l-ol (28)

[0327] To a stirred solution of 5-((quinazolin-4-ylamino)methyl)-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzaldehyde (25-10) and (2-formyl-4-((quinazolin-4-ylamino)methyl)phenyl)boronic acid (25-10A) (500 mg, 1.28 mmol, 1.0 equiv.) in EtOH and water (3:1, 20 mL) was added hydroxylamine hydrochloride (133.4 mg, 1.92 mmol, 1.5 equiv.) at room temperature under nitrogen atmosphere and stirred for 2 hours. After consumption of the starting material, the reaction mixture was concentrated, then diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The product was purified by reverse phase prep-HPLC with the following conditions: column, Luna C18 (250x50 mm, 10 pm); mobile phase, ACN in lOmM ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 10, 2 / 10, 12 / 40, 17 / 40, 17.5 / 98, 22 / 98, 25 / 10]; PDA detector, UV 220 and 254 nm; which generated 6-((quinazolin-4-ylamino)methyl)-U / -benzo[ ][l,2,6]oxazaborinin-l-ol (28) (40 mg, 10.3% yield) as an off-white solid.

[0328] LCMS: [M+H]: 305

[0329] 'H-NMR (400 MHz, DMSO- s) 59.33 (s, 1H), 8.96 (t, J= 6.0 Hz, 1H), 8.63 (s, 1H), 8.44 (s, 1H), 8.32 (d, J 8.0 Hz, 1H), 8.03 (d, J 7.6 Hz, 1H), 7.82-7.78 (m, 1 H), 7.75- 7.70 (m, 3H), 7.58-7.54 (m, 1H), 4.93 (d, J= 6.0 Hz, 2H).Example 29Synthesis of 5-(((l-hydroxy-lH-benzo[d] [1,2,6 loxazaborinin-7-yl)methyl)amino)-l,8- aphthyridin-2( lH)-one105MF-369911600Attorney Docket No.: 314352001641

[0330] The compound was synthesized using Scheme 26.Scheme 26BrettPhos.t-BuONa,dioxaneMethyl (2E)-3-(4-hromo-2-fluoropyridin-3-yl)prop-2-enoate (26-3)

[0331] A solution of 4-bromo-2-fluoropyridine-3-carbaldehyde (26-1) (10.0 g, 49.0 mmol, 1.0 equiv) and methyl 2-(triphenyl-lambda5-phosphanylidene) acetate (26-2) (19.7 g, 58.8 mmol, 1.2 equiv) in THF (100 mL) was stirred at room temperature overnight under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (6 / 1), which afforded methyl (2£')-3-(4-bromo-2-fluoropyridin-3-yl)prop-2-enoate (26-3) (10.1 g, 79.2% yield) as an off-white solid.

[0332] LCMS (ESI): [M+Hp: 260Methyl (2E)-3-(2-amino-4-bromopyridin-3-yl) prop-2-enoate (26-4)

[0333] A solution of methyl (2£)-3-(4-bromo-2-fluoropyridin-3-yl) prop-2-enoate (26-3) (5.0 g, 19.2 mmol, 1.0 equiv.) in ammonia (1.3 M in THE, 500 mL) was stirred at 60 °C for 2 days under nitrogen atmosphere. The mixture was allowed to cool down to room temperature.106MF-369911600Attorney Docket No.: 314352001641The resulting mixture was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (5 / 1), which afforded methyl (2£)-3-(2-amino-4-brom opyri din-3 -yl) prop-2-enoate (26-4) (2.2 g, 44.5% yield) as a white solid.

[0334] LCMS (ESI): [M+H]+: 2577-Methoxy-3H-pyrido[2,3-dlpyrimidin-4-one (26-5)

[0335] A solution of methyl (2E)-3-(2-amino-4-bromopyridin-3-yl) prop-2-enoate (26-4) (1.5 g, 5.8 mmol, 1.0 equiv.) and MeONa (1.6 g, 29.0 mmol, 5.0 equiv.) in MeOH (20 mL) was stirred at 80 °C for 3 hours. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 10% to 50% gradient in 10 min; detector, UV 254 nm; which afforded 5-bromo-lH-l,8-naphthyridin-2-one (26-5) (600 mg, 45.7% yield) as a light-yellow solid.

[0336] LCMS (ESI): [M+H]L 2255-(((l~Hydroxy-lH-benzo[d] [1,2,6 ]oxazaborinin-7-yl)methyl)amino)-l,8-naphthyridin~ 2(lH)-one (29)

[0337] To a stirred solution of 5-bromo-l / / -l,8-naphthyridin-2-one (26-5) (150 mg, 0.7 mmol, 1.0 equiv.) and 7-(aminomethyl)-2,3,l-benzoxazaborinin-l-ol hydrochloride (26-6, 2-7 Scheme 2) (113 mg, 0.56 mmol, 0.8 equiv.) in 1,4-dioxane (1 mL) were added BrettPhos Pd G3 (60 mg, 0.07 mmol, 0.1 equiv), BrettPhos (72 mg, 0,14 mmol, 0.2 equiv) and t-BuONa (320 mg, 3.5 mmol, 5.0 equiv) in one portion at 25 °C under nitrogen atmosphere. The reaction mixture was stirred at 90 °C for overnight under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure and the product was purified by Prep-HPLC (conditions: Column: XBridge BEH C18 OBD Prep Column, 5 pm, 30 mm * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 8% B to 30% B in 8min; Wave Length: 254 / 220 nm); which afforded 5-{[(l -hydroxy-2, 3,1 -benzoxazaborinin-7-yl)methyl]amino}-l H-1,8-naphthyridin-2-one (29) (5.4 mg, 2.5% yield) as a white solid.

[0338] LCMS (ESI): [M+H]+: 321

[0339] fll NMR (400 MHz, DMSO-6) 8 11.63 (s, I H), 9.36 (s, I H), 8.61 (s, 1 H), 8.27 (d, J= 9.7 Hz, 1H), 8.10 - 7.86 (m, 3H), 7.86 - 7.65 (m, 2H), 6.39 (d, J= 9.7 Hz, 1H), 6.20 (d, J ------ 5.9 Hz, 1H), 4.64 (d, J - 5.9 Hz, 2H).107MF-369911600Attorney Docket No.: 314352001641Example 30Synthesis of 5-{[(l -hydroxy-2, 3, 1-benzoxazaborinin- 7-yl)methyl ]amino}-3, 4-dihydro-lH-l, 8-naphthyridin-2-one hydrochloride

[0340] The compound was synthesized using Scheme 27.Scheme 27Methyl 3-(2-amino-4-bromopyridm-3-yl) propanoate (27-2)

[0341] A mixture of methyl (2£)-3-(2-amino-4-bromopyri din-3 -yl ) prop-2-enoate (27-1, 26-4 in Scheme 26) (1.5 g, 5.9 mmol, 1.0 equiv.) and 10% Rh / AhCh (0.75 g, 50 wt.%) in IP A (30 mL) was stirred at room temperature for 16 hours under hydrogen atmosphere (1 atm). The reaction mixture was filtered through Celite and the filter cake was washed with methanol (3 x 30 mL). The filtrate was concentrated under reduced pressure that provided methyl 3-(2-amino-4-bromopyridin-3-yl) propanoate (27-2) (1.3 g) as a white solid, which was used for next step without further purification.

[0342] LCMS (ESI): [M+Hp: 2595-Bromo-3,4-dihydro-l,8-naphthyridin-2(lH)-one (27-3)108MF-369911600Attorney Docket No.: 314352001641

[0343] A solution of methyl 3-(2-amino-4-bromopyridin-3-yl)propanoate (27-2) (1.3 g, 5.1 mmol, 1.0 equiv.) and DBU (3.9 g, 25.5 mmol, 5,0 equiv.) in MeOH (20 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 10% to 50% gradient in 10 min; detector, UV 254 nm, which afforded 5-bromo- 3.4-dihydro-l,8-naphthyridin-2(l / 7)-one (27-3) (700 mg, 60.8% yield) as a white solid.

[0344] LCMS (ESI): [M+H]f 2275-{[( 1 -Hydroxy-2, 3, 1-benzoxazaborinin- 7-yl)methyl amino}-3, 4-dihydro-lH-l, 8-naphthyridin-2-one hydrochloride (30)

[0345] To a stirred solution of 5-bromo-3,4-dihydro-l / 7-l,8-naphthyridin-2-one (27-3) (500 mg, 2.2 mmol, 1.0 equiv.) and 7-(aminomethyl)-2,3,l-benzoxazaborinin-l-ol hydrochloride (27-4, 2-7 Scheme 2) (374 mg, 1.8 mmol, 0.8 equiv.) in DMF (5 mL) were added t-BuONa (635 mg, 6.6 mmol, 3.0 equiv.) and {l,3-bis[2,6-bis(pentan-3-yl)phenyl]-2,3- dihydro-177-imidazol-2-ylidene}dichloropalladium (174 mg, 0.22 mmol, 0.1 equiv.) in one portion at 25 °C under nitrogen atmosphere. The reaction mixture was stirred at 60 °C for 16 hours under nitrogen atmosphere. The product was purified by Prep-HPLC (Column:XBridge BEH C18 5 μm, 19 × 250 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 3% B to 15%B in 8 min; Wave Length: 254 nm / 220 nm), which afforded 5-{[(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)methyl]amino}- 3.4-dihydro-lH-l,8-naphthyridin-2-one hydrochloride (30) (42.5 mg, 5.4% yield) as a white solid.

[0346] LCMS (ESI): [M+H]L 323

[0347] 'HNMR (400 MHz, DMSCW6) 0 10.91 (s, 1H), 8.64 (s, 1H), 8.51 (s, 1H), 8.02 (d, J= 1.7 Hz, 1H), 7.87 (d, J= 7.3 Hz, 1H), 7.82 - 7.68 (m, 2H), 6.56 (d, J= 7.4 Hz, 1H), 4.77 (d, J= 6.1 Hz, 2H), 2.90 (t, J= 7.7 Hz, 2H), 2.70 (dd, 8.3, 7.2 Hz, 2H).Example 31Synthesis of 4-{[(l-hydroxy-2,3,l-benzoxazaborinm-7-yl)methyl]amino}-5H,6H,8H- pyrido[ 2, 3-d]pyrimidin- 7 -one109MF-369911600Attorney Docket No.: 314352001641

[0348] The compound was synthesized using Scheme 28.Scheme 28BrettPhos, Brettphos Pd G3.t-BuONa, dioxaneMethyl 3-( 4-amino-6-chloropyrimidin-5-yl)propanoate (28-2)

[0349] A mixture of methyl (2£ -3-(4-amino-6-chloropyrimidin-5-yl)prop-2-enoate (28- 1, 3-2 in Scheme 3) (2.0 g, 9.4 mmol, 1.0 equiv.) and Pd / C (0.10 g, 1.0 mmol, 0.1equiv.) in MeOH (30 mL) was stirred at room temperature for4 days under hydrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with MeOH (2 x 30 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in methyl 3-(4-amino-6-chloropyrimidin-5-yl)propanoate (28-2) (1.6 g, 79.3% yield) as a yellow oil.

[0350] LCMS (ESI): [M+H];: 2164-Chloro-5H,6H,8H-pyrido[2,3-d]pyrimidin-7-one (28-3)

[0351] A mixture of methyl 3-(4-amino-6-chloropyrimidin-5-yl)propanoate (28-2) (1.6 g, 7.4 mmol, 1.0 equiv.) and TEA (2.3 g, 22.3 mmol, 3.0 equiv.) in MeOH (10 mL) was stirred110MF-369911600Attorney Docket No.: 314352001641at room temperature for 3 hours under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobilephase, MeOH in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in 4-chloro-577,6H,8 / / -pyrido[2,3-<7]pyrimidin-7-one (28-3 ) (1.1 g, 80.7% yield) as a yellow oil.

[0352] LCMS (ESI): [M+H]+: 1844-{[(1-Hydroxy-2,3,1-benzoxazaborinin-7-yl)methyl]amino}-5H,6H,8H-pyrido[2,3-d]pyrimidin-7-one (31)

[0353] A solution of 4-chloro-5H,6H,8H-pyrido[2,3-d]pyrimidin-7-one (28-3) (300 mg, 1.6 mmol, 1.0 equiv.) in 1,4-dioxane (5 mL) was treated with BrettPhos Pd G3 (148 mg, 0.2 mmol, 0,1 equiv.), BrettPhos (88 mg, 0.2 mmol, 0.1 equiv.) and t-BuONa (471 mg, 4.9 mmol, 3.0 equiv.) at room temperature for 5 minutes under nitrogen atmosphere, followed by the addition of 7-(aminomethyl)-2,3,l-benzoxazaborinin-l-ol hydrochloride (28-4, 2-7 in Scheme 2) (431 mg, 2.5 mmol, 1.5 equiv.). The mixture was stirred for 3 hours at 40 °C. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: Column: XBridge BEH C18 5 μm, 19 × 250 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 7% B to 15%B in 7 min; Wave Length: 254 nm / 220 nm. This resulted in 4-{[(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)methyl]amino}-5H,6H,8H-pyrido[2,3-< / ]pyrimidin-7-one (31) (15.8 mg, 3.0% yield) as a yellow semi-solid.

[0354] LCMS (ESI): [M+H]+: 324

[0355] 10.53 (brs, 1H), 8.61 (s, 1H), 8.19 - 8.16 (m, 1H), 7.98 (s, 1H), 7.82 - 7.65 (m, 2H), 4.77 (s, 2H), 2.82 - 2.71 (m, 2H), 2.60 (s, 2H).Example 32Synthesis of 7 -[( {8-methoxypyrido [ 3, 4-d]pyrimidin-4-yI }amino)methyl -2, 3,1-benzoxazaborinin-l-ol (32)111MF-369911600Attorney Docket No.: 314352001641

[0356] The compound was synthesized using Scheme 29.Scheme 294-Chloro-8-methoxypyrido[3,4-d]pyrimidine (29-2)

[0357] To a stirred solution of 8-methoxy-3 -pyrido[3,4- J pyrimidin-4-one (29-1) (1.0 g, 5.6 mmol, 1.0 equiv.) in CHCh (40 mL) were added phosphoryl trichloride (1.8 mL,19.6 mmol, 3.5 equiv.) and TEA (2.2 g, 20.7 mmol, 3.7 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was heated to 80 °C overnight under nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The resulting mixture was diluted with water (50 mL) and extracted with CH2Q2 (2 x 50 mL). The combined organic layers were washed with water (2 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in 4-chloro-8-methoxypyrido[3,4-<7] pyrimidine (29-2) (600 mg, 55.0% yield) as a light-yellow solid, which was used directly in the next step without further purification.

[0358] LCMS (ESI): [M+Hf: 196.07-[({8-Methoxypyrido[3,4-d]pyrimidin-4-yl}amino)methyl]-2,3,1-benzoxazaborinin-1-ol (32)

[0359] To a stirred solution of 4-chloro-8-methoxypyrido[3,4-tZ] pyrimidine (29-2) (450 mg, 2.3 mmol, 1.0 equiv.) and 7-(aminomethyl)-2,3,l-benzoxazaborinin-l-ol hydrochloride (29-3, 2-7 in Scheme 2) (405 mg, 2.3 mmol, 1.0 equiv.) in DMSO (10.0 mL) were added TEA (1.2 g, 11.5 mmol, 5.0 equiv.) and CsF (1.7 g, 11.5 mmol, 5.0 equiv.) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 2 hours. The product was purified by Prep-HPLC (Column: XBridge BEH112MF-369911600Attorney Docket No.: 314352001641C185 pm, 19 * 250 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 7% B to 15%B in 9 min; Wave Length: 254 nm / 220 nm) followed by further purification by Prep-HPLC (Column: YMC-Actus Triart C18 ExRS5 pm, 30 mm X 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1%NH3FhO), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 15%B in 9 min; Wave Length: 254 nm / 220 nm), which afforded 7-[({8-methoxypyrido[3,4-t / ]pyrimidin-4-yl}amino)methyl]-2,3,l-benzoxazaborinin-l-ol (32) (27.9 mg, 3.3% yield) as a white solid.

[0360] LCMS (ESI): [M+H]+: 336

[0361] 1H NMR (400 MHz, DMSO-d6) δ 9.34 (s, 1H), 9.07 (t, J= 6.0 Hz, 1H), 8.61 (s, 1H), 8.52 (s, 1H), 8.13 (d, J - 5.8 Hz, 1H), 8.02 (s, 1H), 7.80 (d,. / 8.1 Hz, 111) 7.72 (dd, J = 7.0, 4.3 Hz, 2H), 4.91 (d, J= 5.8 Hz, 2H), 4.01 (s, 3H).Example 33Synthesis of 7-[({7-methoxypyrido[2,3-d]pyrimidin-4-yl}amino)methyl]-2,3,l-benzoxazaborinin-l-ol33

[0362] The compound was synthesized using Scheme 30.Scheme 302-Chloro-6-met.hoxypyndine-3-carboxam.ide (30-2)113MF-369911600Attorney Docket No.: 314352001641

[0363] A solution of methyl 2-chloro-6-methoxypyridine-3-carboxylate (30-1) (2.0 g, 9.9 mmol, 1.0 equiv.) in NH3. H2O (50 mL) was stirred at 100 °C overnight. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in the 2-chloro-6-methoxypyridine-3-carboxamide (30-2) (900 mg, 48.6% yield) as a white solid.

[0364] LCMS (ESI): [M+H]+: 1876-Methoxy-2-{[(4-inethoxyphenyl)methyl ]amino}pyridine-3-carboxamide (30-3)

[0365] To a stirred mixture of 2-chloro-6-methoxypyridine-3-carboxamide (30-2) (900 mg, 4.8 mmol, 1.0 equiv.) and K2CO3 (2.0 g, 14.4 mmol, 3.0 equiv.) in DMF (10 mL) was added (4-niethoxyphenyl)methanamine (992 mg, 7.2 mmol, 1.5 equiv.) in portions at 25 °C under nitrogen atmosphere. The mixture was heated to 100 °C for 2 hours. The mixture was allowed to cool down to 25 °C. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% F ), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in 6- methoxy-2-{[(4-methoxyphenyl)methyl]amino}pyridine-3-carboxamide (30-3) (1.0 g, 72.1% yield) as a white solid.

[0366] LCMS (ESI): [M+H]+: 2882-Amino-6-methoxypyridine-3-carboxamide (30-4)

[0367] To a stirred solution of 6-methoxy-2-{[(4- methoxyphenyl)methyl]amino}pyridine-3-carboxamide (30-3) (1.0 g, 3.4 mmol, 1.0 equiv.) in i-PrOH (20 mL) was added palladium (0.5 g, 0.4 mmol, 0.1 equiv., 10% wt on carbon) in portions at 25 °C under hydrogen atmosphere. The resulting mixture was stirred at 25 °C for 16 hours under hydrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 10 mL). The filtrate was concentrated under reduced pressure. This resulted in 2-amino-6-methoxypyridine-3-carboxamide (30-4) (560 mg) as a white solid, which was used directly in the next step without further purification.

[0368] LCMS (ESI): [M+H]+: 1687-Methoxy'-3H-pyrido[2,3-dpyrimidm-4-one (30-5)

[0369] To a stirred mixture of 2-amino-6-methoxypyridine-3 -carboxamide (30-4) (560 mg, 3.3 mmol, 1.0 equiv.) in trimethoxymethane (6 mL) was added 4-m ethylbenzene- 1- sulfonic acid hydrate (127 mg, 0.6 mmol, 0.2 equiv.) in portions at 25 °C under nitrogen 114MF-369911600Attorney Docket No.: 314352001641atmosphere. The mixture was heated to 90 °C for 16 hours under nitrogen atmosphere. The mixture was allowed to cool down to 25 °C. The precipitated solids were collected by filtration and the filter cake was washed with water (2 x 5 mL). This resulted in 7-methoxy-3H-pyrido[2,3-d]pyrimidin-4-one (30-5) (300 mg, 50.5% yield) as an off-white solid.

[0370] LCMS (ESI): [M+H]+: 1787-[({7-Methoxypyrido[2,3-d]pyrimidin-4-yl}amino)methyl]-2,3,1-benzoxazaborinin-1-ol (33)

[0371] To a stirred mixture of 7-methoxy-3Z / -pyrido[2,3- ]pyrimidin-4-one (30-5) (250 mg, 1.4 mmol, 1.0 equiv.) and BOP (1.5 g, 3.5 mmol, 2.5 equiv.) in DMSO (5 mL) were added DBU (644 mg, 4.2 mmol, 3.0 equiv.) in portions at 25 °C under nitrogen atmosphere. To the above mixture was added 7-(aminomethyl)-2,3,l-benzoxazaborinin-l-ol hydrochloride (30-6, 2-7 in Scheme 2) (248 mg, 1.4 mmol, 1.0 equiv.) in portions at 25 °C. The resulting mixture was stirred at 25 °C for 16 hours. The product was initially purified by reversed-phase flash chromatography with the following conditions: column. Cl 8 silica gel; mobile phase, MeCN in water, 10% to 50% gradient in 10 min; detector, UV 254 nm. The product was further purified by prep-HPLC with the following conditions (Column: XBridge BEH C18 OBD Prep Column, 5 pm, 30 mm x 150 mm; Mobile Phase A: water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 7% B to 12% B in 9min; Wave Length: 254 / 220 nm), which afforded 7~[({ 7- methoxypyrido[2,3- ]pyrimidin-4-yl}amino)methyl]-2,3,l-benzoxazaborinin-l-ol (33) (11.4 mg, 2.4% yield) as a white solid.

[0372] LCMS (ESI): [M+H]+: 336

[0373] 1H NMR (400 MHz, DMSO-d6) δ 11.38 (t,. / 6.0 Hz, 1H), 9.16 (d,. / 9.1 Hz, 1H), 8.86 (s, 1H), 8.63 (s, 1H), 8.07 (s, 1H), 7.88 (d, J= 8.0 Hz, 1H), 7.73 (s, 1H), 7.33 (d, J = 9.0 Hz, 1H), 5.04 (d, J= 5.8 Hz, 2H), 4.07 (s, 4H).Example 34Synthesis of 4-{[( 1 S)-l-(l -hydroxy-2, 3, 1-benzoxazaborinin- 7-yl) ethyl ]amino}-8H-pyrido[ 2,3-dpyrimidin- 7 -one115MF-369911600Attorney Docket No.: 314352001641

[0374] The compound was synthesized using Scheme 31.Scheme 31Methyl 4-acetyl-2-hydroxybenzoate (31-2)

[0375] To a stirred solution of methyl 4-bromo-2-hydroxybenzoate (31-1) (5.0 g, 21.6 mmol, 1.0 equiv.) and tributyl(l -ethoxy vinyl)stannane (9.4 g, 26.0 mmol, 1.2 equiv.) in 1,4-dioxane (100 mL) was added PdfPPhs^Ch (1.5 g, 2.2 mmol, 0.1 equiv.) at room temperature under N2 atmosphere. The reaction mixture was heated to 90 °C overnight under N2 atmosphere. The resulting mixture was concentrated under vacuum. The initial product was purified by silica gel column chromatography, eluted with the following conditions: mobile phase, EA in PE, 0% to 10% gradient in 20 min; detector, UV 254 nm. The initial product116MF-369911600Attorney Docket No.: 314352001641was dissolved in 1 M HC1 aqueous solution (50 mL) and THF (50 mL), the solution was stirred for another 2 hours. The resulting mixture was concentrated under vacuum. This resulted in methyl 4-acetyl-2-hydroxybenzoate (31-2) (5.0 g) as a yellow solid, which was used directly without further purification.

[0376] LCMS (ESI): [M-H]': 193Methyl 2-hydroxy-4-(l-{[(R)-2-methylpropane-2-siilfmyl]imino}ethyl)benzoate (31-3)

[0377] To a stirred solution of methyl 4-acetyl-2 -hydroxybenzoate (31-2) (10.0 g, 51.5 mmol, 1.0 equiv.) and (7?)-2-methylpropane-2-sulfinamide (9.36 g, 77.2 mmol, 1.5 equiv.) in THF (200 mL) was added tetraethoxytitanium (58.7 g, 257.5 mmol, 5.0 equiv.) at room temperature under N2 atmosphere. The resulting mixture was heated to 80 °C for 3 hours under N2 atmosphere. The reaction mixture was cooled down to 60 °C and 2-({2-[bis(2-hydroxyethyl)amino]ethyl}(2-hydroxyethyl)amino)ethan-l -ol (60.9 g, 257.5 mmol, 5.0 equiv.) was added. The resulting mixture was stirred at 60 °C for 20 minutes. The reaction was quenched by the addition of H2O (100 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography with the following conditions: EA in PE, 0% to 25% gradient in 30 min; detector, UV 254 nm. This resulted in the methyl 2-hydroxy-4-(l- {[(7?)-2-methylpropane-2-sulfinyl]imino}ethyl)benzoate (31-3) (7.8 g, 48.6% yield) as a light-yellow oil.

[0378] LCMS (ESI): [M+H]+: 312Methyl 2-hydroxy-4-(1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl)benzoate (31-4)

[0379] To a stirred solution of methyl 2-hydroxy-4-(l-{[(7?)-2-methylpropane-2-sulfmyl]imino}ethyl)benzoate (31-3) (2.0 g, 6.7 mmol, 1.0 equiv.) in THF (100 mL) at 0 °C was added dropwise L-selectride (1.0 M in THF, 12.2 mL, 12.1 mmol, 1.8 equiv.). The resulting mixture was stirred at 0 °C for 30 minutes. The reaction mixture was quenched by the addition of NH4CI aqueous solution (30 ml) at 0 °C. The resulting mixture was extracted with EA (3 x 100 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, which generated methyl 2 -hydroxy -4-(l-{ [(7?)-2-methylpropane-2-sulfinyl]amino}ethyl)benzoate (31 -4) (2,8 g) as a light-yellow oil, which was used in the next step directly without further purification.117MF-369911600Attorney Docket No.: 314352001641

[0380] LCMS (ESI): [M+H]+: 314(R)-N-[(lS)-l-[3-Hydroxy-4-(hydroxymethyl)phenyl]ethyl]-2-methylpropane-2-sulfmamide (31-5)

[0381] To a stirred mixture of ethyl 2-hydroxy-4-[(15)-l-{ [(7^)-2-methylpropane-2-sulfinyl]amino}ethyl]benzoate (31-4) (25.0 g, 79,7 mmol, 1.0 equiv.) in THE (300 mL) at 0 °C was added dropwise lithium borohydride (4.0 M in THF, 39.8 mL, 159.5 mmol, 2.0 equiv.), the resulting mixture was stirred at room temperature for overnight. The reaction was quenched by the addition of saturated H4CI aqueous solution (40 mL) at 0 °C. The resulting mixture was filtered and the filter cake was washed with EtOAc (2 30 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 20% to 30% gradient in 10 min; detector, UV 254 nm, which afforded (?)-7V-[(LS)- 1-[3-hydroxy-4-(hydroxymethyl)phenyl]ethyl]-2-methylpropane-2-sulfmamide (31-5) (12.0 g, 55.4% yield) as a light-yellow oil.

[0382] LCMS (ESI): [M+H]+: 272(R)-N-[ ( lS)-l-(4-Formyl-3-hydroxyphenyl)ethyl ]-2-methylpropane-2-sulfinamide (31 -6)

[0383] To a stirred mixture of ( / ?)-A / -[(LSr)-l-[3-hydroxy-4-(hydroxymethyl)phenyl]ethyl]-2-methylpropane-2-sulfinamide (31-5) (11.0 g, 40.5 mmol, 1.0 equiv.) in DCE (400 mL) was added MnCh (35.2 g, 405.3 mmol, 10.0 equiv.) at room temperature, the resulting mixture was heated to 60 °C overnight. The resulting mixture was filtered and the filter cake was washed with DCM (2 x 20 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chrom tography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 40% to 50% gradient in 10 min; detector, UV 254 nm, which afforded (A)-A / -[(LSr)-l-(4-formyl-3-hydroxyphenyl)ethyl]-2-methylpropane-2-sulfmamide (31-6) (5.0 g, 45.8% yield) as a brown oil,

[0384] LCMS (ESI): [M+H]+: 2702-Formyl-5-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]phenyl trifluoromethanesulfonate (31-7)

[0385] To a stirred mixture of (A)-V-[(LS -l-(4-formyl-3-hydroxyphenyl)ethyl]-2-methylpropane-2-sulfmamide (31-6) (8.0 g, 29.7 mmol, 1.0 equiv.) and 1,1,1-trifluoro-A-phenyl-7V-(trifluoromethane)sulfonylmethanesulfonamide (26.5 g, 74.2 mmol, 2.5 equiv.) in118MF-369911600Attorney Docket No.: 314352001641THF (350 mL) was added CS2CO3 (48.3 g, 148.5 mmol, 5.0 equiv.) at room temperature, the resulting mixture was heated to 60 °C overnight. The resulting mixture was filtered and the filter cake was washed with EtOAc (3 x 20 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18; mobile phase, MeCN in Water, 50% to 70% gradient in 10 min; detector, UV 254 nm, which afforded 2-formyl-5-[(15)-l-{[(7?)-2-methylpropane-2-sulfmyl]amino}ethyl]phenyl trifluorom ethanesulfonate (31-7) (6.5 g, 54.5% yield) as a brown oil.

[0386] LCMS (ESI): [M+H]+: 4022-Formyl-5-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]phenylboronic acid (31-8)

[0387] To a stirred mixture of 2-formyl-5-[(15)- 1 -{ [(7?)-2-methylpropane-2-sulfinyl]amino}ethyl]phenyl trifluorom ethanesulfonate (31-7) (7.0 g, 17.4 mmol, 1.0 equiv.) and EUPim (5.3 g, 20.9 mmol, 1.2 equiv.) in dioxane (200 mL) were added KOAc (3.4 g, 34.8 mmol, 2.0 equiv.) and Pd(dppf)C12CH2C12 (1.4 g, 1.7 mmol, 0.1 equiv.) at room temperature, the resulting mixture was heated to 80 °C for 2 hours under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18; mobile phase, MeCN in Water, 40% to 90% gradient in 10 min; detector, UV 254 nm, which afforded 2-formyl-5-[(lN)-l-{[(7?)-2-methylpropane-2-sulfinyl]amino}ethyl]phenylboronic acid (31-8) (6.0 g) as a brown oil, which was used directly in the next step without further purification.

[0388] LCMS (ESI): [M+H]+: 298(R)-N-[(1S)-1-(1-Hydroxy-2,3,1-benzoxazaborinin-7-yl)ethyl]-2-methylpropane-2-sulfinamide (31-9)

[0389] To a stirred solution of intermediate 2-formyl-5-[(15)- l-{ [(7?)-2-methylpropane-2-sulfinyl]amino}ethyl]phenylboronic acid (31-8) (10.0 g, 33.6 mmol, 1.0 equiv.) and NaOAc (3.8 g, 47.1 mmol, 1.4 equiv.) in THF / H2O (60 mL / 60 mL) was added NH2OH HC1 (2.8 g, 40.3 mmol, 1,2 equiv.) at room temperature, the resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 80 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, which afforded ( )-N-119MF-369911600Attorney Docket No.: 314352001641[(LST)-l-(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)ethyl]-2-methylpropane-2-sulfmamide (31-9) (6.8 g) as a yellow solid, which was used directly in the next step without further purification.

[0390] LCMS (ESI): [M+H]+: 2957-[(1S)-1-Aminoethyl]-2,3,1-benzoxazaborinin-1-ol, hydrochloride (31-10)

[0391] To a stirred mixture of (7?)-V-[(LS -l-( 1 -hydroxy-2,3, 1 -benzoxazaborinin-7-yl)ethyl]-2-niethylpropane-2-sulfmamide (31-9) (5.0 g, 16.9 mmol, 1.0 equiv.) in HC1 (40 mL, 4.0 M in 1,4-dioxane) at room temperature, the resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under vacuum, which generated 7-[(15)-l-aminoethyl]-2,3,l-benzoxazaborinin-l-ol, hydrochloride (31-10) (4,1 g) as a white solid, which was used directly in the next step without further purification.

[0392] LCMS (ESI): [M+H]+: 191Methyl (2E)-3-( 4-amino-6-{ [( 1 S)-l-( 1 -hydroxy-2, 3, 1-benzoxazaborinin- 7-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (31-12)

[0393] To a stirred solution of 7-[(LS -l-aminoethyl]-2,3,l-benzoxazaborinin-l-ol, hydrochloride (31-10) (500 mg, 2.6 mmol, 1.0 equiv.) and methyl (2£)-3-(4-amino-6-chloropyrimidin-5-yl)prop-2-enoate (31-11, 3-2 in Scheme 3) (450 mg, 2.1 mmol, 0.8 equiv.) in DMSO (12 mL) was added CsF (2.0 g, 13.1 mmol, 5.0 equiv.) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 80 °C overnight under nitrogen atmosphere. The reaction residue was purified by reversed-phase fl sh chrom tography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 50% to 70% gradient in 10 min; detector, UV 254 nm, which afforded methyl (2£)-3-(4-amino-6-{[(15)-l-(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (31-12) (180 mg, 18.6% yield) as a brown yellow solid.

[0394] LCMS (ESI): [M+H]+: 3684-{[(IS)-l-(l-Hydroxy-2, 3, 1-benzoxazaborinin-7-yl)ethyl]amino}-8H-pyrido[2, 3-d]pyrimidin-7-one (34)

[0395] To a stirred solution of methyl (2£’)-3-(4-amino-6-{[(15)-l-(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (31-12) (180 mg, 0.5 mmol, 1.0 equiv.) in MeOH (6 mL) was added sodium methoxide (3 mL, 30% in methanol) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 80 °C for 1 hour under nitrogen atmosphere. The resulting mixture was concentrated under reduced 120MF-369911600Attorney Docket No.: 314352001641pressure. The product (100 mg) was initially purified by Prep-HPLC (Column: YMC-Actus Triart C18 ExRS5 pm, 30 mm X 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 2% B to 15% B in 8 min; Wave Length: 254 / 220 nm) followed by further purification by Prep-CHIRAL- SFC (Column: CHIRALP / XK EH, 3.0 * 50 mm, 3 pm; Tvlobile Phase A: CO2, Mobile Phase B: MeOH: DCM = 1:1 (0.1% 7 M NH3-MeOH); Flow rate: 90 mL / min; Gradient (B%): isocratic 45% B; Column Temperature (°C): 35; Back Pressure (bar): 100; Wave Length: 254 nm; RT1 (min)), which resulted in the 4-{[(15)-l-(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)ethyl]amino}-8 -pyrido[2,3-d]pyrimidin-7-one (34) (25.8 mg, 15.7% yield) as a white solid.

[0396] LCMS (ESI): [M+H];: 336

[0397] JH NMR (400 MHz, DMSO-t / e) 8 12.00 (s, 1H), 9.37 (s, 1H), 8.59 (s, 1H), 8.37 - 8.35 (m, 2H), 8.20 (s, 1H), 8.07 (d,. / = 1.8 Hz, 1H), 7.85 (dd,. / = 8.0, 1.9 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 6.45 (d, J = 9.7 Hz, 1H), 5.57 (p, J = 7.1 Hz, 1H), 1.58 (d, J = 7.0 Hz, 3H).Example 35Synthesis of 4-{[( lS)-l-(l-hydr oxy-2, 3, l-henzoxazahorinm-6-yl)ethyl ]amino}-8H-pyrido[ 2,3-dpyrimidin- 7 -one35

[0398] The compound was synthesized using Scheme 32.121MF-369911600Attorney Docket No.: 314352001641Scheme 32(R)-N-[l-( 4-Hydroxyphenyl)ethylidene ]-2-methylpropane-2-sulfinamide (32-2)

[0399] To a stirred solution of hydroxyacetophenone (32-1) (5.0 g, 36.7 mmol, 1.0 equiv.) and (7?)-2-methylpropane-2-sulfinamide (5.8 g, 47.7 mmol, 1.3 equiv.) in THF (120 mL) was added titanium tetrakis(ethanolate) (50.2 g, 220.3 mmol, 6.0 equiv.) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 80 °C for 1 day under nitrogen atmosphere. The mixture was allowed to cool down to 60 °C. To the mixture was then added 2-({2-[bis(2-hydroxyethyl)amino]ethyl}(2-hydroxyethyl)amino)ethan-l-ol (52,0 g, 220.3 mmol, 6.0 equiv.) at 60 °C, the resulting mixture was stirred at 60 °C for additional 20 minutes. The resulting mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (1 / 4), which afforded (7?)-A-[l-(4-hydroxyphenyl)ethylidene]-2-methylpropane-2- sulfinamide (32-2) (7.5 g, 85.3% yield) as a light-yellow solid.122MF-369911600Attorney Docket No.: 314352001641

[0400] LCMS (ESI): [M+Hf: 240(R)-R’-[(lS)-l-(4-Hydroxyphenyl)ethyl]-2-methylpropane-2-sulfinamide (32-3)

[0401] To a stirred solution of (A)-A-[l-(4-hydroxyphenyl)ethylidene]-2-methylpropane-2-sulfinamide (32-2) (2.5 g, 10.4 mmol, 1.0 equiv.) in THF (50 mL) was added L-selectride (1 M in THF, 20.9 mL, 20.9 mmol, 2.0 equiv.) dropwise at 0 °C under air atmosphere, the resulting mixture was stirred at 0 °C for 1 hour. The reaction was quenched with saturated NH4CI aqueous solution (100 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over anhydrous Na^SC After filtration, the filtrate was concentrated under reduced pressure, which afforded (A)-Ar-[(15')-l-(4-hydroxyphenyl)ethyl]-2-methylpropane-2-sulfinamide (32-3) (3.3 g) as a light-yellow solid, which was used directly in the next step without further purification.

[0402] LCMS (ESI): [M+H];: 242(R)-N- [( 1 S)- I -(3 -Formyl-4-hydr oxyphenyl) ethyl] -2-methyIpropane-2-sulfinamide (32-4)

[0403] To a stirred solution of (A)-A-[(15)-l-(4-hydroxyphenyl)ethyl]-2-methylpropane-2-sulfinamide (32-3) (7.5 g, 31,0 mmol, 1.0 equiv.) and paraformaldehyde (13.7 g, 310.7 mmol, 10.0 equiv.) in THF (400 mL) were added MgCh (14.8 g, 155.3 mmol, 5.0 equiv.) and TEA (15.7 g, 155,3 mmol, 5.0 equiv.) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 70 °C for 1 day under nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The product was purified by silica gel column chromatography, eluted with DCM / MeOH (8 / 1) and then further purified by reversed-phase flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 30% to 50% gradient in 10 min; detector, UV 254 nm, which afforded (A)-Ar-[(15,)-1- (3-formyl-4-hydroxyphenyl)ethyl]-2-niethylpropane-2-sulfmamide (32-4) (2.1 g, 25.0% yield) as a yellow oil.

[0404] LCMS (ESI): [M+Hf: 2702-Formyl-4-[ ( 1S)-1~{[ (R)-2-methylpropane-2-sulfmyl amino}ethylphenyl trifluoromethanesulfonate (32-5)

[0405] To a stirred solution of (A)-Ar-[(LS)-l-(3-formyl-4-hydroxyphenyl)ethyl]-2-methylpropane-2-sulfmamide (32-4) (2.0 g, 7.4 mmol, 1.0 equiv.) and 1,1,1-trifluoro-A-phenyl-A-trifluoromethanesulfonylmethanesulfonamide (5.3 g, 14.8 mmol, 2,0 equiv.) in THF (80 mL) was added TEA (3.7 g, 37.1 mmol, 5.0 equiv.) at room temperature, the 123MF-369911600Attorney Docket No.: 314352001641resulting mixture was stirred at room temperature for 5 hours under nitrogen atmosphere. The resulting mixture was diluted with water (80 mL) and extracted with EtOAc (3 x 50 ml.,). The combined organic layers were washed with brine (1 x 150 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18; mobile phase, MeCN in Water, 20% to 30% gradient in 10 min; detector, UV 254 nm, which afforded 2-formyl-4-[(LS)-l-{[(?)-2-methylpropane-2-sulfmyl]amino}ethyl]phenyl trifluoromethanesulfonate (32-5) (2.7 g, 90.5% yield) as a yellow oil.

[0406] LCMS (ESI): [M+H]+: 4022-Formyl-4-[(lS)-l-{[(R)-2-methylpropane-2-sulfinyl]ainino}ethyl]phenylboronic acid (32-6)

[0407] To a stirred solution of 2-formyl-4-[(LS)-l-{[(7^)-2-methylpropane-2-sulfinyl]amino}ethyl]phenyl trifluoromethanesulfonate (32-5) (2.7 g, 6.7 mmol, 1.0 equiv.) and EhPim (2.5 g, 10.0 mmol, 1.5 equiv.) in 1,4-dioxane (50 mL) were added KOAc (1.3 g, 13.4 mmol, 2.0 equiv.) and Pd(dppf)C12CH2C12 (549 mg, 0.6 mmol, 0.1 equiv.) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 80 °C for 3 hours under nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with EtOAc (3 10 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 40% to 90% gradient in 10 min; detector, UV 254 nm, which afforded 2-formyl-4-[(lS)-l-{[(7?)-2-methylpropane-2-sulfmyl]amino}ethyl]phenylboronic acid (32-6) (1.8 g, 90.0% yield) as a yellow oil.

[0408] LCMS (ESI): [M+H]+: 298(R)-N-[ ( 1 S)-l-(l-Hydroxy-2, 3, l-benzoxazabormm-6-yl)ethyl j-2-methylpropane-2-sulfinamide (32-7)

[0409] To a stirred solution of 2-formyl-4-[(15)-l-{[(J?)-2-methylpropane-2-sulfinyl]amino}ethyl]phenylboronic acid (32-6) (1.8 g, 6.0 mmol, 1.0 equiv.) in TIIF / II2O (15 mL / 15 mL) was added hydroxylamine hydrochloride (1.2 g, 18.1 mmol, 3.0 equiv.) at room temperature, the resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (1 x 150 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, which afforded124MF-369911600Attorney Docket No.: 314352001641(A)-A'-[(LS -l-(l-hydroxy-2,3,l-benzoxazaborinin-6-yl)ethyl]-2-methylpropane-2- sulfinamide (32-7) (1.3 g) as a yellow solid, which was used directly in the next step without further purification.

[0410] LCMS (ESI): [M+H]+: 2956-[(lS)-l -Aminoethyl ] -2, 3, l-benzoxazaborinin-l-ol, hydrochloride (32-8)

[0411] A solution of (A)-Ar-[(LS -1-(I -hydroxy-2,3, l-benzoxazaborinin-6-yl)ethyl]-2-methylpropane-2-sulfinamide (32-7) (1.3 g, 4.4 mmol, 1.0 equiv.) in HC1 (15 mL, 4.0 M in 1,4-di oxane) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under vacuum, which afforded 6-[(lA)-l-aminoethyl]-2,3, l-benzoxazaborinin- l-ol, hydrochloride (1.2 g) as a yellow solid, which was used directly in the next step without further purification.

[0412] LCMS (ESI): [M+H]+: 191Methyl (2E)-3-( 4-amino-6-{ [( 1 S)-l-( I -hydroxy-2, 3, l-benzoxazabormin-6-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (32-10)

[0413] To a stirred solution of 6-[(lA)-l-aminoethyl]-2, 3, l-benzoxazaborinin-l-ol, hydrochloride (32-8) (500 mg, 2.6 mmol, 1.0 equiv.) and methyl (2E)-3-(4-amino-6-chloropyrimidin-5-yl)prop-2-enoate (32-9, 3-2 from Scheme 3) (562 mg, 2.6 mmol, 1.0 equiv.) in DMSO (10 mL) was added CsF (1.2 g, 7.8 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 70CC overnight under nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 40% to 60% gradient in 10 min; detector, UV 254 nm, which afforded methyl (2E)-3-(4-amino-6-{[(lA)-l-(l-hydroxy-2,3, I-benzoxazaborinin-6-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (32-10) (190 mg, 19.6% yield) as a brown¬ yellow solid.

[0414] LCMS (ESI): [M+H]+: 3684-{[ ( lS)-l-( 1 -hydroxy-2, 3, l-benzoxazaborinin-6-yl)ethyl ]amino -8H-pyrido[2, 3-d]pyrimidin-7-one (35)

[0415] To a stirred solution of methyl (2£)-3-(4-amino-6-{[(15T)-l-(l-hydroxy-2,3,l-benz.oxazaborinin-6-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (32-10) (190 mg, 0.5 mmol, 1.0 equiv.) in MeOH (10 mL) was added sodium methoxide (5 mL, 30% in methanol) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 70 °C for 125MF-369911600Attorney Docket No.: 314352001641I hour under nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The product was initially purified by Prep-HPLC (conditions: Column: XB ridge BEPI Cl 8 OBD Prep Column, 5 pm, 30 mm * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 3% B to 12% B in 8min; Wave Length: 254 / 220 n ) followed by further purification by Prep-CHIRAL-SFC (conditions: Column: CHIRALPAK IH, 3.0 * 50 mm, 3 pm; Mobile Phase A: CO2, Mobile Phase B: MeOH: DCM = 1: 1 (0.1% 7 M NH3-MeOH); Flow rate: 90 mL / min; Gradient (B%): isocratic 40% B; Column Temperature (°C): 35; Back Pressure (bar): 100; Wave Length: 254 nm). This resulted in the 4-{[(LS)-l-(I -hydroxy-2, 3, 1-benzoxazaborinin-6-yl)ethyl]amino}-877-pyrido[2,3-d]pyrimidin-7-one (35) (40.3 mg, 23.2% yield) as a white solid.

[0416] LCMS (ESI): [M+H]+: 336

[0417] 12.00 (s, IH), 9.32 (s, IH), 8.63 (s, IH), 8.36 - 8.34 (m, 2H), 8.21 (s, IH), 8.03 (d, J= 7.7 Hz, IH), 7.78 (dd, J= 7.9, 1.7 Hz, IH), 7.74 (d, J = 1.6 Hz, IH), 6.45 (d, J= 9.7 Hz, IH), 5.58 (p,.7= 7.0 Hz, IH), 1.59 (d, J= 7.1 Hz, 3H).Example 36Synthesis of 4-{[ (lR)-l-( I -hydroxy-2, 3, 1-benzoxazaborinin- 7-yl)ethyl]amino}-8H-pyrido[ 2, 3-d]pyrimidin-7-one

[0418] The compound was synthesized using Scheme 33.126MF-369911600Attorney Docket No.: 314352001641Scheme 33Ethyl (S)-4-(l-((tert-buty’lsulfinyl)immo)ethyl)-2-hydroxy>benzoate (33-2)

[0419] To a stirred solution of methyl 4-acetyl-2 -hydroxybenzoate (33-1, 31-2 from Scheme 31) (10.0 g, 51.5 mmol, 1.0 equiv.) and (5r)-2-metliylpropane-2-sulfinamide (9.36 g, 77.2 mmol, 1.5 equiv.) in THF (200 mL) was added tetraethoxytitanium (58.7 g, 257.5 mmol, 5.0 equiv.) at room temperature under N2 atmosphere. The resulting mixture was heated to 80CC for 3 hours under N2 atmosphere. The reaction mixture was cooled down to 60 °C and 2- ({2-[bis(2-hydroxyethyl)amino]ethyl }(2-hydroxyethyl)amino)ethan-l -ol (60.9 g, 257,5 mmol, 5.0 equiv.) was added. The resulting mixture was stirred at 60 °C for 20 minutes. The reaction was quenched by the addition of H2O (100 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were dried over anhydrous 127MF-369911600Attorney Docket No.: 314352001641Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography with the following conditions: EA in PE, 0% to 25% gradient in 30 min; detector, UV 254 nm. This resulted ethyl (5)-4-(l-((tert-butylsulfinyl)imino)ethyl)-2-hydroxybenzoate (33-2) (7.8 g, 48.6% yield) as a light-yellow oil.

[0420] LCMS (ESI): [M+Hf: 312Ethyl 4-((R)~l-(((S)-tert-butylsnlfinyl)amino)ethyl)-2-hydroxybenzoate (33-3)

[0421] To a stirred solution of ethyl (5)-4-(l-(( / er / -butylsulfinyl)imino)ethyl )-2-hydroxybenzoate (33-2) (2.0 g, 6.7 mmol, 1.0 equiv.) in THF (100 mL) at 0 °C was dropwise added I, -selectride (1.0 M in THF, 12.2 mL, 12,1 mmol, 1.8 equiv.). The resulting mixture was stirred at 0CC for 30 minutes. The reaction mixture was quenched by the addition of NH4CI aqueous solution (30 mL) at 0 °C, The resulting mixture was extracted with EA (3 x 100 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, which afforded ethyl 4-((7?)-l-(((5r)-terLbutylsulfinyl)amino)ethyl)-2-hydroxybenzoate (33-3) (2.8 g) as a light-yellow oil, which was used in the next step directly without further purification.

[0422] LCMS (ESI): [M+H]+: 314(S)-N-[(lR)-l-[3-Hydroxy-4-(hydroxymethyl)phenyl ethyl]-2-methylpropane-2-sulfinamide (33-4)

[0423] To a stirred mixture of ethyl 2-hydroxy-4-[(17?)-l-{[(6T)-2-methylpropane-2-sulfinyl]amino}ethyl]benzoate (33-3) (2.0 g, 6.4 mmol, 1.0 equiv.) in THF (20 mL) was added lithium borohydride (4.0 M in THF, 15.95 mL, 63.8 mmol, 10.0 equiv.) dropwise at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The reaction was quenched by the addition of saturated NH4CI aqueous solution (10 mL) at 0 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8 silica gel; mobile phase, MeCN in Water, 20% to 30% gradient in 10 min; detector, UV 254 nm. This resulted in (5’)-A'-[(lZ)-l-[3-hydroxy-4-(hydroxymethyl)phenyl]ethyl]-2-methylpropane-2-sulfmamide (33-4) (1.2 g, 69.3% yield) as a light-yellow oil.

[0424] LCMS (ESI): [M+H];: 272(S)-N-[(lR)-l-(4-Formyl-3-hydroxyphenyl)ethyl]-2-methylpropane-2-sulfmamide (33-5)128MF-369911600Attorney Docket No.: 314352001641

[0425] To a stirred mixture of (5 A-[(lA)-l-[3-hydroxy-4-(hydroxymethyl)phenyl]ethyl]-2-methylpropane-2-sulfinamide (5.9 g, 21.7 mmol, 1.0 equiv.) in DCM (100 niL) was added M11O2 (18.9 g, 217.4 mmol, 10.0 equiv.) at room temperature. The resulting mixture was stirred at room temperature for overnight. The resulting mixture was filtered and the filter cake was washed with DCM (2 x 5 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column. Cl 8 silica gel; mobile phase, MeCN in Water (0.1% FA), 40% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in (5’)-N-((A)-l-(4-formyl-3-hydroxyphenyl)ethyl)-2-methylpropane-2-sulfmamide (33-5) (1.4 g, 23.9% yield) as an orange oil.

[0426] LCMS (ESI): [M+H];: 2705-((R)-l-( ( (S)-tert-butylsulfinyl)ammo)ethyl)-2-formylphenyl trifluoromethane sulfonate (33 -6)

[0427] To a stirred mixture of (5)-A-((7?)-l-(4-formyl-3-hydroxyphenyl)ethyl)-2-methylpropane-2-sulfmamide (33-5) (210 mg, 0.8 mmol, 1.0 equiv.) and 1,1,1-trifluoro-A’-phenyl-Ar-(trifluoromethane)sulfonylmethanesulfonamide (334 mg, 0.9 mmol, 1.2 equiv.) in THF (4 mL) was added CS2CO3 (635 mg, 1.9 mmol, 2.5 equiv.) at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The product was directly purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 30% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in 5-((7?)-l-(((5’)-tert-butylsulfinyl)amino)ethyl)-2-fomiylphenyl trifluoromethanesulfonate (33-6) (200 mg, 63.9% yield) as a light-orange oil.

[0428] LCMS (ESI): [M+H]+: 4022-Formyl~5-[(lR)-l-{[(S)-2-methylpropane-2-sulfinyriamino}ethyl]phenylboromc acid (33-

[0429] To a stirred mixture of 5-((A)-l-(((5)-ZerZ-butylsulfinyl)amino)ethyl)-2-formylphenyl tri fluoromethanesulfonate (33-6) (1.0 g, 2.5 mmol, 1.0 equiv.) and Pin2B2 (949 mg, 3.7 mmol, 1.5 equiv.) in 1,4-dioxane (15 mL) were added AcOK (611 mg, 6.2 mmol, 2.5 equiv.) and Pd(dppf)C12 CII2CI2 (182 mg, 0.25 mmol, 0.1 equiv.) in portions at room temperature. The resulting mixture was stirred at 80 °C for 2 hours under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column,129MF-369911600Attorney Docket No.: 314352001641Cl 8 silica gel; mobile phase, MeCN in Water, 20% to 25% gradient in 10 min; detector, UV 254 nm. This resulted in 2-fomiyl-5-[(l / ?)-l-{[(5)-2-methylpropane-2- sulfmyl]amino}ethyl]phenylboronic acid (33-7) (360 mg, 48.6% yield) as a colorless oil.

[0430] LCMS (ESI): [M+H]+: 298(S)-N-[(1R)-1-(1 -hydroxy-2, 3, 1-benzoxazaborinin- 7-yl) ethyl ]-2-methylpropane-2-sulfinamide (33-8)

[0431] To a stirred mixture of 2-formyl-5-[(17^)-l-{[(, S)-2-methylpropane-2- sulfinyl]amino}ethyl]phenylboronic acid (33-7) (15 mg, 0.05 mmol, 1.0 equiv.) and hydroxylamine hydrochloride (4 mg, 0.06 mmol, 1.2 equiv.) in THF / H2O (1 mL / 0.1 mL) was added AcONa (6 mg, 0.07 mmol, 1.4 equiv.) at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. This resulted in (5)-A7-[(l / ?)-l-(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)ethyl]-2-methylpropane-2-sulfinamide (33-8) (420 mg) as a colorless oil, which was used in the next step directly without further purification.

[0432] LCMS (ESI): [M+H]+: 2957-[(lR)-l-Aminoethyl]-2,3, l-benzoxazaborimn-l-ol, hydrochloride (33-9)

[0433] A mixture of (5)-A'r-[(lA)-l-(l-hydroxy-2,3,l-benzoxazaborinin-7-yl)ethyl]-2-methylpropane-2-sulfinamide (33-8) (420 mg, 1.4 mmol, 1.0 equiv.) in HC1 in 1,4-dioxane (4.0 M, 10 mL) was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobilephase, MeCN in Water, 5% to 10% gradient in 10 min; detector, UV 254 nm. This resulted in 7-[(lA)-l-aminoethyl]-2,3,l-benzoxazaborinin-l-ol, hydrochloride (33-9) (400 mg) as a light-yellow oil, which was used directly in the next step without further purification.

[0434] LCMS (ESI): [M+H]+: 191Methyl (2E)-3-(4-amino-6-{[(lR)-l-(l-hydroxy-2,3,l-benzoxazabormin-7-yl)ethyl ]ammo}pyrimidin-5-yl)prop-2-enoate (33-11)

[0435] A solution of 7-[(TA)-l-aminoethyl]-2,3,l-benzoxazaborinin-l-ol, hydrochloride (33-9) (200 mg, 1.0 mmol, 1.0 equiv.) in DMSO (5 mL) was treated with methyl (2E)-3-(4- amino-6-chloropyrimidin-5-yl)prop-2-enoate (33-10, 3-2 from Scheme 3) (270 mg, 1.3 mmol, 1.2 equiv.) at room temperature for 5 minutes under nitrogen atmosphere, followed by the addition of CsF (480 mg, 3,2 mmol, 3.0 equiv.) in portions at room temperature. The 130MF-369911600Attorney Docket No.: 314352001641resulting mixture was stirred at 80 °C for 2 hours under nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with acetone (2 x 10 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobilephase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 220 nm. This resulted in the methyl (2E)-3-(4-amino-6-{[(1R)-1-(1-hydroxy-2,3,1-benzoxazaborinin-7-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (33-11) (110 mg, 28.5% yield) as a white semi-solid.

[0436] LCMS (ESI): [M+H]+: 3684-{[(1R)-1-(1-Hydroxy-2,3,1-benzoxazaborinin-7-yl)ethyl]amino}-8H-pyrido[2,3-d]pyrimidin-7-one (36)

[0437] A solution of intermediate methyl (2A)-3-(4-amino-6-{[(1R)-1-(1-hydroxy-2,3,1-benzoxazaborinin-7-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (33-11) (100 mg, 0.3 mmol, 1.0 equiv.) in MeOH (2 mL) was treated with sodium methanolate (44 mg, 0.8 mmol, 3.0 equiv.) at 50 °C for 1 hour under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: Column: XBridge BEH C18 5 μm, 19 * 250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3+ 0.1% NH3·H2O), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 5% B to 17% B in 8 min; Wave Length: 254 nm / 220 nm. This resulted in the 4-{[(1R)-1-(1-hydroxy-2,3,1-benzoxazaborinin-7-yl)ethyl]amino}-8H-pyrido[2,3-d]pyrimidin-7-one (36) (13.4 mg, 11.2% yield) as a white solid.

[0438] LCMS (ESI): [M+H]+: 336

[0439] ’HNMR (400 MHz, DMSO-O 8 11.99 (s, 1H), 9.35 (s, 1H), 8.59 (s, 1H), 8.37 - 8.35 (m, 2H), 8.20 (s, 1H), 8.07 (s, 1H), 7.84 (d, J - 8.4 Hz, 1H), 7.71 (d,. / 8.0 Hz, H I), 6.45 (d, J= 9.6 Hz, 1H), 5.57 (t, J= 7.2 Hz, 1H), 1.59 (d, J= 7.6 Hz, 3H).Example 37Synthesis of (R)-4-((1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one131MF-369911600Attorney Docket No.: 31435200164137

[0440] The compound was synthesized using Scheme 34.Scheme 342-Formyl-4-hydroxyphenylboronic acid (34-2)

[0441] To a stirred solution of 2-bromo-5-hydroxybenzaldehyde (34-1) (15.0 g, 74.6 mmol, 1.0 equiv.), B2Pin2(94.7 g, 373.1 mmol, 5.0 equiv.) and AcOK (18.3 g, 186.5 mmol, 2.5 equiv.) in 1,4-dioxane (300 mL) were added Pd(dppf)C12 (5.4 g, 7.4 mmol, 0.1 equiv.) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred at132MF-369911600Attorney Docket No.: 31435200164190 °C overnight under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was filtered and the filter cake was washed with EtOAc (3 x 100 mL). The filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (10 / 1), which afforded 2-formyl-4-hydroxyphenylboronic acid (34-2) (15.0 g, 80.7% yield) as a brown solid.

[0442] LCMS (ESI): [M+H]+: 1671H-benzo[d][1,2,6]oxazaborinine-1,6-diol (34-3)

[0443] To a stirred solution of 2-formyl-4-hydroxyphenylboronic acid (34-2) (10.0 g, 60.2 mmol, 1.0 equiv.) in THF (100 mL) and H2O (100 mL) was added NH2OH·HCl (12.5 g, 180,7 mmol, 3.0 equiv.) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 3 hours under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, CI 8 silica gel; mobile phase, MeOH in Water (0.1% NH3 H2O + 10 mmol / 'L NH4HCO3), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in 1H-benzo[d][1,2,6]oxazaborinine-1,6-diol (34-3) (5.0 g, 50.9% yield) as a white solid.

[0444] LCMS (ESI): [M+H]+: 1641-Hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl trifluoromethanesulfonate (34-4)

[0445] To a stirred solution of 1H-benzo[d][1,2,6]oxazaborinine-1,6-diol (34-3) (5.0 g, 30.6 mmol, 1.0 equiv.) in DMF (40 mL) was added NaH (1.1 g, 46.0 mmol, 1.5 equiv.) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at 0 °C for 30 minutes under nitrogen atmosphere. To the above mixture was added 1,1,1-trifluoro-N-phenyl-N-trifluoromethanesulfonylmethanesulfonamide (13.1 g, 36.8 mmol, 1.2 equiv.) in portions over 5 minutes at 0 °C. The resulting mixture was stirred at room temperature for 2 hours. The mixture was cooled to 0 °C. Then ice water (10 mL) was added. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeOH in Water (0.1% NH3 H2O + 10 mmol / L NH4HCO3), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in the 1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl trifluoromethanesulfonate (34-4) (2.2 g, 24.3% yield) as a white solid.

[0446] LCMS (ESI): [M+H]+: 2966-(1-Ethoxyvinyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (34-5)133MF-369911600Attorney Docket No.: 314352001641

[0447] To a stirred solution of 1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl trifluoromethanesulfonate (34-4) (2.2 g, 7.4 mmol, 1.0 equiv.) and tributyl(1-ethoxyethenyl)stannane (3.2 g, 8.9 mmol, 1.2 equiv.) in 1,4-dioxane (20 niL) was added Pd(PPh3)2C12 (0.5 g, 0.7 mmol, 0.1 equiv.) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 90 °C overnight under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in 6-(1-ethoxyvinyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (34-5) (1.5 g, 92.6% yield) as a white solid.

[0448] LCMS (ESI): [M+H]+: 2181-(1-Hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethan-1-one (34-6)

[0449] To a stirred solution of 6-(1-ethoxyvinyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (34-5) (1.5 g, 6.9 mmol, 1.0 equiv.) in THF (15 mL) was added HC1 (1 M in H2O, 6.9 mL, 6.9 mmol, 1.0 equiv.) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 1 hour under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in 1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethan-1-one (34-6) (1.0 g, 76.5% yield) as a white solid.

[0450] LCMS (ESI): [M+H]+: 190(S)-N-(1-(1-Hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethylidene)-2-methylpropane-2-sulfinamide (34-7)

[0451] To a stirred solution of 1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethan-1-one (34-6) (1.0 g, 5.2 mmol, 1.0 equiv.) and (S’)-2-methylpropane-2-sulfinamide (0.7 g, 6.3 mmol, 1.2 equiv.) in THF (20 mL) was added Ti(OEt)4 (6.0 g, 26.4 mmol, 5.0 equiv.) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 80 °C overnight under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was concentrated under reduced pressure. This resulted in (S)-N-(1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethylidene)-2-134MF-369911600Attorney Docket No.: 314352001641methylpropane-2-sulfinamide (34-7) (1.3 g) as a yellow solid, which was used in the next step directly without further purification.

[0452] LCMS (ESI): [M+H]+: 293(S)-N-((R)-1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethyl)-2-methylpropane-2-sulfinamide (34-8)

[0453] To a stirred solution of (S)-N-(1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethylidene)-2-methylpropane-2-sulfinamide (34-7) (1.3 g, 4.4 mmol, 1.0 equiv.) in THF (20 mL) at -20 °C was added L-selectride (1 M in THF, 13.3 mL, 13.3 mmol, 3.0 equiv.) dropwise under nitrogen atmosphere. The resulting mixture was stirred at -20 °C for 0.5 h under nitrogen atmosphere. The reaction was quenched by the addition of ice water (10 mL) at 0 °C. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 20 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, CI 8 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in (S)-N-((R)-1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethyl)-2-methylpropane-2-sulfinamide (34-8) (1.3 g) as a white solid, which was used in the next step directly without further purification.

[0454] LCMS (ESI): [M+H]+: 295(R)-6-(1-aminoethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol hydrochloride (34-9)

[0455] To a stirred solution of (S)-N-((R)-1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethyl)-2-methylpropane-2-sulfinamide (34-8) (250 mg, 0.8 mmol, 1.0 equiv.) in 1,4-dioxane (5 mL) was added HC1 in 1,4-dioxane (4.0 M, 0.2 mL) dropwise at room temperature under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% HC1), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in (R)-6-(1-aminoethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol hydrochloride (34-9) (150 mg, 92.8% yield) as a yellow solid.

[0456] LCMS (ESI): [M+H]+: 191Methyl (R,Z)-3-(4-amino-6-((1-(1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethyl)amino)pyrimidin-5-yl)acrylate (34-11)135MF-369911600Attorney Docket No.: 314352001641

[0457] To a stirred solution of methyl (2E)-3-(4-amino-6-chloropyrimidin-5-yl)prop-2-enoate (34-10, 3-2 in Scheme 3) (200 mg, 0.9 mmol, 1.0 equiv.) and 6-[(l / ?)-l-aminoethyl]-2,3,1-benzoxazaborinin-l-ol, hydrochloride (34-9) (177 mg, 0.9 mmol, 1.0 equiv.) in DMSO (10 mL) was added CsF (711 mg, 4.5 mmol, 5.0 equiv.) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 80 °C overnight under a nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in methyl (R,Z)-3-(4-amino-6-{[(1R)-1-(1-hydroxy-2,3,1-benzoxazaborinin-6-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (34-11) (120 mg) as a yellow solid.

[0458] LCMS (ESI): [M+H]+: 368(R)-4-((1-(1-Hydroxy-1H-benzo[d][1,2,6]oxazaborinin-6-yl)ethyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (37)

[0459] To a stirred solution of methyl (R,Z)-3-(4-amino-6-{[(1R)-1-(1-hydroxy-2,3,1-benzoxazaborinin-6-yl)ethyl]amino}pyrimidin-5-yl)prop-2-enoate (34-11) (120 mg, 0.3 mmol, 1.0 equiv.) in MeOH (4 mL) was added sodium thiomethoxide (23 mg, 0.3 mmol, 1.0 equiv.) in portions at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 80 °C for 2 hours under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 5 mL). The filtrate was concentrated under reduced pressure. The product was purified by Prep-HPLC with the following conditions (Column: X Bridge BEH Cl 85 pm, 19 * 250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3+ 0.1% NH3·H2O), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 5% B to 15% B in 8 min; Wave Length: 254 nm / 220 nm; RT1 (min): 7.38. This generated 4-{[(1R)-1-(1-hydroxy-2,3,1-benzoxazaborinin-6-yl)ethyl]amino}-8H-pyrido[2,3-d]pyrimidin-7-one (37) (23.9 mg, 9.1% yield) as a white solid.

[0460] LCMS (ESI): [M+H]+: 336

[0461] 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 9.30 (s, 1H), 8.62 (s, 1H), 8.36 - 8.34 (m, 2H), 8.20 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.86 - 7.68 (m, 2H), 6.45 (d, J = 9.9 Hz, 1H), 5.70 - 5.21 (m, 1H), 1.58 (d, J = 7.0 Hz, 3H).136MF-369911600Attorney Docket No.: 314352001641Example 38Synthesis of 7-[ (lS)-l-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2, 3, 1-benzoxazaborinin-l-ol

[0462] The compound was synthesized using Scheme 35.Scheme 357-[(1S)-1-[(8-Methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol hydrochloride (38, hydrochloride)

[0463] To a stirred solution of 7-[(1S)-1-aminoethyl]-2,3,1-benzoxazaborinin-1-ol, hydrochloride (35-1, 31-10 in Scheme 31) (600 mg, 3.1 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (35-2) (430 mg, 2.2 mmol, 0.7 equiv.) in DMSO (12 mL) was added CsF (2.4 g, 15.8 mmol, 5.0 equiv.) at room temperature, the resulting mixture was heated to 50 °C for 1 hour under a nitrogen atmosphere. The product was directly purified by reversed-phase flash chromatography (conditions: column, Cl 8; mobile phase, MeCN in Water, 20% to 30% gradient in 10 min; detector, UV 254 nm) followed by further purification (Column: Ultimate XB / XQ-C18 50 * 250 mm, 10 μm; Mobile Phase A: Water (0.1% HCl), Mobile Phase B: ACN; Flow rate: 100 mL / min; Gradient (B%): 5% B to 18%B in 35 min; Wave Length: 254 nm / 220 nm). This resulted in 7-[(1S)-1-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol hydrochloride (38, hydrochloride) (600 mg, 54.5% yield) as a light¬ yellow solid.

[0464] LCMS (ESI): [M+H]+: 3497-[(1S)-1-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol (38)

[0465] A mixture of 7-[(15')-l-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,l-benzoxazaborinin-l-ol hydrochloride (38, hydrochloride) (1.5 g) in MeOH (20 mL) was137MF-369911600Attorney Docket No.: 314352001641basified to pH 9 with Na2CO3aqueous solution. The resulting mixture was concentrated under reduced pressure. The product was purified by Prep-HPLC with the following conditions: Column: XBridge BEH C18 5 pm, 30 * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 17%B in 9 min; Wave Length: 254 nm / 220 nm. This resulted in the 7-[(1S)-1-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol (38) (904.2 mg, 66.5% yield) as a white solid.

[0466] LCMS (ESI): [M+H]+: 349

[0467] 1H NMR (400 MHz, DMSO-d6+HCl) δ 14.29 (s, 1H), 10.74 (d, J = 7.6 Hz, 1H), 8.73 (s, 1H), 8.63 (s, 1H), 8.48 (d, J = 8.4 Hz, 1H), 8.16 (d, J = 1.8 Hz, 1H), 7.99 (dd, J = 8.1, 1.9 Hz, 1H), 7.77 - 7.75 (m, 2H), 7.66 (d, J = 8.1 Hz, 1H), 5.92 (q, J = 7.1 Hz, 1H), 4.05 (s, 3H), 1.77 (d, J = 7.0 Hz, 3H).Example 39Synthesis of 6-[ ( lS)-l-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2, 3, 1-benzoxazaborinin-l-ol

[0468] The compound was synthesized using Scheme 36.Scheme 3636-1396-[(1S)-1-[(8-Methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol (39)

[0469] To a stirred solution of 6-[(1S)-1-aminoethyl]-2,3,1-benzoxazaborinin-1-ol hydrochloride (36-1, 32-8 in Scheme 32) (200 mg, 1.0 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (36-2) (143 mg, 0.7 mmol, 0.7 equiv.) in DMSO (5 mL) was added CsF138MF-369911600Attorney Docket No.: 314352001641(479 mg, 3.1 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere, the resulting mixture was heated to 50 °C and for 2 hours under a nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with MeCN (2 x 5 niL). The filtrate was concentrated under reduced pressure. The product was initially purified by Prep-HPLC (conditions: Column: XBridge BEH C185 pm, 30 * 150 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 7% B to 20% B in 8 min; Wave Length: 254 nm / 220 nm) followed by a second Prep-HPLC (conditions: Column: XBridge BEH C18 5 μm, 19 × 250 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 10% B to 30% B in 8 min; Wave Length: 254 nm / 220 nm), which generated 6-[(15)-l-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,l-benzoxazaborinin-l-ol (39) (16.2 mg, 4.4% yield) as a light-yellow solid.

[0470] LCMS (ESI): [M+H]+: 349

[0471] 1H NMR (400 MHz, DMSO-d6) δ 10.39 (brs, 1H), 8.65 (s, 1H), 8.59 (s, 1H), 8.19 (t, J = 7.8 Hz, 1H), 8.04 (d, J = 7.7 Hz, 1H), 7.87 - 7.78 (m, 2H), 7.73 (t, J = 8.2 Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 5.87 (q, J = 7.0 Hz, 1H), 4.02 (s, 3H), 1.72 (d, J = 7.0 Hz, 3H).Example 40Synthesis of 7-[ (lR)-l-[ ( 8-methoxyquinazolin-4-yl)amino ] ethyl -2, 3, 1-benzoxazaborinin-l-ol hydrochloride

[0472] The compound was synthesized using Scheme 37.139MF-369911600Attorney Docket No.: 3143520016417-[(1R)-1-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol hydrochloride (40)

[0473] To a stirred solution of 7-[(1R)-1-aminoethyl]-2,3,1-benzoxazaborinin-1-ol, hydrochloride (37-1, 33-9 from Scheme 33) (100 mg, 0.5 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (37-2) (72 mg, 0.4 mmol, 0.7 equiv.) in DMSO (2 mL) was added CsF (400 mg, 2.6 mmol, 5.0 equiv.) in portions at room temperature under air atmosphere. The precipitated solids were collected by filtration and washed with MeOH (2 x 5 mL). The product was purified by Prep-HPLC (Column: Xselect CSH C185 pm, 19 mm X 250 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 8% B to 20%B in 8 min; Wave Length: 254 nm / 220 nm), which afforded 7-[(1R)-1-[(8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol, hydrochloride (40) (31.9 mg, 15.7% yield) as an off-white solid.

[0474] LCMS (ESI): [M+H]+: 349

[0475] 1H NMR (400 MHz, DMSO-d6) δ 14.27 (brs, 1H), 10.51 - 10.48 (m, 1H), 8.79 - 8.75 (m, 1H), 8.63 (s, 1H), 8.34 (d, J = 8.4 Hz, 1H), 8.14 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.79 - 7.77 (m, 2H), 7.72 - 7.56 (m, 2H), 5.92 - 5.86 (m, 1H), 4.06 (s, 3H), 1.74 - 1.72 (m, 3H).Example 41Synthesis of (R)-6-(1-((8-methoxyquinazolin-4-yl)amino)ethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol

[0476] The compound was synthesized using Scheme 38.140MF-369911600Attorney Docket No.: 314352001641Scheme 38(R)-6-(l -( (8-methoxyquinazolin-4-yl) amino) ethyl) - 1 H-benzo [d] [ 1, 2, 6 ]oxazaborinin-l-ol (41 )

[0477] To a stirred solution of (7()-6-(l-aminoethyl)-177-benzo[r / ][l,2,6]oxazaborinin-l-ol hydrochloride (38-1, 34-9 in Scheme 34) (100 mg, 0.5 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (38-2) (102 mg, 0.5 mmol, 1.0 equiv.) in DMSO (5 mL) were added CsF (239 mg, 1.5 mmol, 3,0 equiv.) and TEA (160 mg, 1.5 mmol, 3.0 equiv.) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 60 °C overnight under a nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The product was purified by Prep-HPLC (Column: X Bridge BEH C18 OBD Prep Column, 5 pm, 30 mm * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 23% B in 8min; Wave Length:254 / 220 nm; RT1 (min): 6.8), which afforded ( / ?)-6-(l-((8-methoxyquinazolin-4-yl)amino)ethyl)-177-benzo[ef|[l,2,6]oxazaborinin-l-ol (41) (11.7 mg, 6.3% yield) as a white solid.

[0478] LCMS (ESI): [M+H]+: 349

[0479] 1H NMR (400 MHz, DMSO-d6) 59.31 (s, 1 H), 8.63 (s, 1 H), 8.46 (d, J = 7.3 Hz, 1H), 8.38 - 8.36 (m, 1H), 8.16 - 7.93 (m, 2H), 7.88 - 7.73 (m, 2H), 7.52 - 7.40 (m, 1H), 7.24 - 7.27 (m, 1H) 5.67 - 5.65 (m, 1H), 3.90 (s, 3H), 1.63 - 1.61 (m, 3H).Example 42Synthesis of 7-(((8-methoxyquinazolin-4-yl)amino)methyl)-4-methyl-lH-benzo d] [1, 2, 6 ]oxazaborinin-l-ol, hydrochloride141MF-369911600Attorney Docket No.: 31435200164142

[0480] The compound was synthesized using Scheme 39.Scheme 39-tert-Butyl ( 4-acetyl-3-hydroxybenzyl)carbamate (39-2)

[0481] To a stirred solution of 1 -(4-bromo-2-hydroxyphenyl)ethan-l-one (39-1) (10.0 g, 46.5 mmol, 1.0 equiv.) and tert-butyl ((trifluoro- A4-boraneyl)methyl)carbamate, potassium salt (13.2 g, 55.8 mmol, 1.2 equiv.) in 1,4-dioxane (150 mL) and H2O (30 mL) were added Pd(PPh3)2Cl2 (3.2 g, 4.6 mmol, 0.1 equiv.) and CS2CO3 (45.4 g, 139.5 mmol, 3.0 equiv.) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at 80 °C overnight under a nitrogen atmosphere. After which water (200 mL) was added. The resulting mixture was extracted with EtOAc (3 x 200 mL), The combined organic layers were dried over anhydrousAfter filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (5 / 1 ),142MF-369911600Attorney Docket No.: 314352001641which afforded tert-butyl (4-acetyl-3-hydroxybenzyl)carbamate (39-2) (7.0 g, 56.7% yield) as an off-white solid.

[0482] LCMS (ESI): [M-H]': 2642-Acetyl-5-( ( (tert-butoxy carbonyl)amino)methyl)phenyl trifluoromethanesulfonate (39-3)

[0483] To a stirred solution of / ert-butyl (4-acetyl-3-hydroxybenzyl)carbamate (39-2) (3.5 g, 13.1 mmol, 1.0 equiv.) and PhNTf? (11.7 g, 32.9 mmol, 2.5 equiv.) in THF (40 mL) at room temperature was added CS2CO3 (12.8 g, 39.5 mmol, 3.0 equiv.). After overnight, water (60 mL) was added. The resulting mixture was extracted with EtOAc (3 x 80 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (8 / 1), which afforded 2-acetyl-5-(((tert-butoxycarbonyl)amino)methyl)phenyl trifl uorom ethanesulfonate (39-3) (3.0 g, 57,2% yield) as a light-yellow solid.

[0484] LCMS (ESI): [M-H]’: 396(2-Acetyl-5-(((tert-butoxycarbonyl)ammo)methyl)phenyl)boronic acid (39-4)

[0485] To a stirred solution of 2-acetyl-5-(((tert-butoxycarbonyl ) amino)methyl)phenyl trifluoromethanesulfonate (39-3) (3.5 g, 8.8 mmol, 1.0 equiv.) and Pin2B2 (6.7 g, 26.4 mmol, 3.0 equiv.) in 1,4-dioxane (30 mL) were added Pd(PPh3)2C12 (618 mg, 0.8 mmol, 0.1 equiv.) and AcOK (2.1 g, 22.0 mmol, 2.5 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 80 °C overnight under a nitrogen atmosphere. Then water (50 mL) was added. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in (2-acetyl-5-(((tert-butoxy carbonyl) amino) methyl)phenyl)boronic acid (39-4) (1.5 g, 58.1% yield) as a light-yellow solid.

[0486] LCMS (ESI): [M-H]’: 292tert-Butyl ((1-hydroxy-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)carbamate (39-5)

[0487] A solution of (2-acetyl-5-(((tert-butoxycarbonyl) amino)methyl)phenyl)boronic acid (39-4) (1.8 g, 6,1 mmol, 1.0 equiv.) and hydroxylamine hydrochloride (1.2 g, 18,4143MF-369911600Attorney Docket No.: 314352001641mmol, 3.0 equiv.) in THF (15 mL) and H2O (15 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in tert-butyl ((1 -hydroxy -4-methyl-l / 7-benzo[7] [1,2,6] oxazaborinin-7-yl)methyl)carbamate (39-5) (1.0 g, 58.9% yield) as a light-yellow solid.

[0488] LCMS (ESI): [M+H]+: 2917-(Aminomethyl)-4-methyl-lH-benzo[d] [ l,2,6]oxazaborinin-l-ol (39-6)

[0489] A solution of tert-butyl ((1-hydroxy-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)carbamate (39-5) (100 mg, 0.3 mmol, 1.0 equiv.) in HC1 in 1,4-dioxane (4,0 M, 3 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. This resulted in 7-(aminomethyl)-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-1-ol (60.0 mg) as a light-yellow solid, which was used directly in the next step without further purification.

[0490] LCMS (ESI): [M+H]+: 1917-(((8-Methoxyquinazolin-4-yl)amino)methyl)-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-1-ol hydrochloride (42)

[0491] To a stirred solution of 7-(aminomethyl)-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-1-ol (39-6) (300 mg, 1.5 mmol, 1.0 equiv.) and 4-chloro-8- methoxyquinazoline (39-7) (307 mg, 1.5 mmol, 1.0 equiv.) in DMSO (5 mL) was added CsF (480 mg, 3.1 mmol, 2.0 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 50 °C for 4 hours under a nitrogen atmosphere. The product was purified by Prep-HPLC (Column: XBridge BEH C18 5 μm, 19 * 250 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 10% B to 20% B in 8 min; Wave Length: 254 nm / 220 nm), which afforded 7-(((8-m ethoxy quinazolin-4-yl) amino) methyl)-4-methyl-l / / -benzo[d][l,2,6] oxazaborinin-l-ol hydrochloride (42) (98.6 mg, 17.9% yield) as an off-white solid.

[0492] LCMS (ESI): [M+H]+: 349

[0493] 1HNMR (400 MHz, DMSO-^) 6 14.30 (brs, 1H), 11.05 (t, J= 6.0 Hz, 1H), 9.24 (brs, 1H), 8.78 (s, 1H), 8.22 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 1.9 Hz, 1H), 7.88 (dd, J = 8.2, 1.9 Hz, 1H), 7.84 - 7.75 (m, 2H), 7.68 (d, J= 8.1 Hz, 1H), 5.10 (d, J= 5.8 Hz, 2H), 4.08 (s, 3H), 2.45 (s, 3H)144MF-369911600Attorney Docket No.: 314352001641Example 43Synthesis of 4-( ((1 -hydroxy-4-methyl-lH-benzo[d] [ 1, 2, 6 ]oxazabor inin-7 - yl)methyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one43

[0494] The compound was synthesized using Scheme 40.Methyl (E)-3-(4-amino-6-(((l-hydroxy-4-methyl-lH-benzo[d][l,2,6]oxazaborinin-7-yl)methyl)amino)pyrimidin-5-yl)acrylate (40-3 )

[0495] To a stirred mixture of 7-(aminomethyl)-4-methyl-l / / -benzo[tZJ [1,2,6] oxazaborinin-l-ol hydrochloride (40-1, 39-6 in Scheme 39) (800 mg, 4.2 mmol, 1.0 equiv.) and methyl (E)-3-(4-amino-6-chloropyrimidin-5-yl)acrylate (40-2, 3-2 in Scheme 3) (899 mg, 4.2 mmol, 1.0 equiv.) in DMF (8 mL) was added K2CO3 (873 mg, 6.3 mmol, 1.5 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was heated to 100 °C overnight under nitrogen atmosphere. The reaction mixture was allowed to cool to room temperature. After removal of the solid by filtration, the product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in methyl (E)-3-(4-amino-6-(((l-hydroxy-4-methyl-17 - benzo[d][l,2,6]oxazaborinin-7-yl)methyl)amino)pyrimidin-5-yl)acrylate (40-3) (140.0 mg, 9.0% yield) as a light-yellow solid.

[0496] LCMS (ESI): [M+H]+: 368145MF-369911600Attorney Docket No.: 3143520016414-( ((1 -Hydroxy-4-methyl-lH-benzo [d] [ 1, 2, 6 Joxazaborinin- 7-yl)methyl)amino)pyrido[ 2,3-djpyrimidin- 7 ( 8H)-one (43)

[0497] A mixture of methyl (E)-3-(4-amino-6-(((1-hydroxy-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)amino)pyrimidin-5-yl)acrylate (40-3) (200 mg, 0.5 mmol, 1.0 equiv.) and sodium thiomethoxide (191 mg, 2.7 mmol, 5.0 equiv.) in DCM (2 mL) was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure and the product was purified by Prep-HPLC (Column: XBridge BEH Cl 8 OBD Prep Column, 5 pm, 30 mm * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1% NH4OH), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 3% B to 12% B in 8.5min; Wave Length: 254 / 220 nm; RT1 (min): 8.1), which afforded 4-(((1-hydroxy-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (43) (28.4 mg, 15.5% yield) as an off-white solid.

[0498] LCMS (ESI): [M+H]+: 336

[0499] 1HNMR (400 MHz, DMSO-d4) 6 11.04 (br.s, 1H), 9.21 (br.s, 1H), 8.70 (5.9 Hz, 1H), 8.30 - 8.16 (m, 2H), 8.00 (s, 1H), 7.79 - 7.77 (m, 2H), 6.44 (d, J= 9.7 Hz, 1H), 4.85 (d, J= 5.8 Hz, 2H), 2.44 (s, 3H).Example 44Synthesis of 4-(((1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)amino)-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one hydrochloride

[0500] The compound was synthesized using Scheme 41.146MF-369911600Attorney Docket No.: 3143520016414-(((1-Hydroxy-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)amino)-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one hydrochloride (44)

[0501] To a stirred solution of 7-(aminomethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol hydrochloride (41-1, 2-7 in Scheme 2) (173 mg, 0.9 mmol, 1.0 equiv.) and 4-chloro-6-methyl-5,6-dihydro-777-pyrrolo[3,4-(7]pyrimidin-7-one (41-2) (180 mg, 0.9 mmol, 1.0 equiv.) in DMSO (3 mL) was added K2CO3 (271 nig, 1.9 mmol, 2.0 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 60 °C overnight under a nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 20 mL). The filtrate was concentrated under reduced pressure. The product was purified by Prep-HPLC (Column: XBridge BEH C18 5 μm, 19 * 250 mm; Mobile Phase A: Water (0.1% HCl), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 6% B to 15%B in 8 min; Wave Length: 254 / 220 nm), which afforded 4-(((1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-7-yl)methyl)amino)-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one hydrochloride (44) (8.3 mg, 2.3% yield) as a red solid.

[0502] LCMS (ESI): [M+H]+: 324

[0503] 1H NMR (400 MHz, DMSO-d6) δ 9.83 (br.s, 1H), 8.76 (s, 1H), 8.63 (s, 1H), 8.04 (d,,7= 1.8 Hz, 1H), 7.81 (dd,.7= 8.0, 1.8 Hz, 1H), 7.74 (d,,7= 8.0 Hz, IH), 4.91 (d,.7= 5.9 Hz, 2H), 4.50 (s, 2H), 3.13 (s, 3H).Example 46Synthesis of 4-{[(1-hydroxy-8-methoxy-2,3,1-benzoxazaborinin-7-yl)methyl]amino}-8H-pyrido[2,3-d]pyrimidin-7-one

[0504] The compound was synthesized using Scheme 42.147MF-369911600Attorney Docket No.: 314352001641Scheme 422-Bromo-3-hydroxy-4-iodobenzaldehyde (42-2)

[0505] To a stirred solution of 3-hydroxy-4-iodobenzaldehyde (42-1) (5.0 g, 20.1 mmol, 1.0 equiv.) in DCM (50 mL) was added NBS (3.9 g, 22.1 mmol, 1.1 equiv.) at room temperature, the reaction mixture was stirred at room temperature overnight under a nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The product was purified by silica gel column chromatography, eluted with PE / EA (9 / 1), which afforded 2-bromo-3-hydroxy-4-iodobenzaldehyde (6.5 g) as a yellow solid, which was used directly in the next step without further purification.

[0506] 10.29 (s, 1H), 10.16 (s, 1H), 7.94 (d, J= 8.0 Hz, 1H), 7.11 (d, J === 8.0 Hz, 1H).2-Bromo-4-iodo-3-methoxybenzaldehyde (42-3)

[0507] To a stirred solution of 2-bromo-3-hydroxy-4-iodobenzaldehyde (42-2) (6.5 g, 19.8 mmol, 1.0 equiv.) and Mel (3.1 g, 21.8 mmol, 1.1 equiv.) in DMF (20 mL) was added K2CO3 (4.1 g, 29.8 mmol, 1.5 equiv.) at room temperature, and the reaction mixture was148MF-369911600Attorney Docket No.: 314352001641stirred overnight. Then to the resulting mixture was added water (50 mL). The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (1 x 150 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18; mobile phase, MeCN in Water (0.1% FA), 50% to 70% gradient in 10 min; detector, UV 220 nm. This generated 2-bromo-4-iodo-3 -methoxy benzaldehyde (42-3) (2.8 g, 41.3% yield) as a white solid.

[0508] 'HNMR (400 MHz, DMSO-t / 6) 6 10.17 (s, 1H), 8.04 (d, J= 8.1 Hz, 1H), 7.35 (d, J= 8.1 Hz, 1H), 3.84 (s, 3H).(2-Bromo-4-iodo-3-methoxyphenyl)methanol (42-4)

[0509] To a stirred solution of 2-bromo-4-iodo-3-methoxybenzaldehyde (42-3) (5.0 g, 14.6 mmol, 1.0 equiv.) in MeOH (100 mL) was added NaBFL (1.1 g, 29.3 mmol, 2.0 equiv.) in portions at 0 °C, then the resulting mixture was stirred at room temperature for 1 hour. Then water (50 mL) was added. The resulting mixture was concentrated under reduced pressure. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (1 / 1), which afforded (2-bromo-4-iodo-3-methoxyphenyl)methanol (42-4) (4.9 g, 97.4% yield) as a white solid.

[0510] LCMS (ESI): [M-H]‘: 341[(2-Bromo-4-iodo-3-methoxyphenyl)methoxy](tert-butyl)dimethylsilane (42-5)

[0511] To a stirred solution of (2-bromo-4-iodo-3-methoxyphenyl)methanol (42-4) (4.9 g, 14.2 mmol, 1.0 equiv.) and TEA (1.7 g, 17.1 mmol, 1.2 equiv.) in DCM (150 mL) at 0 °C were added DMAP (175 mg, 1.4 mmol, 0.1 equiv.) and TBSC1 (4.3 g, 28.5 mmol, 2.0 equiv. ), the resulting mixture was stirred at room temperature overnight. The resulting mixture was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (10 / 1), which afforded [(2-bromo-4-iodo-3-methoxyphenyl)methoxy](tert-butyl)dimethylsilane (42-5) (5.5 g, 84.1% yield) as a light¬ yellow oil.tert-Butyl N-[(3-bromo-4-{[(tert-butyldimethylsilyl)oxy]methyl}-2-methoxyphenyl) methyl ]carbamate (42-6)149MF-369911600Attorney Docket No.: 314352001641

[0512] To a stirred solution of [(2-bromo-4-iodo-3-methoxyphenyl)methoxy](tert-butyl)dimethyl silane (42-5) (4,9 g, 10.7 mmol, 1.0 equiv.) and tert-butyl / V-[(trifluoro-lambda4-boranyl)methyl]carbamate potassium (5.1 g, 21.4 mmol, 2.0 equiv.) in 1,4-dioxane / H2O (150 mL / 30 mL) were added CS2CO3 (10.5 g, 32.1 mmol, 3.0 equiv.) and Pd(PPh3)2C12 (752 mg, 1.0 mmol, 0.1 equiv.) at room temperature. The resulting mixture was heated to 80 °C overnight under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography (conditions: column, C18; mobile phase, MeCN in Water, 90% to 100% gradient in 10 min; detector, UV 254 nm), which afforded tert-butyl N-[(3-bromo-4-{[(tert-butyldimethylsilyl)oxy]methyl}-2-methoxyphenyl)methyl]carbamate (42-6) (2.2 g, 44.5% yield) as a light-yellow oil.tert-Butyl N-{[3-bromo-4-(hydroxymethyl)-2-methoxyphenyl]methyl}carbamate (42-7)

[0513] To a stirred solution of tert-butyl A-[(3-bromo-4-{[(tert-butyldimethylsilyl)oxy]methyl}-2-methoxyphenyl)methyl]carbamate (42-6) (2.2 g, 4.7 mmol, 1.0 equiv.) in THF (20 mL) was added tetra-n-butylammonium fluoride (11.9 mL, 11.9 mmol, 2.5 equiv, 1.0 M in THF) at room temperature, the resulting mixture was stirred at room temperature for 2 hours under nitrogen atmosphere. The resulting mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed- phase flash chromatography with the following conditions: column, C18; mobile phase, MeCN in Water, 50% to 60% gradient in 10 min; detector, UV 254 nm. This afforded tert-butyl N-{[3-bromo-4-(hydroxymethyl)-2-methoxyphenyl]methyl}carbamate (42-7) (1.1 g, 67.7% yield) as a brown oil.tert-Butyl N-[(3-bromo-4-formyl-2-methoxyphenyl)methyri carbamate (42-8)

[0514] To a stirred solution of tert-butyl N-{[3-bromo-4-(hydroxymethyl)-2-methoxyphenyl]methyl}carbamate (42-7) (1.1 g, 3.2 mmol, 1.0 equiv.) in DCM (30 mL) was added MnO2 (2.8 g, 32.3 mmol, 10.0 equiv.) at room temperature, the resulting mixture was stirred at room temperature overnight. The resulting mixture was filtered and the filter cake was washed with EtOAc (3 x 10 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography (conditions: column, Cl 8; mobile phase, MeCN in Water, 60% to 70% gradient in 10 min; detector, UV 254 nm), which150MF-369911600Attorney Docket No.: 314352001641afforded tert-butyl A-[(3-bromo-4-formyl-2-methoxyphenyl)methyl]carbamate (42-8) (870 mg, 78.1% yield) as a yellow oil.3-{[(tert-Butoxycarbonyl)amino]methyl}-6-formyl-2-methoxyphenylboronic acid (42-9)

[0515] To a stirred solution of tert-butyl A-[(3-bromo-4-formyl-2-methoxyphenyl)methyl]carbamate (42-8) (200 mg, 0.5 mmol, 1.0 equiv.) and B2Pin2(737 mg, 2.9 mmol, 5.0 equiv.) in 1,4-di oxane (20 mL) were added potassium 2,2-dimethylpropanoate (244 mg, 1.7 mmol, 3.0 equiv.) and Pd(PPh3)2Cl2(203 mg, 0.3 mmol, 0.5 equiv.) at room temperature, the resulting mixture was heated to 80 °C for 2 hours under nitrogen atmosphere. The resulting mixture was filtered and concentrated under reduced pressure that generated 3-{[(tert-butoxycarbonyl)amino]methyl}-6-formyl-2-methoxyphenylboronic acid (42-9), which was immediately used in the next step directly without further purification.

[0516] LCMS (ESI): [M+H]+: 310tert-Butyl N-[ ( 1 -hydroxy-8-methoxy-2, 3, 1-benzoxazaborinin- 7 -yl)methyl] carbamate (42- 10)

[0517] To 3-{ [(tert-butoxycarbonyl)amino]methyl }-6-formyl-2-methoxyphenylboronic acid (42-9) was added NH2OHHCI (121 mg, 1.7 mmol, 3.0 equiv.) and H2O (5 mL) at room temperature, the resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 30 mL), dried over anhydrous N 2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 50% to 60% gradient in 10 min; detector, UV 254 nm. This afforded tert-butyl A-[(l- hydroxy-8-methoxy-2,3,l-benzoxazaborinin-7-yl)methyl]carbamate (42-10) (90 mg, 50.5% yield over two steps) as a yellow solid.

[0518] LCMS (ESI): [M+H]+: 3077-(Aminomethyl)-8-methoxy-2, 3, 1-benzoxazaborinin- l-ol hydrochloride (42- 11)

[0519] A solution of tert-butyl A-[(l-hydroxy-8-methoxy-2,3, l-benzoxazaborinin-7-yi)methyl]carbamate (42-10) (680 mg, 2.2 mmol, 1.0 equiv.) in HC1 (7 mL, 4.0 M in 1,4-dioxane) was stirred at room temperature for 1 hour. The resulting mixture was concentrated under vacuum, which afforded 7-(aminomethyl)-8-methoxy-2, 3, 1-benzoxazaborinin- 1 -ol hydrochloride (42-11) (440 mg, 81.7% yield) as a brown solid.

[0520] LCMS (ESI): [M+H]+: 207151MF-369911600Attorney Docket No.: 314352001641Methyl (2E)-3-(4-amino-6-{[ ( 1 -hydroxy-8-methoxy-2, 3, l-benzoxazaborinin-7-yl)methyl]amino}pyrimidin-5-yl)prop-2-enoate (42-13)

[0521] To a stirred solution of 7-(aminomethyl)-8-methoxy-2,3, 1-benzoxazaborinin-l-ol hydrochloride (42-11) (330 mg, 1,3 mmol, 1.0 equiv.) and methyl (2E)-3-(4-amino-6-chloropyrimidin-5-yl)prop-2-enoate (42-12, 3-2 in Scheme 3) (232 mg, 1.0 mmol, 0.8 equiv.) in DMSO (15 mL) were added TEA (688 mg, 6.8 mmol, 5.0 equiv.) and KF (395 mg, 6.8 mmol, 5.0 equiv.) at room temperature. The resulting mixture was heated to 90 °C overnight under a nitrogen atmosphere. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18; mobile phase, MeCN in Water, 30% to 50% gradient in 10 min; detector, UV 254 nm. This afforded methyl (2£)-3-(4-amino-6-{[(l-hydroxy-8-methoxy-2,3,l-benzoxazaborinin-7-yl)methyl]amino}pyrimidin-5-yl)prop-2-enoate (42-13) (400 mg, 76.7% yield) as a light-yellow solid.

[0522] LCMS (ESI): [M+H]+: 3844-{[(1-Hydroxy-8-methoxy-2,3,1-benzoxazaborinin-7-yl)methyl]amino}-8H-pyrido[2,3-d]pyrimidin-7-one (46)

[0523] To a stirred solution of methyl (2E)-3-(4-amino-6-{[(l-hydroxy-8-methoxy-2,3,l-benzoxazaborinin-7- T)methyl]amino}pyrimidin-5-yl)prop-2-enoate (42-13) (200 mg, 0.5 mmol, 1.0 equiv.) in MeOH (5 mL) was added sodium thiomethoxide (183 mg, 2.6 mmol, 5.0 equiv.) at room temperature, the resulting mixture was heated to 80 °C for 1 hour. The resulting mixture was filtered and the filter cake was washed with MeOH (2 x 3 mL). The filtrate was concentrated under reduced pressure. The product was initially purified by Prep-HPLC (Column: XBridge BEH C18 5 μm, 19 * 250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3+ 0.1% NH3·H2O), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 3% B to 13%B in 10 min; Wave Length: 254 nm / 220 nm) followed by further purified by trituration with MeOH (3 mL). This resulted in 4-{[(l-hydroxy-8-methoxy-2,3, l-benzoxazaborinin-7-yl )methyl]amino}-877-pyrido[2,3-d]pyrimidin-7-one (46) (18.9 mg, 10.3% yield) as a white solid.

[0524] LCMS (ESI): [M+H]+: 352

[0525] JH NMR (400 MHz, DMSO-6) δ 12.01 (s, 1H), 9.15 (s, 1H), 8.58 - 8.56 (m, 2H), 8.28 - 8.20 (m, 2H), 7.697.9 Hz, 1H), 7.46 (d, 7.9 Hz, 1H), 6.44 (d, J= 9.7 Hz, 1H), 4.83 (d, J 5.7 Hz, 2H), 3.91 (s, 3H).152MF-369911600Attorney Docket No.: 314352001641Examples 47-51 (Omitted)Example 52Synthesis of 7-[ ({8-hydroxypyrido[3, 4-d]pyrimidin-4-yl}amino)methyl -2, 3.1-benzoxazaborinin-l-ol

[0526] The compound was synthesized using Scheme 43.7-[({8-Hydroxypyrido[3,4-d]pyrimidin-4-yl}amino)methyl]-2,3,1-benzoxazaborinin-1-ol (52)

[0527] To a stirred solution of 7-(aminomethyl)-2,3,1-benzoxazaborinin-1-ol hydrochloride (43-1, 2-7 in Scheme 2) (500 mg, 2.8 mmol, 1.0 equiv.) and 8-methoxy-377-pyrido[3,4- ] pyrimidin-4-one (43-2) (604 mg, 3.4 mmol, 1.2 equiv.) in DMF (5 mL) were added DIEA (1.1 g, 8.4 mmol, 3.0 equiv.) and BOP (1.9 g, 4.2 mmol, 1.5 equiv.) in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at room temperature overnight under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure and the product was initially purified by Prep-HPLC (Column:XBridge BEH C18 5 μm, 19 × 250 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 7% B to 15% B in 9 min; Wave Length: 254 nm / 220 nm) followed by further purified by Prep-HPLC (Column: YMC-Actus Triart C18 ExRS5 pm, 30 mm X 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1%NH3H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 15%B in 9 min; Wave Length: 254 nm / 220 nm), which afforded 7-[({8-hydroxypyrido[3,4-153MF-369911600Attorney Docket No.: 314352001641]pyrimidin-4-yl}amino)methyl]-2,3,1-benzoxazaborinin-1-ol (52) (9.3 mg, 1.0% yield) as a white solid.

[0528] LCMS (ESI): [M+H]+: 322

[0529] 1H NMR (400 MHz, DMSO-6+ HCl) δ 12.85 (s, 1H), 11.23 (t,.7= 6.1 Hz, 1H), 8.75 (s, 1H), 8.63 (s, 1H), 8.04 (s, 1H), 7.85 (d, J= 7.8 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.68 (d,.7 = 7.2 Hz, 1H), 7.36 (d,.7 = 7.2 Hz, 1H), 5.02 (d,.7= 5.9 Hz, 2H).Example 53 (Omitted)Example 54Synthesis of 8-methoxy-7-{[(8-methoxyquinazolin-4-yl)amino]methyl}-2,3, 1-benzoxazaborinin-l-ol

[0530] The compound was synthesized using Scheme 45.8-Methoxy-7-{[(8-methoxyquinazolin-4-yl)amino]methyl}-2,3,1-benzoxazaborinin-1-ol (54)

[0531] To a stirred solution of 7-(aminomethyl)-8-methoxy-2,3,l-benzoxazaborinin-l-ol hydrochloride (45-1, 42-11 in Scheme 42) (70 mg, 0.3 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (45-2) (53 mg, 0.3 mmol, 0.8 equiv.) in DMSO (2 mL) was added TEA (103 mg, 1.0 mmol, 3.0 equiv.) at room temperature, the resulting mixture was heated to 60 °C for 2 hours under a nitrogen atmosphere. The product was initially purified by reversed-phase flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 30% to 50% gradient in 10 min; detector, UV 254 nm. The product was further purified by Prep-HPLC with the following conditions: Column: XBridge BEH Cl 85154MF-369911600Attorney Docket No.: 314352001641im, 19 * 250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1%NH3. H2O), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 10% B to 15%B in 10 min; Wave Length: 254 nm / 220 nm. This resulted in 8-methoxy-7-{[(8-methoxyquinazolin-4-yl)amino]methyl}-2,3,l-benzoxazaborinin-l-ol (54) (12.0 mg, 9.7% yield) as a white solid.

[0532] LCMS (ESI): [M+H]+: 365

[0533] 1H NMR (400 MHz, Methanol / 4) 58.45 (s, 1 H), 7.79 (s, 1 H), 7.72 (dd, J = 8.4, 1.1 Hz, 1H), 7.49 (t, J= 8.1 Hz, 1H), 7.31 (dd, J= 8.0, 1.1 Hz, 2H), 7.03 (d, J= 7.7 Hz, 1H), 4.95 (s, 2H), 4.01 (d, J= 14.3 Hz, 6H).Example 55Synthesis of 7 -[( {8-methoxypyrido [ 3, 4-d]pyrimidin-4-yl }amino)methyl ]-5-methyl-2, 3,1-benzoxazaborinin-l-ol

[0534] The compound was synthesized using Scheme 46.155MF-369911600Attorney Docket No.: 314352001641Scheme 46ttriflate, Pd(OAc)2, Cs2CO3p-TsOH, AcOHdioxane, H2O 46-34-Bromo-2-hydroxy-6-methylbenzaldehyde (46-2)

[0535] To a stirred solution of 4-bromo-2-methylbenzaldehyde (46-1) (2,0 g, 10,0 mmol, 1.0 equiv.) and Pd(OAc)2 (225 mg, 1.0 mmol, 0.1 equiv.) in AcOH (100 mL) were added 2- amino-4-(trifluoromethyl)benzoic acid (1.0 g, 5.0 mmol, 0.5 equiv.), l-fluoro-2,4,6- trimethylpyrdinium triflate (4.3 g, 15.0 mmol, 1.5 equiv.) and p-TsOH (3.5 g, 20.0 mmol, 2.0 equiv.) at room temperature, the resulting mixture was heated to 90 °C for 1 day. The resulting mixture was concentrated under vacuum. The product was purified by silica gel column chromatography, eluted with PE / EA (9 / 1), which afforded 4-bromo-2-hydroxy-6-methylbenzaldehyde (46-2) (1.6 g, 74.0% yield) as a yellow oil.tert-Butyl N-[ (4-formyl-3-hydroxy-5-methylphenyl )methyl ] carbamate (46-3 )

[0536] To a stirred solution of 4-bromo-2-hydroxy-6-methylbenzaldehyde (46-2) (1.6 g, 7.4 mmol, 1.0 equiv.) and tert-butyl A'-[(trifluoro-lambda4-boranyl)methyl]carbamate potassium (2.3 g, 9.6 mmol, 1.3 equiv.) in dioxane / H2O (60 mL / 12 mL) were added CS2CO3 (4.8 g, 14.8 mmol, 2.0 equiv.), Pd(OAc)2 (167 mg, 0.7 mmol, 0.1 equiv.) and XPhos (709 mg, 1.4 mmol, 0.2 equiv.) at room temperature, the resulting mixture was heated to 80 °C156MF-369911600Attorney Docket No.: 314352001641overnight under a nitrogen atmosphere. The resulting mixture was diluted with water (30 niL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (2 x 50 niL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (3 / 1 ), which afforded tert-butyl A-[(4-formyl-3-hydroxy-5-methylphenyl)methyl]carbamate (46-3) (1.7 g, 86.1% yield) as a yellow solid.tert-Butyl N-{[4-formyl-3-methyl-5-(lrifluoromethanesulfonyloxy)phenyl] methyl} carbamate (46-4)

[0537] To a stirred solution of tert-butyl A-[(4-formyl-3-hydroxy-5-methylphenyl)methyl]carbamate (46-3) (1.7 g, 6.4 mmol, 1.0 equiv.) and TEA (1.9 g, 19.2 mmol, 3.0 equiv.) in THF (100 niL) was added 1,1,1-trifluoro-A-phenyl-A- trifluoromethanesulfonylmethanesulfonamide (4.6 g, 12.8 mmol, 2.0 equiv.) at room temperature, the resulting mixture was heated to 60 °C overnight under a nitrogen atmosphere. The resulting mixture was diluted with water (30 mL) and extracted with EtOAc (3x30 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8 silica gel; mobile phase, MeCN in Water, 60% to 70% gradient in 10 min; detector, UV 254 nm, which afforded tert-butyl A-{[4-formyl-3-methyl-5- (trifluoromethanesulfonyloxy)phenyl]methyl}carbamate (46-4) (1.3 g, 51.8% yield) as a light-yellow solid.5-{[( tert-Butoxycarbony'l)amino ]methyl}-2-formyl-3-methylphenylboronic acid (46-5)

[0538] To a stirred solution of / ert-butyl N-{ [4-formyl-3-methyl-5-(trifluoromethanesulfonyloxy)phenyl]methyl] carbamate (46-4) (1.3 g, 3.2 mmol, 1.0 equiv.) and B2Pin2(997 mg, 3.9 mmol, 1.2 equiv.) in dioxane (30 mL) were added KOAc (642 mg, 6.5 mmol, 2.0 equiv.) and Pd(dppf)C12CH2Cl2 (267 mg, 0.3 mmol, 0.1 equiv.) at room temperature, the resulting mixture was heated to 80 °C for 3 hours under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 40% to 60% gradient in 10 min; detector, UV 254 nm, which afforded 5-{[(tert-butoxycarbonyl)amino]methyl}-2-formyl-3-methylphenylboronic acid (46-5) (800 mg, 83.4% yield) as a light-yellow solid.tert-Butyl B’-[(l-hydroxy-5-methyl-2, 3, l-benzoxazaborinm-7-yl)methyl] carbamate (46-6)157MF-369911600Attorney Docket No.: 314352001641

[0539] To a stirred solution of 5-{[(tert-butoxycarbonyl)amino]methyl}-2-formyl-3-methylphenylboronic acid (46-5) (720 mg, 2.4 mmol, 1.0 equiv.) and NaOAc (282 mg, 3.4 mmol, 1.4 equiv.) in THF / H2O (10 mL / 10 mL) was added NH2OH. HCI (205 mg, 2.9 mmol, 1.2 equiv.) at room temperature, the resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8; mobile phase, MeCN in Water, 50% to 60% gradient in 10 min; detector, UV 254 nm, which afforded tert-butyl N-[(1-hydroxy-5-methyl-2,3,1-benzoxazaborinin-7-yl)methyl]carbamate (46-6) (320 mg, 44.9% yield) as a light-yellow solid.

[0540] LCMS (ESI): [M+H]+: 2917-(Aminomethyl)-5-methyl-2, 3, 1 -benzoxazaborimn-l-ol hydrochloride (46-7)

[0541] A solution of tert-butyl A-[(l-hydroxy-5-methyl-2,3,l-benzoxazaborinin-7-yl)methyl]carbamate (46-6) (310 mg, 1.0 mmol, 1.0 equiv.) in HC1 (3 mL, 4.0 M in 1,4-dioxane) was stirred at room temperature for 1 hour. The resulting mixture was concentrated under vacuum, which afforded 7-(aminomethyl)-5-methyl-2,3,l-benzoxazaborinin-l-ol hydrochloride (46-7) (300 mg) as a light-yellow solid, which was used directly in the next step without further purification.

[0542] LCMS (ESI): [M+H]+: 1917-[ {8-Methoxypyrido[3, 4-dpyrimidin-4-yl}amino)methyl]-5-methyl-2, 3, 1-benzoxazaborinin-l-ol (55)

[0543] To a stirred solution of 7-(aminomethyl)-5-methyl-2,3,l-benzoxazaborinin-l-ol hydrochloride (46-7) (290 mg, 1.5 mmol, 1.0 equiv.) and 8-methoxy-3-pyrido[3,4-]pyrimidin-4-one (46-8) (189 mg, 1.0 mmol, 0.7 equiv.) in DMF (20 mL) were added BOP (1.0 g, 2.2 mmol, 1.5 equiv.) and TEA (463 mg, 4.5 mmol, 3.0 equiv.) at room temperature, the resulting mixture was stirred at room temperature overnight under a nitrogen atmosphere. The produce was initially purified by reversed-phase flash chromatography (column, Cl 8; mobile phase, MeCN in Water, 20% to 50% gradient in 10 min; detector, UV 254 nm) followed by further purified by Prep-HPLC (Column: XBridge BEH C185pm, 19*250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3+ 0.1% NH3·H2O), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 8%B to 50%B in 12 min; Wave Length: 254 nm / 220158MF-369911600Attorney Docket No.: 314352001641nm). This resulted in 7-[({8-methoxypyrido[3,4-]pyrimidin-4-yl}amino)methyl]-5-methyl-2,3,1-benzoxazaborinin-1-ol (55) (1.6 mg, 0.3% yield) as a white solid.

[0544] LCMS (ESI): [M+H]+: 350

[0545] 1H NMR (400 MHz, DMSO-6) δ 9.28 (brs, 1H), 9.04 (s, 1H), 8.71 (s, 1H), 8.51 (s, 1H), 8.13 (d, 5.8 Hz, 1H), 7.83 (s, 1H), 7.72 (d, J= 5.9 Hz, 1H), 7.59 (s, 1H), 4.86 (d, J= 5.8 Hz, 2H), 4.01 (s, 3H), 2.54 (s, 3H).Example 56Synthesis of (S)-5-fluoro- 7-( 1 -( (8-methoxyquinazolin-4-yl)ammo)ethyl)-lH-benzo[d][ 1, 2, 6 oxazaborinin-l-ol

[0546] The compound was synthesized using Scheme 47.159MF-369911600Attorney Docket No.: 314352001641Scheme 47Methyl 4-( I -ethoxyvinyl)-2-jluoro-6-hydroxybenzoate (47-2)

[0547] To a stirred solution of methyl 4-bromo-2-fluoro-6-hydroxybenzoate (47-1) (10.0 g, 40.2 mmol, 1.0 equiv.) and tributyl( 1 -ethoxy ethenyl) stannane (17.4 g, 48.2 mmol, 1.2 equiv.) in 1,4-dioxane (150 mL) was added Pd(PPh3)2Cl2(2.8 g, 4.0 mmol, 0.1 equiv.) in one portion at 25 °C under nitrogen atmosphere. The reaction mixture was heated to 90 °C for 3 hours under a nitrogen atmosphere. The mixture was allowed to cool down to 25 °C. To the mixture was then added saturated KF aqueous solution (200 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with brine (3 x 200 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column160MF-369911600Attorney Docket No.: 314352001641chromatography, eluted with PE / EA (2 / 3), which afforded methyl 4-(1-ethoxyvinyl)-2-fluoro-6-hydroxybenzoate (47-2) (9.6 g, 99.5% yield) as a yellow solid.

[0548] LCMS (ESI): [M-H]': 239Methyl 4-acetyl-2-fluoro-6-hydroxybenzoate (47-3)

[0549] To a stirred solution of methyl 4-(1-ethoxyethenyl)-2-fluoro-6-hydroxybenzoate (47-2) (10.1 g, 42.0 mmol, 1.0 equiv.) in 1,4-dioxane (150 mL) was added HC1 in 1,4-di oxane (4.0 M, 100 mL) in one portion at 25 °C. The resulting mixture was stirred at 25 °C for 1 hour. The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over anhydrous Na2SO4 After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (3 / 2), which afforded methyl 4-acetyl- 2-fluoro-6-hydroxybenzoate (47-3) (8.8 g, 98.6% yield) as a yellow solid.

[0550] LCMS (ESI): [M-H]': 211Ethyl (R)-4-( 1 -((tert-butylsulfinyl)imino)ethyl)-2-jluoro-6-hydroxybenzoate (47-4)

[0551] To a stirred solution of methyl 4-acetyl-2-fluoro-6-hydroxybenzoate (47-3) (9.6 g, 45.2 mmol, 1.0 equiv.) and (7?)-2-methylpropane-2-sulfinamide (6.6 g, 54.3 mmol, 1.2 equiv.) in THF (150 mL) was added Ti(OEt)4 (51.6 g, 226.2 mmol, 5.0 equiv.) in one portion at 25 °C under nitrogen atmosphere. The reaction mixture was heated to 90 °C for 2 hours under a nitrogen atmosphere. The mixture was allowed to cool down to 25 °C. To this mixture was added 2-({2-[bis(2-hydroxy ethyl) amino] ethyl }(2-hydroxyethyl)amino)ethan-l -ol (58.8 g, 248.8 mmol, 5.5 equiv.) in one portion over 5 minutes at 25 °C. The resulting mixture was stirred at 60 °C for 1 hour. The mixture was allowed to cool down to 25 °C. The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (3 / 2), which afforded ethyl (R)-4-(1-((tert-butylsulfinyl)imino)ethyl)-2-fluoro-6-hydroxybenzoate (47-4) (5.4 g, 36.2% yield) as a yellow solid.

[0552] LCMS (ESI): [M+H]+: 330Ethyl 4-((S)-l-(((R)-tert-biit’lsulfinyl) amino) ethyl)-2-fluoro-6-hydroxybenzoate (47-5):

[0553] To a stirred solution of ethyl 2-fluoro-6-hydroxy-4-(1-{[(R)-2-methylpropane-2-sulfinyl]imino}ethyl)benzoate (47-4) (5.3 g, 16.1 mmol, 1.0 equiv.) in THF (100 mL) at 0 °C under a nitrogen atmosphere was added lithium tri-sec-butylborohydride (1.0 M in THF, 48.3161MF-369911600Attorney Docket No.: 314352001641mL, 48.3 mmol, 3.0 equiv.) dropwise. The reaction mixture was stirred at 25 °C for 3 hours under a nitrogen atmosphere. The reaction was quenched with saturated NH4CI aqueous solution (100 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, which afforded ethyl 4-((5)-l-(((7?)-tert-butyl sulfinyl) amino) ethyl)-2-fluoro-6-hydroxybenzoate (47-5) (8.0 g) as a yellow oil. This material was directly used for next step without further purification.

[0554] LCMS (ESI): [M+H]+: 332(R)-N-((S)-l-(3-fluoro-5-hydroxy-4-(hydroxymethyl) phenyl) ethyl)-2-methylpropane-2-sulfinamide (47-6)

[0555] To a stirred solution of ethyl 2-fluoro-6-hydroxy-4-[(lS)-l-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]benzoate (47-5) (5.6 g, 16,9 mmol, 1.0 equiv.) in THF (60 mL) at 0 °C under a nitrogen atmosphere was added LiBH4 (4.0 M in THF, 8.5 mL, 33.8 mmol, 2.0 equiv.) dropwise. The reaction mixture was stirred at 25 °C for 3 hours under nitrogen atmosphere. The reaction was quenched with saturated NH4CI aqueous solution (100 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 80 mL). The combined organic layers were washed with brine (2 x 100 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, ACN in water, 20% to 30% gradient in 10 min; detector, UV 254 nm, which afforded (R)-N-((S)-1-(3-fluoro-5-hydroxy-4-(hydroxymethyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (47-6) (3.5 g, 71.5% yield) as a yellow oil.

[0556] LCMS (ESI): [M+H]+: 290(R)-N-((S)-l-(3-fluoro-4-formyl-5-hydroxyphenyl)ethyl)-2-methylpropane-2-sulfmamide (47-

[0557] To a stirred solution of (R)-N-[(1S)-1-[3-fluoro-5-hydroxy-4-(hydroxymethyl)phenyl]ethyl]-2-methylpropane-2-sulfinamide (47-6) (3.6 g, 12.3 mmol, 1.0 equiv.) in DCM (40 mL) was added MnO2 (16.0 g, 184.5 mmol, 15.0 equiv.) in one portion at 25 °C, The reaction mixture was stirred at 25 °C overnight. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 50 mL). The filtrate was concentrated under reduced pressure. The residue was dissolved in MeOH (15 mL). The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel;162MF-369911600Attorney Docket No.: 314352001641mobile phase, ACN in water, 25% to 35% gradient in 10 min; detector, UV 254 nm, which afforded (R)-N-((S)-1-(3-fluoro-4-formyl-5-hydroxyphenyl)ethyl)-2-methylpropane-2-sulfinamide (47-7) (1.72 g, 48.6% yield) as a white solid.

[0558] LCMS (ESI): [M+H]+: 2885-( (S)-l-( ( (R)-tert-Butylsulfmyl)amino)ethyl)-3-fluoro-2-formylphenyltrifluoromethane sulfonate (47-8)

[0559] To a stirred solution of (R)-N-[(1S)-1-(3-fluoro-4-formyl-5-hydroxyphenyl)ethyl]-2-methylpropane-2-sulfinamide (47-7) (1.7 g, 5.9 mmol, 1.0 equiv.) and PhNTfj (2.5 g, 7.1 mmol, 1.2 equiv.) in THF (20 mL) was added CS2CO3 (4.8 g, 14.8 mmol, 2.5 equiv.) in one portion at 25 °C under nitrogen atmosphere. The reaction mixture was stirred at 25 °C for 30 minutes under nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with EA (3 x 50 mL). The filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, ACN in water, 45% to 55% gradient in 10 min; detector, UV 254 nm, which afforded 5-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-3-fluoro-2-formylphenyl trifluoromethanesulfonate (47-8) (2.1 g, 83.4% yield) as a brown oil.(5-((S)-l-(((R)-tert-Butylsulfinyl)ammo)ethyl)-3-fluoro-2-formylphenyl)boronic acid (47-9)

[0560] To a stirred solution of 3-fluoro-2-formyl-5-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]phenyltrifluoromethanesulfonate (47-8) (2.1 g, 4.9 mmol, 1.0 equiv.) and Pin2B2 (1.9 g, 7.3 mmol, 1.5 equiv.) in 1,4-dioxane (20 mL) were added KOPiv (1.4 g, 9.8mmol, 2.0 equiv.) and Pd(PPh3)2Cl2 (340 nig, 0.5 mmol, 0.1 equiv.) in one portion at 25 °C under a nitrogen atmosphere. The reaction mixture was heated to 80 °C for 3 hours under a nitrogen atmosphere. The mixture was allowed to cool down to 25 °C. The resulting mixture was diluted with water (80 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8 silica gel; mobile phase, ACN in water, 25% to 35% gradient in 10 min; detector, UV 254 nm, which afforded (5-((S)-1-(((R)-tert-butylsulfinyl)amino)ethyl)-3-fluoro-2-formylphenyl)boronic acid (47-9) (1.05 g, 68.1% yield) as a white solid.

[0561] LCMS (ESI): [M+H]+: 316163MF-369911600Attorney Docket No.: 314352001641(R)-N-((S)-l-(5-fluoro-l-hydroxy>-lH-benzo[d [ 1,2,6] oxazaborinin-7 -yl)ethyl)-2-methylpropane-2-sulfinamide (47-10)

[0562] To a stirred solution of 3-fluoro-2-formyl-5-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]phenylboronic acid (47-9) (1.1 g, 3.3 mmol, 1.0 equiv.) and NH2OHHCI (690 mg, 10.0 mmol, 3.0 equiv.) in THF (10 mL) was added H2O (10 mL) in one portion at 25 °C under nitrogen atmosphere. The reaction mixture was stirred at 25 °C for 1 hour under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure that afforded (R)-N-((S)-1-(5-fluoro-1-hydroxy-1H-benzo[d][1,2,6]oxazaborinin-7-yl)ethyl)-2-methylpropane-2-sulfinamide (47-10) (1.0 g) as a white solid, which was used directly in the next step without further purification.

[0563] LCMS (ESI): [M+H]+: 313(S)-7-(l-aminoethyl)-5-fltioro-lH-benzo[d][ l,2,6]oxazaborinm-l-ol hydrochloride (47-11)

[0564] To a stirred solution of (R)-N-[(1S)-1-(5-fluoro-1-hydroxy-2,3,1-benzoxazaborinin-7-yl)ethyl]-2-methylpropane-2-sulfinamide (47-10) (990 mg, 3.2 mmol, 1.0 equiv.) in 1,4-dioxane (9 mL) was added HQ in 1,4-dioxane (4.0 M, 9 mL) dropwise at 25 °C. The reaction mixture was stirred at 25 °C for 1 hour. The resulting mixture was purified by prep-HPLC with the following conditions (Column: Xselect CSH Cl 85 pm, 30 mm X 150 mm; Mobile Phase A: water (0.1% FA), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 2% B to 8%B in 4 min; Wave Length: 254 nm / 220 nm), which afforded (S)-7-(1-aminoethyl)-5-fluoro-1H-benzo[d][1,2,6]oxazaborinin-1-ol hydrochloride (400 mg, 60.6% yield) as a white solid.

[0565] LCMS (ESI): [M+H]+: 209(S)-5-Fluoro-7-(l-( 8-methoxyquinazolin-4-yl)amino)ethyl)- IH-benzo d] [1, 2, 6 ] oxazaborinin-l-ol (56)

[0566] To a stirred solution of 7-[(1S)-1-aminoethyl]-5-fluoro-2,3,1-benzoxazaborinin-1-ol hydrochloride (47-11) (60 mg, 0.3 mmol, 1.0 equiv.) and 4-chloro-8-methoxyquinazoline (47-12) (56 mg, 0.3 mmol, 1.0 equiv.) in DMSO (1 mL) were added CsF (219 mg, 1.4 mmol, 5.0 equiv.) and TEA (146 mg, 1.4 mmol, 5.0 equiv.) in one portion at 25 °C under a nitrogen atmosphere. The reaction mixture was heated to 60 °C for 1 hour under a nitrogen atmosphere. The mixture was allowed to cool down to 25 °C. The resulting mixture was purified by prep-HPLC (Column: XB ridge BEH Cl 85 pm, 19 * 250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient164MF-369911600Attorney Docket No.: 314352001641(B%): 10% B to 25% B in 8 min; Wave Length: 254 nm / 220 nm), which afforded (S)-5-fluoro-7-(1-((8-methoxyquinazolin-4-yl)amino)ethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (56) (15.8 mg, 14.9% yield) as a white solid.

[0567] LCMS (ESI): [M+H]+: 367

[0568] 'HNMR (400 MHz, DMS0 ) δ 9.53 (brs, 1H), 8.70 (s, 1H), 8.467.5 Hz, 1H), 8.36 (s, 1H), 8.03 - 7.93 (m, 1H), 7.92 (s, 1H), 7.71 (d, J= 11.1 Hz, 1H), 7.56 - 7.47 (m, 1H), 7.28 (d, 7.8 Hz, 1H), 5.68 - 5.61 (m, 1H), 3.90 (s, 3H), 1.63 (d, J= 7.1 Hz, 3H).Example 57Synthesis of (S)-5-fluoro- 7-( 1 -( (8-methoxypyrido[3, 4-d] pyrimidin-4-yl) amino) ethyl)-lH-benzofd] [1,2,6] oxazaborinin-l-ol

[0569] The compound was synthesized using Scheme 48.Scheme 48(S)-5-Fluoro-7-(l-((8-methoxypyrido[3,4-d] pyrimidin-4-yl) amino) ethyl) -lH-benzo[d][1,2,6] oxazaborinin-l-ol (57)

[0570] To a stirred solution of 7-[(15’)-l-aminoethyl]-5-fluoro-2,3,l-benzoxazaborinin-l- ol hydrochloride (48-1, 47-11 in Scheme 47) (60 mg, 0.3 mmol, 1.0 equiv.) and 4-chloro-8-methoxypyrido[3,4-d]pyrimidine (48-2, 29-2 in Scheme 29) (56 mg, 0.3mmol, 1.0 equiv.) in DMSO (1 mL) was added TEA (146 mg, 1.4 mmol, 5.0 equiv.) in one portion at 25 °C under nitrogen atmosphere. The reaction mixture was heated to 60 °C for 1 hour under nitrogen atmosphere. The mixture was allowed to cool down to 25 °C. The product was purified by 165MF-369911600Attorney Docket No.: 314352001641prep-HPLC (Column: XBridge BEH C18 5 μm, 19 * 250 mm; Mobile Phase A: water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 10% B to 25% B in 8 min; Wave Length: 254 nm / 220 nm), which afforded (S)-5-fluoro-7-(1-((8-methoxypyrido[3,4-d]pyrimidin-4-yl)amino)ethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (57) (11.0 mg, 10.3 % yield) as a white solid.

[0571] LCMS (ESI): [M+H]+: 368

[0572] 'HNMR (400 MHz, Methanol^) δ 8.47 (s, 1H), 8.39 - 8.31 (m, 1H), 8.13 (d, J = 5.9 Hz, 1H), 7.71 (d, J= 5.9 Hz, 1H), 7.59 (s, 1H), 7.29 (d, J= 11.2 Hz, 1H), 5.72 - 5.63 (m, 1H), 4.12 (s, 3H), 1.70 (d, J= 7.1 Hz, 3H).Example 58Synthesis of 7-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)-1H-benzo[d][1,2,6]oxazaborinin-

[0573] The compound above was synthesized using Scheme 49.Scheme 49Methyl 2-bromo-4-(dibromomethyl)benzoate (49-2)166MF-369911600Attorney Docket No.: 314352001641

[0574] To a mixture of methyl 2-bromo-4-methylbenzoate (49-1) (5.0 g, 21.8 mmol, 1.0 equiv.) in CCh (50 mL) were added NBS (9.71 g, 54.56 mmol, 2.5 equiv.) followed by AIBN (1.07 g, 6.54 mmol, 0.3 equiv.) at room temperature and heated to 80 °C for 4 hours under nitrogen atmosphere. After consumption of the starting material, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with water (2 x 100 mL), followed by a brine solution (100 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 10% EtOAc in hexane to obtain methyl 2-bromo-4-(dibromomethyl)benzoate (49-2) (4.5 g) as a gummy liquid that was used in the next step without further purification.

[0575] ‘H-NMR (400 MHz, DMSO- s) 57.95 (d, 2.0 Hz, 1H), 7.86 (d, 8.0 Hz, 1H), 7.77 (dd, J= 2.0, 8.0 Hz, 1H), 7.41 (s, 1H), 3.88 (s, 3H).Methyl 2-bromo-4-formylbenzoate (49-3)

[0576] To a stirred solution of methyl 2-bromo-4-(dibromomethyl)benzoate (49-2) (4.5 g, 11.63 mmol, 1.0 equiv.) in EtOH (90 mL) was added silver nitrate (3.95 g, 23.26 mmol, 2.0 equiv.) dissolved in water (20 mL) at room temperature and stirred at 90 °C for 30 minutes. After consumption of the starting material, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 150 mL). The combined organic layers were filtered through a celite pad and the filtrate was washed with a brine solution (50 mL), dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 50% EtOAc in hexane, which generated methyl 2-bromo-4-formylbenzoate (49-3) (2.4 g, 85.1% yield) as an off-white solid.

[0577] 10.03 (s, 1H), 8.23 (d,. / 1.2 Hz, 1H), 7.99 (dd, J= 1.2, 8.0 Hz, 1H), 7.93 (d, J= 7.6 Hz, 1H), 3.90 (s, 3H).Methyl 2-bromo-4-(hydroxymethyl)benzoate (49-4)

[0578] To a stirred solution of methyl 2-bromo-4-formylbenzoate (49-3) (2.8 g, 11.51 mmol, 1.0 equiv.) in THF (60 mL) was added NaBHi (0.651 g, 17.26 mmol, 1.5 equiv.) portion wise at 0 °C and stirred for 2 hours. After consumption of the starting material, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (50 mL), followed by a brine solution (50 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced167MF-369911600Attorney Docket No.: 314352001641pressure. The product was purified by flash chromatography and eluted with 0% to 80% EtOAc in hexane to obtain methyl 2-bromo-4-(hydroxymethyl)benzoate (49-4) (2.2 g, 78.0% yield) as a pale-yellow gummy solid.

[0579] 'H-NMR (400 MHz, DMSO- s) 67.75 (d, J = 8.0 Hz, 1H), 7.68 (s, 1H), 7.42 (dd,. / 1.2, 8.0 Hz, IH), 5.45 (t,. / 5.6 Hz, IH), 4.55 (d, J 6.0 Hz, 2H), 3.85 (s, 3H) Methyl 2-bromo-4-(((6, 7-dimethoxyquinazolin-4-yl)oxy)niethyI)benzoate (49-6)

[0580] To a stirred solution of methyl 2-bromo-4-(hydroxymethyl)benzoate (49-4) (1.30 g, 5.82 mmol, 1.2 equiv.) in DMF (15 mL) was added NaH (0.128 g, 5.82 mmol, 1.2 equiv.) portion wise at 0 °C and stirred for 30 min. Then 4-chloro-6,7-dimethoxyquinazoline (49-5) (1.0 g, 4.85 mmol, 1.0 equiv.) was added portion wise at same temperature and allowed to stir at room temperature for 1 hour. The progress of the reaction was monitored by TLC. After consumption of the starting material, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (30 mL), followed by a brine solution (50 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 80% EtOAc in hexane, which generated methyl 2-bromo-4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzoate (49-6) (0.35 g, 18.2% yield) as a pale yellow gummy solid.

[0581] 'H-NMR (400 MHz, DMSO-cfe) 68.64 (s, 1H), 7.92 (d, J= 1.6 Hz, 1H), 7.81 (d, J = 8.0 Hz, IH), 7.65 (dd,. / = 1.6, 8.2 Hz, IH), 7.40 (s, IH), 7.34 (s, IH), 5.69 (s, 2H), 3.96 (s, 3H), 3.93 (s, 3H), 3.86 (s, 3H).(2-Bromo-4-(((6, 7-dimethoxyqtiinazoUn-4-yl)oxy)methyl)phenyl)rnethanol (49-7)

[0582] To a stirred solution of methyl 2-bromo-4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzoate (0.35 g, 0.8 mmol, 1.0 equiv.) in THF (10 mL) was added LAH (0.030 g, 0.8 mmol, 1.0 equiv.) portion wise at 0 °C and stirred for 10 minutes. After consumption of the starting material, the reaction mixture was quenched with a saturated NazSCU solution (5 mL) at 0 °C and stirred for 10 min. The reaction mixture was diluted with water (20 mL), extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 80% EtOAc in hexane, which generated (2-bromo-4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)phenyl)methanol (49-7) (0.3 g, 91.7% yield) as an off-white gummy solid.168MF-369911600Attorney Docket No.: 314352001641

[0583] ’H-NMR (400 MHz, DMSO- e) 68.65 (s, 1H), 7.75 (s, 1H), 7.57 (d,.7= 1.6 Hz, 2H), 7.34 (d, J 10.4 Hz, 2H), 5.62 (s, 2H), 5.45 (s, 1H), 4.52 (d, J 4.0 Hz, 2H), 3.96 (s, 3H), 3.91 (s, 3H).2-Bromo-4-(((6, 7-dimethoxyquinazolin-4-yl)oxy)methyl)benzaldehyde (49-8)

[0584] To a stirred solution of (2-bromo-4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)phenyl)methanol (49-7) (0.30 g, 0.74 mmol, 1.0 equiv.) in DCM (10 mL) was added DMP (0.47 g, 1.11 mmol, 1.5 equiv.) portion-wise at 0 °C and then warmed to room temperature for 1 hour. After consumption of the starting material, the reaction mixture was quenched with sodium thiosulfate (10% solution, 25 mL) and extracted with EtOAc (2 x 75 mL). The combined organic layers were washed with NaHCCh (10%, 2 x 50 mL) and water (50 mL), followed by a brine solution (50 mL) and dried over Na^SCL. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 40% EtOAc in hexane, which generated 2-bromo-4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzaldehyde (49-8) (0.28 g, 93.9% yield) as a gummy solid.

[0585] 'H-NMR (400 MHz, DMSO-O 5 10.21 (s, 1H), 8.64 (s, 1H), 7.95 (s, 1H), 7.89 (d,.7= 8.0 Hz, 1H), 7.72 (d,.7= 8.0 Hz, 1H), 7.43 (s, 1H), 7.34 (s, 1H), 5.74 (s, 2H), 3.97 (s, 3H), 3.94 (s, 3H).4-( ((6, 7-Dimethoxyquinazolin-4-yl)oxy)methyl)-2-( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2- yl)benzaldehyde (49-9)

[0586] To a sealed-tube containing 2-bromo-4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzaldehyde (49-8) (270 mg, 0.66 mmol, 1.0 equiv. ) and potassium acetate (197 mg, 2.0 mmol, 3 equiv.) in 1,4-dioxane (10 mL), was added bis-pinacolato diboron (254 mg, 1.0 mmol, 1.5 equiv.) at room temperature. The reaction mixture was degassed with argon for 10 min. Pd(PPh3)2Cl2 (47.7 mg, 0.066 mmol, 0.1 equiv.) was then added at room temperature under argon atmosphere and stirred at 110 °C for 8 hours. After consumption of the starting material, the reaction was quenched by the addition of cold water (100 mL). The reaction mixture was extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with water (100 mL), followed by a brine solution (100 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by combiflash column chromatography eluted with 0-50% EtOAc in hexane, which generated 4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)-2-(4, 4, 5, 5-tetramethyl-l, 3,2-169MF-369911600Attorney Docket No.: 314352001641dioxaborolan-2-yl)benzaldehyde (49-9) (0.3 g) as pale brown solid. This material was used in the next step without further purification,

[0587] 1H-NMR (400 MHz, DMSO-d6) 5 10.34 (s, IH), 8.65 (s, IH), 7.79 (d,.7= 7.6 Hz, 1H), 7.65-7.60 (m, IH), 7.58-7.55 (m, IH), 7.41 (s, IH), 7.34 (s, IH), 5.75 (s, 2H), 3.95 (s, 3H), 3.93 (s, 3H), 1.35 (s, 12H).7-( ((6, 7-Dimethoxyquinazolin-4-yl)oxy)methyl)-lH-benzo[d] [ 1, 2, 6]oxazaborinin-l-ol (58j

[0588] To a stirred solution of 4-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzaldehyde (49-9) (250 mg, 0.55 mmol, 1.0 equiv.) in EtOH and water (1:1, 10 mL) was added hydroxylamine hydrochloride (116.8 mg, 1,66 mmol, 3,0 equiv.) at room temperature under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 5 hours. After consumption of the starting material, the reaction was concentrated under reduced pressure. The obtained residue was diluted with cold water (10 mL). The obtained solids were filtered and product purified by reverse-phase flash chromatography with the following conditions: column, Luna C18 (250x30 mm, 5um); mobile phase, ACN in 0.1% formic acid buffer, 15% to 95% gradient in 30 min [Time / % ACN: 0.01 / 15, 2 / 15, 10 / 45, 20 / 45, 27 / 95]; PDA detector, UV 220 and 254 nm, which generated 7-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (58) (30 nig, 11.6% yield) as an off-white solid.

[0589] LCMS: [M+H]+: 366

[0590] ^I-NMR (400 MHz, DMSO-tT,) δ 9.36 (s, 1H), 8.59 (d, J = 4.4 Hz, 2H), 8.13 (s, IH), 7.91 (d, J= 8.0 Hz, IH), 7.73 (d, J= 8.0 Hz, IH), 7.35 (s, IH), 7.28 (s, IH), 5.73 (s, 2H), 3.90 (s, 3H), 3.86 (s, 3H).Example 59Synthesis of 6-(((6,7-Dimethoxyquinazolin-4-yl)oxy)methyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol

[0591] The compound above was synthesized using Scheme 50.170MF-369911600Attorney Docket No.: 314352001641Scheme 50Methyl 2-bromo-5 -methylbenzoate (50-2)

[0592] To a mixture of 2-bromo-5-methylbenzoic acid (50-1) (5.0 g, 23.25 mmol, 1.0 equiv.) in DMF (50 mL) was added K2CO3 (7.06 g, 51.11 mmol, 2.2 equiv.) followed by Mel (6.61 g, 46.46 mmol, 2.0 equiv.) at room temperature and stirred for 1 hours under nitrogen atmosphere. After consumption of the starting material, the reaction mixture was diluted with water (500 mL) and extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with water (2 x 200 mL), followed by a brine solution (100 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 10% EtOAc in hexane, which generated methyl 2-bromo-5-methylbenzoate (50-2) (4.5 g, 84.6% yield) as a brown, gummy liquid.

[0593] 'H-NMR (400 MHz, CDCI3) 87.87 (s, 1H), 7.81 (d, J= 12.0 Hz, 1H), 7.57 (dd, J = 1.6, 8.4 Hz, 1H), 6.55 (s, 1H), 3.94 (s, 3H).Methyl 2-bromo-5-(dibromomethyl)benzoate (50-3)

[0594] To a mixture of methyl 2-bromo-5-methylbenzoate (50-2) (4.5 g, 19.63 mmol, 1.0 equiv.) in CCI4 (50 mL) was added NBS (8.73 g, 49.08 mmol, 2.5 equiv.) followed by A1BN (0.64 g, 3.92 mmol, 0.2 equiv.) at room temperature and heated to 80 °C for 4 hours under nitrogen atmosphere. After consumption of the starting material, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with water (2 x 200 mL), followed by a brine solution (100 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 10% EtOAc in hexane,171MF-369911600Attorney Docket No.: 314352001641which generated methyl 2-bromo-5-(dibromomethyl)benzoate (50-3) (4.0 g) as a gummy liquid. This material was used in the next step without further purification.

[0595] ^-NMR (400 MHz, DMSO- ) 58.00 (d,.7 = 2.8 Hz, 1 H), 7.85 (d, J = 8.4 Hz, 1H), 7.73 (dd, J = 2.4, 8.4 Hz, 1H), 7.45 (s, 1H), 3.89 (s, 3H).Methyl 2-bromo-5-formylbenzoate (50-4)

[0596] To a stirred solution of methyl 2-bromo-5-(dibromomethyl)benzoate (50-3 ) (4.0 g, 10.34 mmol, 1.0 equiv.) in EtOH (40 mL) was added silver nitrate (3.52 g, 20.71 mmol, 2.0 equiv.) dissolved in water (20 mL) at room temperature and stirred at 90 °C for 30 minutes. After consumption of the starting material, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layers were filtered through a celite pad, and the filtrate was washed with a brine solution (100 mL), dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 50% EtOAc in hexane, which afforded methyl 2-bromo-5-formylbenzoate (50-4) (2.1 g, 91.3% yield) as an off-white solid.

[0597] ^I-NMR (400 MHz, DMSO- e) 5 10.04 (s, 1H), 8.27 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.96 (dd, J = 2.0, 8.4 Hz, 1H), 3.91 (s, 3H).Methyl 2 -bromo-5 -(hydroxymethyl ) benzoate (50 - 5)

[0598] To a stirred solution of methyl 2-bromo-5-formylbenzoate (50-4) (1.0 g, 4.11 mmol, 1.0 equiv.) in THF (15 mL) was added NaBH4 (0.234 g, 6.16 mmol, 1.5 equiv.) porti on wise at room temperature and stirred for 2 hours. After consumption of the starting material, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (100 mL), followed by a brine solution (100 mL) and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 80% EtOAc in hexane to obtain methyl 2-bromo-5-(hydroxymethyl )benzoate (50-5) (502 mg, 50% yield) as an off-white gummy solid.

[0599] 'H-NMR (400 MHz, DMSO-6) 57.72-7.69 (m, 2H), 7.43-7.4 (m, 1H), 5.40 (t, J = 5.6 Hz, 1H), 4.51 (d, J= 5.6 Hz, 2H), 3.87 (s, 3H).Methyl 2-bromo-5-(((6, 7-dimethoxyqiiinazolm-4-yl)oxy)methyl)benzoate (50-6)

[0600] To a stirred solution of methyl 2-bromo-5-(hydroxymethyl)benzoate (50-5) (1 g, 4.08 mmol, 1.0 equiv.) in DMF (15 mL) was added NaH (0.246 g, 6.12 mmol, 1.5 equiv.) portion wise at 0 °C and stirred for 30 min. Then 4-chloro-6,7-dimethoxyquinazoline (49-5 in 172MF-369911600Attorney Docket No.: 314352001641Scheme 49) (1.1 g, 4.89 mmol, 1.2 equiv.) was then added portion wise at same temperature and allowed to stir at room temperature for 30 min. After consumption of the starting material, the reaction mixture was diluted with cold water (100 mL) and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with cold water (3x50 mL), followed by a brine solution (50 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 80% EtOAc in hexane, which generated methyl 2-bromo-5-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzoate (50-6) (0.505 g, 29.70% yield) as a pale¬ yellow gummy solid,

[0601] ’H-NMR (400 MHz, DMSO- e) 68.66 (s, 1H), 7.95 (d,. / = 2.4 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.66 (dd, 2.0, 8.2 Hz, 1H), 7.38 (s, 1H), 7.34 (s, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.87 (s, 3H).(2-Bromo-5-(((6, 7-dimethoxyquinazolin-4-yl)oxy)methyl)phenyl)methanol (50-7)

[0602] To a stirred solution of methyl 2-bromo-5-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzoate (50-6) (500 mg, 1.15 mmol, 1.0 equiv.) in THF (10 mL) was added LAH (44 mg, 1.15 mmol, 1.0 equiv.) portion wise at 0 °C and stirred for 10 minutes. After consumption of the starting material, the reaction mixture was quenched with saturated NaiSO4 solution (10 mL) at 0 °C and stirred for 10 min. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layers were dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 80% EtOAc in hexane, which generated (2-bromo-5-(((6,7-dimethoxyquinazolin-4-yi)oxy)methyl)phenyl)methanol (50-7) (350 mg, 74.9% yield) as a pale-yellow solid.

[0603] fll-NMR (400 MHz, DMSO- e) 58.66 (s, 1H), 7.72 (d, J ------ 2.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.39-7.36 (m, 2H), 7.34 (s, 1H), 5.65 (s, 2H), 5.49 (s, 1H), 4.53 (s, 2H), 3.97 (s, 3H), 3.92 (s, 3H).2-Bromo-5-(((6, 7-dimeth(^xyquinazolin-4-yl)ox )methyl)benzaldehyde (50-8)

[0604] To a stirred solution of (2-bromo-5-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)phenyl)methanol (50-7) (350 mg, 0.86 mmol, 1,0 equiv.) in DCM (15 mL) was added DMP (548 mg, 1.29 mmol, 1.5 equiv.) portion wise at 0 °C and allowed to stir at room temperature for 1 hour. After consumption of the starting material, the reaction mixture was quenched with sodium thiosulfate (10% solution, 50 mL) and extracted with EtOAc (2 x173MF-369911600Attorney Docket No.: 31435200164150 niL). The combined organic layers were washed with NaHCOs (10%, 2 x 30 mL), water (50 mL), followed by a brine solution (20 mL) and dried over Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by flash chromatography and eluted with 0% to 40% EtOAc in hexane, which generated 2-bromo-5- (((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzaldehyde (50-8) (300 mg, 86.2% yield) as a gummy solid.

[0605] JH-NMR (400 MHz, DMSO-6) 6 10.23 (s, I H), 8.64 (s, I H), 8.0 (d, J 2.0 Hz, 1H), 7.85 (d, J= 8.4 Hz, 1H), 7.79 (dd, J= 2.0, 8.2 Hz, 1H), 7.38 (s, 1H), 7.33 (s, 1H), 5.70 (s, 2H), 3.96 (s, 3H), 3.92 (s, 3H).5- ((6, 7-Dimethoxyquinazolin-4-yl)oxy)methyl)-2-(4, 4, 5.5-tetramethyl-l, 3.2-dioxaborolan-2- yl)benzaldehyde (50-9)

[0606] To a sealed-tube containing 2-bromo-5-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)benzaldehyde (50-8) (300 mg, 0.74 mmol, 1.0 equiv.) and potassium acetate (219 mg, 2.23 mmol, 3.0 equiv.) in 1,4-dioxane (10 mL), was added bis-pinacolato diboron (282 mg, 1.11 mmol, 1.5 equiv.) at room temperature. The reaction mixture was degassed with argon for 10 min then Pd(PPh3)2Cl2 (52 mg, 0.07 mmol, 0.1 equiv.) was added at room temperature under argon atmosphere and stirred at 100 °C for 45 minutes. After consumption of the starting material, cold water (100 mL) was added. The reaction mixture was extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with water (100 mL), followed by a brine solution (100 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by combiflash column chromatography eluted with 0-50% EtOAc in hexane, which generated 5-(((6,7-dimethoxyquinazolin-4-yl)oxy )methyl)-2-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)benzaldehyde (50-9) (280 mg) as pale brown solid. This material was used for the next step without any further purification.6-(((6, 7-DimethoxyquinazoUn-4-yl)oxy)methyl)-lH-benzo[d] [l,2,6]oxazaborinm-l-ol (59)

[0607] To a stirred solution of 5-(((6,7-dimethoxyquinazolin-4-yl)oxy)methyl)-2- (4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)benzaldehyde (50-9) (260 mg, 0.57 mmol, 1.0 equiv. ) in EtOH and water (1:1, 10 mL) was added hydroxylamine hydrochloride (120 mg, 1.73 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 5 hours. After consumption of the starting material, the reaction was concentrated under reduced pressure. The obtained residue was diluted with cold water (10 mL). The obtained solids were filtered and the product was purified by 174MF-369911600Attorney Docket No.: 314352001641reverse-phase flash chromatography with the following conditions: column, Luna C18 (250x30 mm, 5pm); mobile phase, ACN in 0,1% formic acid buffer, 20% to 95% gradient in 30 min [Time / % ACN: 0.01 / 20, 2 / 20, 10 / 50, 18 / 50, 28 / 95]; PDA detector, UV 220 and 254 nm; which generated 6-(((6,7-dimethoxyquinaz.olin-4-yl)oxy)methyl)-177-benzo[ ][l,2,6]oxazaborinin-l-ol (59) (18.5 mg, 6.9% yield) as an off-white solid.

[0608] LCMS: [M+H]+: 366

[0609] 'H-NMR (400 MHz, DMSO- s) 59.42 (s, 1H), 8.67 (d, 15.6 Hz, 2H), 8.11 (d, J = 8.4 Hz, 1H), 7.90 (dd, J= 2.4, 4.0 Hz, 2H), 7.43 (s, 1H), 7.34 (s, 1H), 5.80 (s, 2H), 3.97 (s, 3H), 3.94 (s, 3H).Example 60Synthesis of 4-(((l-hydroxy-lH-benzo[d] [1,2, 6 oxazabormin-7-yl)methyl)amino)-5, 7- dihydro-6H-pyrrolo[2, 3-d]pyrimidin-6-one hydrochloride (60)

[0610] The compound was synthesized using Scheme 51.Scheme 514-(((l-Hydroxy-lH-benzo[d][l,2,6]oxazaborinin-7-yl)methyl)amino)-5, 7-dihydro-6H-pyrrolo[2, 3-d]pyrimidin-6-one hydrochloride (60)

[0611] To a stirred solution of 4-chloro-5,7-dihydro-6 / 7-pyrrolo[2,3- ] pyrimidin-6-one (51-1) (150 mg, 0.8 mmol, 1.0 equiv.) and 7-(aminomethyl)-177-benzo[tZ] [1,2,6] oxazaborinin-l-ol hydrochloride (51-2, 2-7 from Scheme 2) (156 mg, 0.8 mmol, 1.0 equiv.) in DM SO (2 mL) was added CsF (269 mg, 1.7 mmol, 2.0 equiv. ) at room temperature under a 175MF-369911600Attorney Docket No.: 314352001641nitrogen atmosphere. The resulting mixture was stirred at room temperature for 4 hours under a nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with MeOH (3 x 20 mL). The filtrate was concentrated under reduced pressure. The product was purified by Prep-HPLC (Column: XBridge BEH C18 5 μm, 19 * 250 mm; Mobile Phase A:Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 6% B to 15%B in 8 min; Wave Length: 254 / 220 nm), which afforded 4-(((l-hydroxy-l / 7-benzo[<7][I,2,6]oxazaborinin-7-yl)methyl)amino)-5,7-dihydro-6H-pyrrolo[2,3-< / |pyrimidin-6- one hydrochloride (60) (25.8 mg, 8.4% yield) as a yellow solid.

[0612] LCMS (ESI): [M+H]+: 310

[0613] ^INMR (400 MHz, DMSO-6) 5 11.28 (s, IH), 8.62 (s, IH), 8.31 - 8.27 (m, 2H), 8.01 (s, IH), 7.81 - 7.69 (m, 2H), 4.78 (s, IH), 3.45 (s, 2H).Example 61Synthesis of 7-( {2H-[1, 3 dioxolo[ 4, 5-h ]quinazolm-6-ylamino}methyl)-2, 3, 1-benzoxazaborinin-l-ol hydrochloride

[0614] The compound was synthesized using Scheme 52.Scheme 524-Aminobenzo[d][l, 3 ]dioxole-5-carboxylic acid (52-2)176MF-369911600Attorney Docket No.: 314352001641

[0615] To a stirred solution of 5-bromobenzo[tZ][l,3]dioxol-4-amine (52-1 ) (500 mg, 2.3 mmol, 1,0 equiv.) in THE (25 mL) at -78 °C under a nitrogen atmosphere was added n-BuLi (1.5 M in THF, 5.8 mL, 9.3 mmol, 4.0 equiv.) dropwise. The resulting mixture was stirred at -78 °C for 2 hours under a nitrogen atmosphere. To the above mixture was added dry ice in portions at -78 °C. The resulting mixture was stirred at room temperature for additional I hour under a nitrogen atmosphere. Then water (50 mL) was added. The mixture was acidified to pH 2 with a concentrated HC1 aqueous solution. The resulting mixture was extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 0% to 10% gradient in 10 min; detector, UV 220 nm. This resulted in 4-aminobenzo[d][l,3]dioxole-5-carboxylic acid (52-2) (80 mg, 19.1% yield) as a light-yellow solid.

[0616] LCMS (ESI): [M+H]+: 182[1, 3 ]Dioxolo[ 4, 5-h ]quinazolin-6( 7H)-one (52-3)

[0617] To a stirred mixture of 4-aminobenzo[t / ][l,3]dioxole-5-carboxylic acid (52-2) (380 mg, 2.1 mmol, 1.0 equiv.) in EtOH (5 mL) was added NHtOAc (210 mg, 2.8 mmol, 1.3 equiv.) and triethyl orthoformate (497 mg, 3.4 mmol, 1.6 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was heated to 90 °C for 6 days under a nitrogen atmosphere. The precipitated solids were collected by filtration and washed with hexane (3 x 10 mL). This resulted in [l,3]dioxolo[4,5- / ?]quinazolin-6(7 / / )-one (52-3) (268 mg) as a brown solid, which was used directly in the next step without further purification.

[0618] LCMS (ESI): [M+H]+: 1916-Chloro-2H-[ 1, 3 ]dioxolo[ 4, 5-h quinazolme (52-4)

[0619] To a stirred mixture of 2 / 7,7J7-[l,3]dioxolo[4,5-A]quinazolin-6-one (52-3) (160 mg, 0.8 mmol, 1.0 equiv.) in CHCI3 (8 mL) was added TEA (315 mg, 3.1 mmol, 3.7 equiv.) and POCI3 (452 mg, 2.9 mmol, 3.5 equiv.) in portions at room temperature. The mixture was heated to 80 °C for 48 hours. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in H2O (30 mL) and extracted with DCM (2 x 50 mL), The combined organic layers were washed with brine (2 x 30 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in the 6-177MF-369911600Attorney Docket No.: 314352001641chloro-2 7-[l,3]dioxolo[4,5- ]quinazoline (52-4) (210 mg) as a yellow solid, this material was used in the next step directly without further purification.

[0620] LCMS (ESI): [M+H]+: 2097-( {2H-[ 1, 3 ]dioxolo[ 4, 5-h ]qninazolin-6-ylamino}methyl)-2, 3, 1-benzoxazaborinin-l-ol hydrochloride (61)

[0621] I o the stirred solution of 6-chloro-2 / 7-[l,3]dioxolo[4,5-h]quinazoline (52-4) (100 mg, 0.5 mmol, 1.0 equiv.) and 7-(aminomethyl)-2, 3, 1-benzoxazaborinin-l-ol hydrochloride (52-5, 2-7 from Scheme 2) (85 mg, 0.5 mmol, 1.0 equiv.) in DMSO (6 mL) was added TEA (243 mg, 2.4 mmol, 5.0 equiv.) and CsF (84 mg, 1.4 mmol, 3.0 equiv.) at room temperature. The resulting mixture was heated to 50 °C for 4 hours. The resulting mixture was concentrated under reduced pressure and collected the residue. The product was purified by prep-HPLC (Column: X select CSH Cis 5 pm, 30 mm X 150 mm; Mobile Phase A: Water (0.1% HO), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 23% B in 8 min; Wave Length: 254 nm), which resulted in 7-({2H-[l,3]dioxolo[4,5-A]quinazolin-6- ylamino]methyl)-2, 3, 1-benzoxazaborinin-l-ol hydrochloride (61) (54.0 mg, 32.4% yield) as a light-yellow solid.

[0622] LCMS (ESI): [M+H]+: 349

[0623] 11.21 (t, J= 6.0 Hz, 1H), 8.73 (s, 1H), 8.64 (s, 1H), 8.43 (d, J= 8.9 Hz, 1H), 8.05 (d, J= 1.8 Hz, 1H), 7.87 (dd, J= 8.0, 1.8 Hz, 1H), 7.74 (d, J 8.0 Hz, 1H), 7.56 (d,. / 8.8 Hz, 1H), 6.45 (s, 2H), 5.07 (d, J - 5.8 Hz, 2H).Example 62Synthesis of 2-chloro-4- {[(1 -hydroxy-2, 3, 1-benzoxazaborinin- 7-yl)methyl ]amino}-5H-furo[3, 4-dpyrimidin- 7 -one

[0624] The compound was synthesized using Scheme 53.178MF-369911600Attorney Docket No.: 314352001641Scheme 532-Chloro-4-{[ (1 -hydroxy-2, 3, l-benzoxazabormin-7-yl) methyl ]amino}-5H-furo[3, 4-dpyrimidin- 7 -one (62)

[0625] To a stirred mixture of 2,4-dichloro-5 / 7-furo[3,4-d]pyrimidin-7-one (53-1) (300 mg, 1.4 mmol, 1.0 equiv.) and 7-(aminomethyl)-2, 3, 1-benzoxazaborinin-l-ol hydrochloride (53-2, 2-7 in Scheme 2) (309 mg, 1.7 mmol, 1.2 equiv.) in DMSO (3 mL) was added TEA (444 mg, 4.3 mmol, 3.0 equiv.) dropwise at 25 °C under nitrogen atmosphere. The resulting mixture was stirred at 25 °C for 4 hours. The product was initially purified by silica gel column chromatography, eluted with PE / EA (1 / I ), followed by further purification by prep-HPLC (Column: Xselect CSH Cl 85 pm, 19 mm X 250 mm; Mobile Phase A: water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 25 mL / min; Gradient (B%): 25% B to 40% B in 8 min; Wave Length: 254 / 220 nm), which afforded 2-chl oro-4- {[(1 -hydroxy-2, 3,1- benz.oxazaborinin-7-yl)methyl]amino}-5 / 7-furo[3,4-< ]pyrimidin-7-one (62) (10.1 mg, 2,0% yield) as an off-white solid.

[0626] LCMS (ESI): [M+Hf: 345

[0627] 'HNMR (400 MHz, DMSO-O 89.38 (t, J = 5.8 Hz, 1H), 8.64 (s, 1H), 8.04 (d, J = 1.8 Hz, 1H), 7.81 (dd, J= 8.0, 1.8 Hz, 1H), 7.75 (d, J= 8.0 Hz, 1H), 5.29 (s, 2H), 4.80 (d, J = 5.8 Hz, 2H).Example 63Synthesis of 7~{[(2, -diiiieih()xyiiiiina-(>lin~-l--yliaiiiiii(> Jmethyl f-2, 3, 1-benzoxazaborinin-l-ol

[0628] The compound was synthesized using Scheme 54.179MF-369911600Attorney Docket No.: 314352001641Scheme 547-{[(2-Chloro-8-methoxyquinazolin-4-yl)amino]methyl}-2, 3, 1-benzoxazaborinin-l-ol (54-3)

[0629] To a stirred solution of 7-(aminomethyi)-2,3,l-benzoxazaborinin-l-ol hydrochloride (54-1, 2-7 in Scheme 2) (200 mg, 1.1 mmol, 1.0 equiv.) and 2,4-dichloro-8-methoxyquinazoline (54-2) (312 mg, 1.4 mmol, 1.2 equiv.) in DMF (5 mL) was added K2CO3 (471 mg, 3.4 mmol, 3.0 equiv.) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at room temperature for 16 hours under a nitrogen atmosphere. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in the 7-{[(2-chloro-8-methoxyquinazolin-4-yl)amino]methyl}-2, 3, 1-benzoxazaborinin-l-ol (54-3) (100, 1 mg, 23.8% yield) as a white solid.

[0630] LCMS (ESI): [M+H]+: 3697-{[(2,8-Dimethoxyquinazolin-4-yl)amino]methyl}-2, 3, 1-benzoxazaborinin-l-ol (63)

[0631] To a stirred solution of 7-{[(2-chloro-8-methoxyquinazolin-4-yl)amino]methyl}-2,3, 1-benzoxazaborinin-l-ol (54-3) (150 mg, 0.4 mmol, 1.0 equiv.) and MeOH (65 mg, 2.0 mmol, 5.0 equiv.) in toluene (3 mL) were added tBuONa (117 mg, 1.2 mmol, 3.0 equiv.), XantPhos Pd G4 (39 mg, 0.04 mmol, 0.1 equiv.) and XantPhos (47 mg, 0.08 mmol, 0.2 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 90 °C for 3 hours under a nitrogen atmosphere. The product was purified by Prep-HPLC (Column: XBridge BEH C18 5 pm, 30 * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3+ 0.1% NH3·H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 22%B in 8 min; Wave Length: 254 nm / 220 nm), which afforded 7-{[(2,8-dimethoxyquinazolin-4-yl)amino]methyl} -2,3, 1-benzoxazaborinin-l-ol (63) (9.5 mg, 6.4% yield) as a white solid.

[0632] LCMS (ESI): [M+H]+: 365180MF-369911600Attorney Docket No.: 314352001641

[0633] ’HNMR (400 MHz, DMSO-6+ HC1) 8 11.40 (t, J = 6.0 Hz, 1H), 8.63 (s, 1H), 8.27 - 8.25 (m, 1H), 8.14 (s, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.74 (d, J === 8.0 Hz, 1H), 7.55 - 7.53 (m, 2H), 5.01 (d, J= 5.8 Hz, 2H), 4.05 (s, 3H), 3.98 (s, 3H).Example 64Synthesis of 7-(((8-methoxypyrido[3,4-d]pyrimidin-4-yl)amino)methyl)-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-1-ol

[0634] The compound was synthesized using Scheme 55.Scheme 557-(((8-Methoxypyrido[3,4-d]pyrimidin-4-yl)amino)methyl)-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-1-ol (64)

[0635] To a stirred mixture of 8-methoxypyrido[3,4-<7] pyrimidin-4(3 / / )-one (55-1) (224 mg, 1.2 mmol, 1.2 equiv.) and BOP (698 nig, 1.5 mmol, 1.5 equiv.) in DMF (5 niL) was added D1EA (408 mg, 3.1 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. To the above mixture was added 7-(aminomethyl)-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-1-ol hydrochloride (55-2, 39-6 in Scheme 39) (200 mg, 1.0 mmol, 1.0 equiv.) at room temperature. The resulting mixture was stirred at room temperature overnight. The resulting mixture was concentrated under reduced pressure. The product was purified by Prep-HPLC (Column: XBridge BEH Cl 8 5 pm, 30 * 150 mm; Mobile Phase A: Water (0.1% HC1), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 15%B in 8 min; Wave Length: 254 nm / 220 nm), which afforded 7-(((8-methoxypyrido[3,4-d]pyrimidin-181MF-369911600Attorney Docket No.: 3143520016414-yl)amino)methyl)-4-methyl-1H-benzo[d][1,2,6]oxazaborinin-1-ol (64) (13.0 mg, 3.5% yield) as an off-white solid.

[0636] LCMS (ESI): [M+H]+: 350

[0637] 'HNMR (400 MHz, DMSO-6) δ 11.57 (s, 1H), 8.85 (s, 1H), 8.42 (d, J= 5.8 Hz, 1H), 8.25 (d, J= 5.9 Hz, 1H), 8.06 (d, J= 1.9 Hz, 1H), 7.89 (dd,8.3, 1.9 Hz, 1H), 7.80 (d, J= 8.2 Hz, 1H), 5.08 (d, J= 5.9 Hz, 2H), 4.15 (s, 3H), 2.45 (s, 3H).Example 65Synthesis of 7-[(1S)-1-({8-methoxypyrido[3,4-d]pyrimidin-4-yl}amino)ethyl]-2,3,1-benzoxazaborinin-1-ol

[0638] The compound was synthesized using Scheme 56.Scheme 567-[( 1 S)-l-( {8-Methoxypyrido [ 3, 4-d]pyrimidin-4-yl}amino)ethyl ]-2, 3, l-benzoxazaborinin-l- ol:

[0639] To a stirred solution of 4-chloro-8-methoxypyrido[3,4-d]pyrimidine (56-1, 29-2 in Scheme 29) (120 mg, 0,6 mmol, 1.0 equiv.) and 7-[(1S)-1-aminoethyl]-2,3,1-benzoxazaborinin-1-ol hydrochloride (56-2, 31-10 in Scheme 31) (117 mg, 0.6 mmol, 1.0 equiv.) in DMSO (15 mL) was added KF (71 mg, 1.2 mmol, 2.0 equiv.) and TEA (310 mg, 3 mmol, 5.0 equiv.) at room temperature. The resulting mixture was stirred at 50 °C for 2 hours. The resulting mixture was concentrated under reduced pressure. The product was initially purified by reversed-phase flash chromatography with the following conditions:182MF-369911600Attorney Docket No.: 314352001641column, Ci8 silica gel; mobile phase, ACN in Water, 0% to 10% gradient in 10 min; detector, UV 220 nm. The product was further purified by prep-HPLC with following conditions:Column: X Bridge BEH Cig 5 pm, 30 * 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3+ 0.1% NH3·H2O), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient (B%): 5% B to 17%B in 8 min; Wave Length: 220 nm. The product was further purified by prep-HPLC with following conditions: Column: X Bridge BEH Cis 5pm, 19 * 250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 25 mL / min;Gradient (B%): 8% B to 18% B in 10 min; Wave Length: 220 nm. This resulted in the 7- [(LS)-l-({8-methoxypyrido[3,4- ]pyrimidin-4-yl}amino)ethyl]-2,3,l-benzoxazaborinin-l-ol (65) (5.6 mg, 2.6% yield) as a white solid.

[0640] LCMS (ESI): [M+H]+: 350

[0641] 1H NMR (400 MHz, DMSO-6) δ 9.33 (brs, 1H), 8.70 (d, J 7.6 Hz, 1H), 8.58 (s, 1H), 8.46 (s, 1H), 8.20 – 8.03 (m, 2H), 7.96 – 7.81 (m, 2H), 7.70 (d, J = 7.8 Hz, 1H), 5.66 – 5.62 (m, 1H), 4.00 (s, 3H), 1.64 (d, J = 7.0 Hz, 3H).Example 66Synthesis of 6-{[(6-methoxyquinoxalin-2-yl)(methyl)amino]methyl}-3H-2,1-benzoxaborol-1-ol66

[0642] The compound was synthesized using Scheme 57.Scheme 57183MF-369911600Attorney Docket No.: 314352001641(S)-7-(1-((2-Chloro-8-methoxyquinazolin-4-yl)amino)ethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (57-3)

[0643] A mixture of 7-[(1S)-1-aminoethyl]-2,3,1-benzoxazaborinin-1-ol hydrochloride (57-1, 31-10 in Scheme 31) (30 mg, 0.16 mmol, 1.0 equiv.), 2,4-dichloro-8-methoxyquinazoline (57-2) (25 mg, 0.11 mmol, 0.7 equiv.) and CsF (240 mg, 1.6 mmol, 10.0 equiv.) in DMSO (2 mL) was stirred at 50 °C for 1 hour under a nitrogen atmosphere. Five batches were performed in parallel and combined. The mixture was allowed to cool down to room temperature. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0,1% FA), 0% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in (5)-7-(l-((2-chloro-8-methoxyquinazolin-4-yl)amino)ethyl)-l / / -benzo[d][l,2,6]oxazaborinin-l-ol (57-3) (88 mg) as a yellow solid, which was used directly in the next step without further purification.

[0644] LCMS (ESI): [M+H]+: 3836-{[(6-Methoxyquinoxalin-2-yl)(methyl)amino]methyl}-3H-2,1-benzoxaborol-1-ol (66)

[0645] A mixture of 7-[(1S)-1-[(2-chloro-8-methoxyquinazolin-4-yl)amino]ethyl]-2,3,1-benzoxazaborinin-1-ol (57-3) (88 mg, -1.0 equiv.), MeOH (67 mg, 1.1 mmol, 5.0 equiv.), t-BuONa (66 mg, 0.68 mmol, 3.0 equiv.), Xantphos (26 mg, 0.05 mmol, 0.2 equiv.) and Xantphos Pd G4 (22 mg, 0.03 mmol, 0.1 equiv.) in toluene (5 mL) was stirred at 90 °C overnight under a nitrogen atmosphere. The mixture was cooled to room temperature. The resulting mixture was concentrated under reduced pressure. The product was initially purified by reversed-phase flash chromatography with the following conditions: column, Cl 8 silica gel; mobile phase, MeCN in Water (10 mmol / L NH4HCO3), 0% to 50% gradient in 15 min; detector, UV 254 nm. The product was further purified by Prep-HPLC with the following conditions: Column: XBridge BEH C18 5 μm, 19 × 250 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3 + 0.1%NH3. H2O), Mobile Phase B: ACN; Flow rate: 25 mL / min;Gradient (B%): 13% B to 25%B in 8 min; Wave Length: 254 nm / 220 nm. This resulted in 6-{ [(6-m ethoxy quinoxalin-2-yl)(methyl)amino]methyl } -3 / 7-2, 1 -benzoxaborol- 1 -ol (66) (13.1 mg, 13.2% yield) as a white solid.

[0646] LCMS (ESI): [M+Hf: 379

[0647] 'HNMR (400 MHz, DMSO-6) δ 9.34 (s, 1H), 8.58 (s, 1H), 8.52 (d, J = 7.5 Hz, 1H), 8.09 (s, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.1 Hz, 1H),184MF-369911600Attorney Docket No.: 3143520016417.29 (t, J= 8.0 Hz, 1H), 7.19 (d, J= 7.8 Hz, 1H), 5.57 (p, J= 7.1 Hz, 1H), 3.87 (s, 3H), 3.78 (s, 3H), 1.62 (d, J = 7.1 Hz, 3H).Example 67Synthesis of 6-(((7-fluoro-8-methoxyquinazolin-4-yl)amino)methyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol

[0648] The compound above was synthesized using Scheme 58.Scheme 58Methyl 2-amino-4-fluoro-3-methoxybenzoate (58-2)

[0649] To a stirred solution of 2-amino-4-fluoro-3 -methoxybenzoic acid (58-1) (2.5 g, 13.50 mmol, 1.0 equiv.) in MeOH (50 mL) was added H2SO4 (1.45 g, 14.85 mmol, 1.1 equiv.) at 0 °C and stirred at 80 °C for 2 hours. After consumption of the starting material, the reaction was quenched by the addition of cold water (100 mL). The reaction mixture was extracted with EtOAc (2 x 150 mL). The combined organic layers were washed with water (100 mL), followed by a brine solution (100 mL), and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by combiflash185MF-369911600Attorney Docket No.: 314352001641column chromatography, by elution with 0-50% EtOAc in hexane, which generated methyl 2- amino-4-fluoro-3-methoxybenzoate (58-2) (1.0 g, 37.3% yield) as pale-yellow solid.

[0650] 1H-NMR (400 MHz, DMSO-6) δ 7.52 (q,.7 = 6.0 Hz, 1H), 6.67 (s, 2H), 6.45 (dd, J= 9.2, 10.4 Hz, 1H), 3.79 (s, 6H).7-Fluoro-8-methoxy’qumazolin-4-ol (58-3)

[0651] To a stirred solution of methyl 2-amino-4-fluoro-3-methoxybenzoate (58-2) (1.0 g, 5.02 mmol, 1.0 equiv.) in n-BuOH (10 mL) were added formamidine acetate (1.56 g, 15.06 mmol, 3.0 equiv.) at room temperature under nitrogen atmosphere and allowed to stir at 110 °C for 16 hours. After consumption of the starting material, the reaction mixture was cooled to 0 °C. The obtained solids were filtered and washed with pentane (20 mL) to obtain 7-fluoro-8-methoxyquinazolin-4-ol (58-3) (0.50 g, 51.3% yield) as an off-white solid.

[0652] 1H-NMR (400 MHz, DMSO-6) δ 12.37 (s, 1H), 8.14 (s, 1H), 7.88 (q, J= 6.0 Hz, 1H), 7.44 (dd, J 8.8, 10.4 Hz, 1H), 4.01 (s, 3H).4-Chloro- 7-fluoro-8-methoxyquinazoline (58-4)

[0653] To a stirred solution of 7-fluoro-8-m ethoxy quinazolin-4-ol (58-3) (500 mg, 2.57 mmol, 1.0 equiv.) in SOCI2 (5 mL) was added DMF (0.3 mL) 0 °C. The reaction mixture was heated to 80 °C for 6 hours. After consumption of the starting material, the reaction mixture was concentrated under reduced pressure. The residue was diluted with cold water (10 mL). The obtained solids were filtered and washed with pentane (15 mL), which afforded 4-chloro-7-fluoro-8-methoxyquinazoline (58-4) (200 mg) as an off- white solid. This compound was used for the next step without any further purification.

[0654] 1H-NMR (400 MHz, DMSO-6) δ 9.12 (s, 1H), 8.08 (q, J= 5.2 Hz, 1H), 7.86 (dd, J -- 9.2, 11.0 Hz, 1H), 4.14 (s, 3H).6-(((7-Fluoro-8-methoxyquinazolin-4-yl)amino)methyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (67)

[0655] To a stirred solution of 4-chloro-7-fluoro-8-methoxyquinazoline (58-4) (200 mg, 0.94 mmol, 1.0 equiv.) in DMSO (3 mL) was added 6-(aminomethyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol hydrochloride (1-7 in Scheme 1) (219 mg, 1.03 mmol, 1.1 equiv.) followed by KF (81 mg, 1.41 mmol, 1.5 equiv.) and TEA (475 mg, 4.7 mmol, 5.0 equiv.) at room temperature and stirred for 16 hours. After consumption of the starting material, the reaction mixture was diluted with water (7 mL) and extracted with EtOAc (2 x 15 mL). The aqueous layer was purified by reverse phase prep-HPLC (conditions: column,186MF-369911600Attorney Docket No.: 314352001641Luna C18 (250x30 mm, 5 pm); mobile phase, ACN in 0.1% ammonium acetate buffer, 0% to 98% gradient in 30 min [Time / % ACN: 0.01 / 15, 2 / 15, 6 / 55, 18 / 55, 25 / 98, 28 / 98]; PDA detector, UV 220 and 254 nm), which generated 6-(((7-fluoro-8-methoxyquinazolin-4-yl)amino)methyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol (67) (32 mg, 10.3% yield) as an off-white solid.

[0656] LCMS: [M+H]+: 353

[0657] 1H-NMR (400 MHz, DMSO-6) δ 9.32 (s, 1H), 9.03 (t, J = 6.0 Hz, 1H), 8.62 (s, 1H), 8.46 (s, 1H), 8.10 (q, J = 5.2 Hz, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.68 (s, 1H), 7.52 (dd, J = 9.2, 10.8 Hz, 1H), 4.89 (s, 2H), 4.01 (s, 3H).Example 68Synthesis of 7-((4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)methyl)-1H-benzo[d][1,2,6]oxazaborinin-1-ol

[0658] The compound was synthesized using Scheme 59.Scheme 59187MF-369911600Attorney Docket No.: 314352001641Methyl 3-bromo-4-( 1,3-dioxolan-2-yl)benzoate (59-2)

[0659] To a stirred solution of methyl 3-bromo-4-formylbenzoate (59-1) (10.0 g, 41.1 mmol, 1.0 equiv.) and ethane- 1,2 -diol (20.4 g, 329,1 mmol, 8.0 equiv.) in toluene (100 mL) at room temperature was added TsOH (708 mg, 4.1 mmol, 0.1 equiv.). The resulting mixture was stirred at 120 °C overnight. After cooling to ambient temperature, the resulting mixture was added to water (150 mL). The resulting mixture was extracted with EtOAc (3 x 150 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by silica gel column chromatography, eluted with PE / EA (5 / 1), which afforded methyl 3-bromo-4-(l,3-dioxolan-2-yl)benzoate (59-2) (8.5 g, 71.9%) as an off-white solid.

[0660] LCMS (ESI): [M+H]+: 287Methyl 4-( 1, 3-dioxolan-2-yl)-3-(4, 4,5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)benzoate (59-3)

[0661] To a stirred solution of methyl 3-bromo-4-(l,3-dioxolan-2-yl)benzoate (59-2) (8.9 g, 31.1 mmol, 1.0 equiv.) and Pin2B2 (19.7 g, 77.8 mmol, 2.5 equiv.) in 1,4-dioxane (100 mL) were added Pd(dppf)C12 (2.2 g, 3.1 mmol, 0.1 equiv.) and AcOK (7.6 g, 77.8 mmol, 2.5 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 90 °C overnight under a nitrogen atmosphere. After cooling, the resulting mixture was added to water (150 mL). The resulting mixture was extracted with EtOAc (3 x 150 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in the methyl 4-(l,3-dioxolan-2-yl)-3-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)benzoate (59-3) (9.0 g, 86.4% yield) as a brown oil.

[0662] LCMS (ESI): [M+H]+: 335(2-Formyl-5-(methoxycarbonyl)phenyl)boronic acid (59-4)

[0663] A solution of methyl 4-(l,3-dioxolan-2-yl)-3-(4, 4, 5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)benzoate (59-3) (8.5 g, 25.4 mmol, 1.0 equiv.) in HC1 in 1,4-dioxane (4.0 M, 60 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN188MF-369911600Attorney Docket No.: 314352001641in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in (2-formyl-5-(methoxycarbonyl)phenyl)boronic acid (59-4) (4.8 g, 90.7%) as a light-yellow oil.

[0664] LCMS (ESI): [M-H]': 207Methyl l-hydroxy-lH-benzo[dl [1, 2, 6 ]oxazaborinine-7 -carboxy late (59-5)

[0665] A solution of (2-formyl-5-(methoxycarbonyl) phenyl)boronic acid (59-4) (4.8 g, 23.0 mmol, 1.0 equiv.) and hydroxylamine hydrochloride (4.8 g, 69.2 mmol, 3.0 equiv.) in THF (50 mL) and H2O (50 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The product was purified by reversed-phase flash chromatography with the following conditions: column, Cl 8 silica gel; mobile phase, MeCN in Water (0.1% FA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in methyl 1-hydroxy-1H-benzo[d][1,2,6]oxazaborinine-7-carboxylate (59-5) (4.2 g, 88.7% yield) as an off-white solid.

[0666] LCMS (ESI): [M+H]+: 2067-(Hy...

Claims

Attorney Docket No.: 314352001641CLAIMSWhat is claimed is:

1. A compound of Formula (A):or a pharmaceutically acceptable salt thereof, wherein:R1is H or alkyl;R2and R3are each independently H or alkyl;R4is H or alkyl;R5is an optionally substituted cyclic ring system that is fused or unfused, comprising at least one aromatic ring;each R6is independently alkyl, haloalkyl, haloalkoxy, halo, cyano, or alkoxy;R7is H, alkyl, or haloalkyl;Y is a bond, alkyl, -alkyl -NRy-alkyl- or -O-alkyl-, whereinRyis H or alkyl;ring F is 5-membered heteroaryl optionally substituted with one or more R\ wherein each R1is independently alkyl;ring G is optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl, whereinring G is optionally substituted with one or more Rs;each Rgis independently alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, or oxo;m is 0-3; andn is 1-3.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the at least one aromatic ring of R5is heteroaromatic.255MF-369911600Attorney Docket No.: 3143520016413. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I):or a pharmaceutically acceptable salt thereof.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-A).or a pharmaceutically acceptable salt thereof.

5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-B):or a pharmaceutically acceptable salt thereof.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system that is unfused.

7. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system that is fused.

8. The compound of any one of claims 1 to 7, or a phar aceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system comprising 1-4 nitrogen atoms.256MF-369911600Attorney Docket No.: 3143520016419. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with one or more groups independently selected from the group consisting of alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, oxo, diphenyl, alkyl-O-alkyl, and -NRaRb, wherein each Raand Rbis independently H or alkyl.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with one or more groups independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with 1, 2, or 3 groups.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R5is:MF-369911600Attorney Docket No.: 314352001641, each optionally substituted.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R4is H.

14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable saltthereof, wherein the moiety represented(wherein n=l).

15. The compound of any one of claims 1, and 3 to 14, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I-C 1):or a pharmaceutically acceptable salt thereof, whereinYcais H, alkoxy, or halo;each Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, alkyl- O-alkyl, and H, orRlcand R2Care taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (II):258MF-369911600Attorney Docket No.: 314352001641or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 or 16, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (II-A):or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 or 16, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I I-B).or a pharmaceutically acceptable salt thereof.

19. The compound of any one of claims 1, and 16 to 18, or a pharmaceutically acceptable salt thereof, wherein ring F is triazolyl optionally substituted with one or more Rf.

20. The compound of any one of claims 1, and 16 to 19, or a pharmaceutically acceptable salt thereof, wherein V is a bond.

21. The compound of any one of claims 1, and 16 to 20, or a pharmaceutically acceptable salt thereof, wherein ring G is phenyl or pyridyl, each optionally substituted with one or more R8.

22. The compound of any one of claims 1, and 16 to 21, or a pharmaceutically acceptable salt thereof, wherein ring G is optionally substituted with 1 or 2 Rsgroups.259MF-369911600Attorney Docket No.: 31435200164123. The compound of any one of claims 1, and 16 to 22, or a pharmaceutically acceptablesalt thereof, wherein the moiety represented by, or(wherein n=l).

24. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (HI):or a pharmaceutically acceptable salt thereof.

25. The compound of any one of claims 1, 2, and 24, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (III- A):or a pharmaceutically acceptable salt thereof.

26. The compound of any one of claims 1, 2, and 24, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (I I LB):or a pharmaceutically acceptable salt thereof.

27. The compound of any one of claims 1, 2, and 24 to 26, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system that is unfused.260MF-369911600Attorney Docket No.: 31435200164128. The compound of any one of claims 1, 2, and 24 to 26, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system that is fused.

29. The compound of any one of claims 1, 2, and 24 to 28, or a pharmaceutically acceptable salt thereof, wherein R5is optionally substituted heteroaromatic ring system comprising 1-4 nitrogen atoms.

30. The compound of any one of claims 1, 2, and 24 to 29, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with one or more groups independently selected from the group consisting of alkoxy, haloalkoxy, cyano, alkyl, haloalkyl, halo, hydroxyl, oxo, O-phenyl, alkyl-O-alkyl, and -NRaRb, wherein each Raand Rbis independently H or alkyl.

31. The compound of any one of claims 1, 2, and 24 to 30, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with one or more groups independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

32. The compound of any one of claims 1, 2, and 24 to 31, or a pharmaceutically acceptable salt thereof, wherein R5is substituted with 1, 2, or 3 groups.

33. The compound of any one of claims 1, 2, and 24 to 32, or a pharmaceutically acceptable salt thereof, wherein R5is:261MF-369911600Attorney Docket No.: 31435200164134. The compound of any one of claims 1, 2, and 24 to 33, or a pharmaceuticallyacceptable salt thereof, wherein the moiety represented by(wherein n=l).

35. The compound of any one of claims 1, and 24 to 34, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (III-C1):or a pharmaceutically acceptable salt thereof, whereinYeais H, alkoxy, or halo;each Ycis independently selected from the group consisting of -N- and -C(RC)-,wherein each Rcis independently H or cyano; andRlcand R2care each independently selected from the group consisting of O-phenyl, alkyl- O-alkyl, and H, or262MF-369911600Attorney Docket No.: 314352001641R,cand Rcare taken together to form a cyclic ring system optionally substituted with one or more substituents independently selected from the group consisting of alkoxy, cyano, alkyl, halo, hydroxyl, and oxo.

36. The compound of any one of claims 1 to 14, and 16 to 34, or a pharmaceutically acceptable salt thereof, wherein R1is H.

37. The compound of any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein m is 0.

38. The compound of any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein m is 1 and Rbis methyl, methoxy, or F.

39. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein R7is H.

40. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein R7is methyl.

41. The compound of any one of claims 1 to 38, or a pharmaceutically acceptable salt thereof, wherein R7is CF3 or CF2FI42. The compound of any one of claims 1 to 41, or a pharmaceutically acceptable salt thereof, wherein each R2is H, and each R3is independently H or alkyl.

43. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein each R2is H, and each R3is methyl.

44. The compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, wherein R2and R3are each H.

45. The compound of any one of claims 1 to 13, 16 to 22, 24 to 33, and 36 to 44, or a pharmaceutically acceptable salt thereof, wherein n is 1.

46. A compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

47. A pharmaceutical composition, comprising:a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof; and263MF-369911600Attorney Docket No.: 314352001641at least one pharmaceutically acceptable excipient.

48. A method of inhibiting ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) and / or ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3) in a subject in need thereof, comprising:administering to the subject a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition of claim 47.

49. A method of treating a disorder, disease, or condition mediated by ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) and / or ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3) in a subject in need thereof, comprising: administering to the subject a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition of claim 47.

50. The method of claim 49, wherein the disorder, disease, or condition is cancer.

51. The method of claim 50, wherein the cancer is a solid tumor,52. The method of claim 50, wherein the cancer is cervical cancer, colorectal cancer, lung cancer, prostate cancer, esophageal cancer, liver cancer, glioblastoma, melanoma, testicular cancer, pancreatic cancer, thyroid cancer, or breast cancer, or any combination thereof.

53. The method of claim 49, wherein the disorder, disease, or condition is an inflammatory disease, a metabolic disease, or a microbial infection, or any combination thereof.

54. The method of claim 49, wherein the disorder, disease, or condition is an autoimmune disease or an autoinflammatory disease.

55. The method of claim 49, wherein the disorder, disease or condition is hypophosphatasia (HPP).

56. The method of claim 49, wherein the disorder, disease, or condition is a cardiovascular disease.

57. The method of claim 56, wherein the compound, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition augments cardiac repair and postinfarct heart function.264MF-369911600Attorney Docket No.: 31435200164158. The method of any one of claims 48 to 57, wherein the subject is a human.

59. The method of claim 48 or 49, wherein the compound, or a pharmaceutically acceptable salt thereof, is a dual ENPP1 / ENPP3 inhibitor.265MF-369911600